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ABSTRACT OF THE DISSERTATION
CHARACTERIZATION OF THE POXAB OPERON ENCODING A CLASS D
CARBAPENEMASE IN PSEUDOMONAS AERUGINOSA
by
Diansy Zincke
Florida International University, 2015
Miami, Florida
Professor Kalai Mathee, Major Professor
Pseudomonas aeruginosa is a dreaded opportunistic pathogen that causes severe and
often intractable infections in immunocompromised and critically ill patients. This
bacterium is also the primary cause of fatal lung infections in patients with cystic fibrosis
and a leading nosocomial pathogen responsible for nearly 10% of all hospital-acquired
infections. P. aeruginosa is intrinsically recalcitrant to most classes of antibiotics and has
the ability to acquire additional resistance during treatment. In particular, resistance to the
widely used β-lactam antibiotics is frequently mediated by the expression of AmpC, a
chromosomally encoded β-lactamase that is ubiquitously found in P. aeruginosa strains.
This dissertation delved into the role of a recently reported chromosomal β-lactamase in
P. aeruginosa called PoxB. To date, no detailed studies have addressed the regulation of
poxB expression and its contribution to β-lactam resistance in P. aeruginosa. In an effort
to better understand the role of this β-lactamase, poxB was deleted from the chromosome
and expressed in trans from an IPTG-inducible promoter. The loss of poxB did not affect
susceptibility. However, expression in trans in the absence of ampC rendered strains

v

more resistant to the carbapenem β-lactams. The carbapenem-hydrolyzing phenotype was
enhanced, reaching intermediate and resistant clinical breakpoints, in the absence of the
carbapenem-specific outer membrane porin OprD. As observed for most class D βlactamases, PoxB was only weakly inhibited by the currently available β-lactamase
inhibitors. Moreover, poxB was shown to form an operon with the upstream located
poxA, whose expression in trans decreased pox promoter (Ppox) activity suggesting
autoregulation. The transcriptional regulator AmpR negatively controlled Ppox activity,
however no direct interaction could be demonstrated. A mariner transposon library
identified genes involved in the transport of polyamines as potential regulators of pox
expression. Unexpectedly, polyamines themselves were able induce resistance to
carbapenems. In summary, P. aeruginosa carries a chromosomal-encoded β-lactamase
PoxB that can provide resistance against the clinically relevant carbapenems despite its
narrow spectrum of hydrolysis and whose activity in vivo may be regulated by
polyamines.
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Chapter 1

Introduction
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1.1

Preface
Pseudomonas aeruginosa is one of the most dreaded pathogens in the clinical

setting. It is one of the leading causes of nosocomial infections and one of the most
troublesome and intractable organisms colonizing the lungs of patients with cystic
fibrosis (CF), a deadly genetic disease. Although there are antibiotics and treatment
strategies to combat such infections, the organism’s inherent and acquired resistance
renders many such antipseudomonal treatments ineffective. One important mechanism of
resistance, the expression of β-lactamases, is the leading cause of β-lactam resistance in
the clinical setting and is the subject of this dissertation. The following introduction is a
review of the relevant literature on this important organism and its mechanisms of
resistance, with special attention to β-lactam antibiotics and the expression of βlactamases.
1. 2

Pseudomonas aeruginosa
P. aeruginosa is an aerobic, non-spore forming, monoflagellated, Gram-negative

rod ubiquitously found in the environment (Figure 1.1) (1). It is positive for catalase and
oxidase, and produces a fruity or grape-like odor due to the production of 2aminoacetophenone (2). Although it is unable to ferment lactose and its metabolism is
mostly respiratory, it can also grow under anaerobic conditions by using nitrate as a
terminal electron acceptor or by fermenting arginine (3, 4).
Like other pseudomonads, renowned for their nutritional versatility, P.
aeruginosa has very simple nutritional needs and can use a multitude of organic
compounds for growth (3). As a chemoorganotroph, it can metabolize a variety of simple
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and complex organic substrates as a sole source of carbon and energy. It is also a very
versatile, adaptable microbe that is able to tolerate a variety of physical conditions. It has
an optimum growth temperature of 37°C, but it is also able to grow at 42°C, unlike some
other species of the same genera (3). Most notably, P. aeruginosa is inherently resistant
to many commonly used antibiotics and chemotherapeutic agents (1, 5).

Figure 1.1. Colored scanning electron micrograph of P. aeruginosa.
(http://www.visualphotos.com/image/1x6040105/coloured_sem_of_pseudomonas_aerugi
nosa_bacteria)
Most strains of P. aeruginosa produce pyocyanin, a blue-green, water-soluble,
non-fluorescent phenazine pigment (3). Phenazine compounds are commonly found in
nature and are produced by bacteria such as the Streptomyces and Pseudomonas spp.
Pyocyanin (1-hydroxy-5-methyl-phenazine) is derived from chorismate, an intermediate
in the biosynthesis of aromatic amino acids in plants and microorganisms (3). Pyocyanin
and other phenazine compounds appear to contribute to the virulence and competitive
fitness of the producing organisms (3, 6). For instance, in P. aeruginosa pyocyanin
contributes to its ability to colonize the lungs of patients with CF as it has been shown to
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disrupt the beating of human cilia and inhibit mammalian cell respiration (7, 8).
Additionally, this pigment inhibits lymphocyte proliferation and epidermal cell growth
(9, 10). Pyocyanin can also act as an antibiotic agent against other bacterial cells by the
generation of reactive oxygen intermediates (6). This antimicrobial activity is oxygendependent and involves the oxidation of NADH to produce superoxide and hydrogen
peroxide (6).
Some strains also produce pyoverdin, a water-soluble, fluorescent pigment that
gives P. aeruginosa a yellowish-green appearance (1). Pyoverdin functions as a
siderophore or iron-scavenging compound, and as such it is known to increase the rate of
bacterial iron transport. Siderophores, in general, are extracellular compounds that have a
high affinity for iron; they are produced under iron-deficient conditions, and have been
known to stimulate and increase bacterial growth rate (1, 11). Production of siderophores
during infection has been implicated with bacterial virulence as a consequence of
increased growth rate; it also appears to be a factor that can limit the growth of other
bacteria as P. aeruginosa can effectively compete for iron with other microorganisms (1,
11).
Besides pyocyanin and pyoverdin, P. aeruginosa can produce and secrete a
myriad of other virulence factors that contribute to its success as a pathogen and allow it
to compete against other microorganisms. These include elastase, a zinc protease that
destroys immunoglobulins and eukaryotic proteins responsible for maintaining cell
structure; exotoxin A, a very toxic protein that inhibits the host cell protein synthesis;
exoenzymes S and T, proteins with cytotoxic activity secreted by the type III secretion
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system; LasA protease, a staphylolytic enzyme that can destroy β-casein, and
rhamnolipids (1, 12). Rhamnolipids, in particular, are very powerful virulence factors
capable of destroying polymorphonuclear leukocytes, inhibiting phagocytosis by
macrophages, and causing disruption of the mucociliary clearance and of epithelial tight
junctions leading to paracellular infiltration of P. aeruginosa (13-16). Rhamnolipids have
also been shown to have antibacterial activity against a number of microbes including
Staphylococcus aureus, Enterobacter aerogenes, Streptococcus faecalis, Serratia
marcescens, Klebsiella pneumoniae and Proteus vulgaris to name a few (17, 18).

1.2.1

Habitat
P. aeruginosa is a ubiquitous microorganism commonly found in water, soil, and

sewage as well as on the surfaces of plants, animals, insects, fruits and vegetables (1, 19).
Natural bodies of water such as lakes and rivers, are also natural sources of the
bacterium, especially near sites of urban drainage. It is sometimes part of the human
microbial flora infrequently colonizing the skin especially in areas that are moist, and the
intestine after ingestion with contaminated foods or fluids (20-23). Its prevalence and
colonization in healthy individuals is often low (2.6-25%) with intestinal loads being
reported at 3% (24-26).
Its ability to thrive in aqueous environments has made it a problem in the hospital
setting where it is often isolated from soaps, ointments, disinfectants, irrigation fluids,
and eye drops (27). Its very simple nutritional needs allow it to grow even on the
negligible impurities contained in aqueous solutions found in hospitals. Specifically, a
study found P. aeruginosa was able to not only grow but thrive in the distilled water of
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several mist therapy units (28). Tap water is also a major source of nosocomial infections
when it is inadvertently used for the preparation of solutions to be used in that setting
(29-33). The prevalence of P. aeruginosa in tap water likely results from the colonization
of showerheads, faucets, and sinks from which it has also been detected (32, 34-38).
Additionally, P. aeruginosa has also been isolated from holy water, aerators, baby baths,
hot tubs, swimming pools, contact lens solutions, cosmetics and even the innersole of
sneakers (39-46). In short, aqueous and moist environments seem to be the natural and
preferred reservoirs for P. aeruginosa and such environments, when contaminated, can be
potential sources of infection.

1.2.2

P. aeruginosa infections in healthy individuals
P. aeruginosa is rarely a cause for concern in healthy individuals with such

infections often resulting from contact with contaminated water or solutions or after
sustaining some form of external trauma like a puncture wound (19). Folliculitis, for
example, is an infection of the hair follicles caused by bacteria such as P. aeruginosa, and
can occur after bathing in swimming pools, hot tubs, and whirlpools that are not
adequately treated with chlorine (43, 44, 47, 48). Individuals involved in aquatic sports as
well as those swimming and bathing in contaminated waters can also develop superficial
infections of the ear canal known as external otitis (49-52).
Minor injury to the eye or cornea, often related to the use of contacts lens,
especially extended wear lenses, can predispose an individual to eye infections, or
keratitis, with P. aeruginosa (53-57). Contact lens solutions that are contaminated, or
even tap water used for the handling of contact lens, can all serve as potential sources of
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infection (19). Osteomyelitis, or infection of the bone, has also been reported, especially
in children after incurring puncture wounds in the feet, with the source of the infection
often being the sole or inner pad of the sneaker that was worn at the time of the injury
(46, 58). Osteomyelitis can also occur in intravenous drug users (59, 60).
One of the most severe P. aeruginosa infections that can affect an otherwise
healthy person is endocarditis, or inflammation of the inner lining of the heart, often
requiring replacement of the affected valve (19). The majority of P. aeruginosa
endocarditis occurs in intravenous drug users, as the drugs are often mixed with
contaminated water leading to bacteremia and endocarditis (61-63). P. aeruginosa-related
endocarditis, however, can also occur in burn and open heart surgery patients (64-66).

1.2.3

P. aeruginosa in nosocomial or healthcare-associated infections
P. aeruginosa is one of the leading causes of hospital-acquired infections

accounting for as much as 10-13% of all nosocomial infections with incidences as high as
22% reported in intensive care units (ICUs) (67-71). P. aeruginosa was the sixth most
frequently isolated pathogen accounting for 7.1% of all healthcare-associated infections
in a recent survey of 183 US hospitals from 10 different states (72). Similarly, the latest
hospital reporting to the CDC ranks P. aeruginosa as the fifth most commonly reported
pathogen in nosocomial infections accounting for 7.5% of all healthcare-associated
infections (73).
Pneumonia accounts for the majority of nosocomial diseases caused by P.
aeruginosa (72, 73). P. aeruginosa can easily colonize endotracheal tubes and
mechanical ventilators and as such has been reported as one of the leading causes of
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ventilator-associated pneumonia (VAP), second only to S. aureus (73-75). VAP has been
associated with high mortality rates that exceed those of other types of pneumonia such
as community-acquired, healthcare-associated or hospital-acquired pneumonia (75, 76).
Mortality rates have been reported as high as or higher than 70% when P. aeruginosa or
Acinetobacter spp. are the causative agents (74, 76-78). About 11% of nosocomial
urinary tract infections (UTIs) are caused by P. aeruginosa (72, 73). A higher incidence
of infection is associated with the use of urinary catheters, P. aeruginosa being the
second most commonly identified pathogen in catheter-associated UTIs (73, 79).
P. aeruginosa is also a leading cause of nosocomial infections in burn units
primarily colonizing burn wounds but also responsible for pneumonia, bacteremia and
UTIs in that setting (80-84). On admission, generally S. aureus and coagulase-negative
staphylococci predominate the wounds of burn patients but the incidence of P.
aeruginosa quickly increases during the first week of admission and continues to rise
with time, often surpassing the incidence of other microorganisms (82, 85, 86). Burn
wound infections with P. aeruginosa are especially worrisome since they are correlated
with bacteremia, a high rate of sepsis and mortality (81, 82, 87, 88). Other nosocomial
infections caused by P. aeruginosa include endocarditis, meningitis, bacteremia,
gastrointestinal and surgical site infections (72, 73, 89).

1.2.4

P. aeruginosa in immunocompromised patients
P. aeruginosa is an opportunistic human pathogen that readily exploits any

deficiency in the host immune system to mount an infection. Since it is often intractable
and resistant to a wide range of antibiotics, it represents a very serious problem not only
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for critically ill individuals, such as those in the hospital setting and ICUs, but also for
immunocompromised patients. P. aeruginosa has often been isolated as one of the most
common pathogens causing septicemia in patients with primary immunodeficiencies (90,
91). A number of other conditions can predispose the host to P. aeruginosa bacteremia
including taking broad spectrum antibiotics, receiving chemotherapy, as well as being an
HIV, leukemia, cancer, diabetes, bone marrow or organ transplant patient (92-99).
Although P. aeruginosa bacteremia has been reported in patients with AIDS (100,
101), a number of studies agree that pathogens other than P. aeruginosa are the most
common cause of bacteremia in that population (95, 102). P. aeruginosa however, is one
of the leading causes of pneumonia in HIV patients (103-106) and a common respiratory
pathogen in patients with AIDS, where pulmonary and respiratory disease infections are
often chronic and intractable (107-111).
Before 1968, P. aeruginosa bacteremia in cancer patients resulted in ∼80-90%
fatalities (112-115). The development of more potent antipseudomonal drugs has greatly
improved outcomes and survival rates in these patients, provided that the bacteremia is
treated rapidly, with studies from the 1980s and 2000s showing a 60 and 80% cure rate,
respectively (92, 98, 116, 117). Although prognosis has improved, the incidence of P.
aeruginosa infections in cancer patients for the decade of the ‘90s was found to range
from 5-12% (118), while in a report from 2008, carbapenem-resistant P. aeruginosa
infections were documented in 20% of the cancer patients (119). A recent study found
that P. aeruginosa was the leading causative agent of bloodstream infections (42%) and
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pneumonia in patients with solid tumors, with 22% incidence of bloodstream infections
in patients with haematological malignancies (120).

1.2.5

P. aeruginosa and cystic fibrosis
P. aeruginosa is the most common and clinically relevant pathogen found in

patients with CF (121-123). It is estimated that over 80% of CF patients will be infected
with this bacterium by the time they reach adulthood (122). Infection of the airways with
P. aeruginosa, and the inflammation that follows, represent a major problem for CF
patients as the lungs steadily deteriorate auguring very poor overall prognosis and high
mortality rates (124-126). As of 2012, the life expectancy for a patient with CF in the
United States was around 37.8 years (122).
CF is an autosomal, recessive genetic disease affecting about 30,000 people in the
US and about 70,000 worldwide (122). This disease mainly affects Caucasian
populations of European descent and is caused by mutations in the cystic fibrosis
transmembrane conductance regulator (CFTR) gene located in the long arm of
chromosome VII (127-129). The CFTR protein is a cAMP-regulated chloride channel
found on the apical surface of various epithelial cells and responsible for the transport of
chloride ions into and out of the cell (130-136). Additionally, the CFTR protein is known
to regulate other membrane conductance channels including the outwardly rectifying
chloride channel (137-139) and the epithelial sodium channel, ENaC (140-143).
More than 1800 CFTR mutations have been reported so far, the majority being
rare and not yet well understood (122, 144). Most mutations can be grouped into one of
six classes according to the level of disruption or impairment of CFTR function (Figure
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1.2). Classes I, II and III are associated with a more severe form of the disease including
pancreatic insufficiency and defective pulmonary function (145-147). Patients with class
IV, V and VI mutations, on the other hand, generally exhibit a milder presentation and
have a functional pancreas (146, 148, 149). The most common mutation, a class II
mutation present in 86.7% of the CF patients worldwide, is a deletion in phenylalanine at
position 508 (ΔF508) resulting in misfolding of the protein and subsequent degradation
by proteasomes (122, 147).

CFTR

CFTR

x
Class IV

x

Class VI
Accelerated
turnover

Class III
Cl¯

Golgi
complex

Class II

Proteosome

Endoplasmic
reticulum

x

Class I

Class V
Nucleus

Figure 1.2. Classes of CFTR mutations. CFTR mutations can result in no CFTR protein
being expressed (class I), misfolded protein that is degraded by proteasome (class II), a
CFTR protein that does not respond to cAMP (class III), defective chloride conductance
or channel gating (class IV), a reduced number of CFTR transcripts due to a promoter or
splicing abnormality (class V) and accelerated turnover from the cell surface (class VI)
(148, 150-153). Reproduced with permission from (153), Copyright Massachusetts
Medical Society.
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There is an ongoing debate as to how CFTR mutations cause lung disease in
patients with CF but most proposed models converge on one point: the imbalance of
water and ions created by a malfunctioning CFTR protein in the apical surfaces of airway
epithelium ultimately leads to abnormal or defective mucociliary clearance (MCC) (154159). MCC is an important defense mechanism against inhaled particles, allergens,
bacteria and viruses (160-162). Normal airway epithelium is ciliated and covered with a
layer of liquid known as the airway surface liquid (ASL) (163-165). The ASL itself is
divided into a fluid layer of low viscosity known as the periciliary liquid (PCL) or sol
layer that keeps the cilia hydrated and facilitates its beating, and a more viscous upper gel
or mucus layer that is responsible for trapping foreign particles (Figure 1.3A) (164-167).
The beating of the cilia continuously propels the mucus layer with its trapped particles
upwards towards the nasopharynx and the mouth where foreign substances can be then
swallowed or expectorated (161, 166, 168, 169).
The most strongly supported and generally accepted hypothesis of pathobiology
in CF is that abnormal transport of chloride ions across epithelial membranes coupled
with the increased absorption of sodium and water through the epithelial sodium channel,
ENaC, leads to dehydration of the ASL layer (Figure 1.3B) (170-174). This hypothesis,
known as the low-volume hypothesis, states that the depletion of the airway surface
liquid reduces the volume or height of the PCL layer and increases the viscosity of the
mucus layer leading to compression and impaction of the cilia (170, 174-176). Impaction
of the cilia is thought to compromise its proper functioning and to diminish its capacity to
work in concert with the mucus layer to remove foreign particles (154, 156). The end
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result is impairment of the MCC apparatus setting up the stage for the persistent and
chronic bacterial infections that are a hallmark of airway disease in CF patients (Figure
1.4).

A

B

Figure 1.3. ASL layer and MCC in the normal and CF airways. A. Normal CFTR
function. Under normal conditions, the PCL layer is hydrated and the cilia beat normally
allowing MCC from the mucus layer. B. Abnormal or nonfunctioning CFTR leads to
dehydration and reduction in volume of the PCL layer resulting in impacted and
improperly beating cilia that hinders MCC (177). Reproduced from (177) with
permission from Elsevier.
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Figure 1.4. Pathobiology of CF lung disease. In the most widely accepted hypothesis of
pathobiology of CF lung disease, reduced airway surface liquid results in impairment of
MCC leading to successive cycles of infection and inflammation eventually resulting in
obstruction of the airways, chronic deterioration of the lungs and death. Reproduced from
(154) with permission from John Wiley and Sons.

CF, however, is a multi-organ disease not just limited to the lungs, as the CFTR
protein is expressed in the epithelium of several other organs including the pancreas,
sweat ducts, intestine, biliary tree and the vas deferens (178-184). For example, in the
intestine it can lead to meconium illium, a condition where the first stool of the newborn
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is impacted in the intestine (182, 185). Additionally, more than 95% of men with CF are
usually infertile (186-188). Lung disease, however, remains one of the main concerns for
patients with CF as continuous cycles of infection and inflammation herald gradual lung
deterioration and eventual pulmonary failure (Figure 1.4).
The conditions present in CF airways, namely dehydrated, thick mucus coupled
with impaired mucociliary clearance, provide the ideal environment that is conducive to
colonization by a number of pathogens (123, 189). S. aureus, for example, often the first
to colonize the respiratory tract of CF patients, is common in children less than 10 years
old, and responsible for infant morbidity and mortality in the preantibiotic era (Figure
1.5) (122, 123). Haemophilus influenzae is another common pathogen and is
predominantly found in young children (123, 189). Other less common pathogens such as
Stenotrophomonas maltophilia (previously Xanthomonas maltophilia), Alcaligenes
xylosoxidans and Burkholderia cepacia complex, have also been isolated from the
respiratory tract of CF patients, the latter having the poorest prognosis, although found in
less than 10% of patients (122). A recent study examined the microbiome of sputum from
CF patients and found that although the patients were not being treated for fungal
infections, many (18/19) did carry pathogenic fugal species of Aspergillus, Candida,
Cryptococcus and Exophiala, among others (190). Fungal infections are in fact not
uncommon in CF patients and can occur in association with other microorganisms (190193). P. aeruginosa, however, remains the main pathogen associated with morbidity and
mortality in CF patients and is more frequently found in adults (Figure 1.5) (122, 124,
126, 194).
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Figure 1.5. Pathogens found on the CF lungs by age. From an early age, CF patients are
infected with a number of different organisms. By the time they reach adulthood, P.
aeruginosa is the predominant pathogen (122).

An important feature of P. aeruginosa infections, is the tendency of this
bacterium to convert to a mucoid phenotype in the lungs of CF patients, an event which
signals the beginning of chronic stage of the infection leading to a progressive decline in
lung function (195-197). This mucoid phenotype is characterized by the production of
large quantities of alginate, a polysaccharide also known as mucoid exopolysaccharide,
which plays a very important role in helping the bacterium evade the host immune system
(123, 198, 199). Alginate promotes a biofilm mode of growth, which in turn not only
protects the bacteria from antimicrobial agents, but also helps the microorganisms escape
phagocytosis by macrophages (200). Alginate overproduction exacerbates the already
detrimental conditions of the CF lungs leading to further blocking of the airways and
inexorable death.
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1.2.6

Treatment
Treatment of P. aeruginosa infections varies greatly given severity of infection

and resistance profile of the organism. Current strategies include treatment with a single
drug, usually a β-lactam or an aminoglycoside, or combination therapy with at least two
different antimicrobial agents (189, 201, 202). β-lactams, include a broad class of
bactericidal agents, widely used in the clinical setting, and with minimal side effects to
eukaryotes (Figure 1.6) (203-205). Several β-lactams have shown reliable results against
P. aeruginosa, including the extended-spectrum penicillins ticarcillin and piperacillin that
can be combined with the β-lactamase inhibitors clavulanic acid and tazobactam,
respectively, to enhance the antibacterial action of the β-lactam (201, 202). The
cephalosporin ceftazidime is stable to most β-lactamases and is the drug of choice if the
isolate is determined to be susceptible (205, 206).

Figure 1.6. Molecular structures of two β-lactams of the penicillin class.
The carbapenem β-lactams can be used if the organism is resistant to extendedspectrum penicillins and cephalosporins (207, 208). Carbapenems have a wide spectrum
of activity but can select for multidrug resistant (MDR) strains of P. aeruginosa,
especially imipenem. The monobactam aztreonam, is the drug of choice if the patient is
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allergic to penicillins and other β-lactams (209, 210). It can be helpful in treating isolates
that produce metallo-β-lactamases as it is resistant to hydrolysis by class B enzymes.
Combination therapy is usually the first line of defense, particularly for MDR
pseudomonal infections (189, 201). The most commonly used combination includes the
administration of a β-lactam with an aminoglycoside. The aminoglycosides are powerful
antimicrobial agents that inhibit bacterial protein synthesis being predominantly active
against aerobic, Gram-negative bacteria (211, 212). The discovery of gentamicin in 1963
was a breakthrough in the treatment against P. aeruginosa infections, and subsequently
other more powerful aminoglycosides, such as tobramycin and amikacin, were developed
(213). Tobramycin has shown greater activity in vitro than most other aminoglycosides,
and thus it is often the drug of choice to treat P. aeruginosa infections (211). Amikacin,
however, is very effective against bacteria that are resistant to other aminoglycosides
such as gentamicin and tobramycin. Its chemical structure makes it less susceptible to the
inactivation by the enzymes that normally inactivate gentamicin and tobramycin (Figure
1.7) (211).

Tobramycin

Amikacin

Figure 1.7. Molecular structures of amikacin and tobramycin.
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Aminoglycosides, however, can often have nephrotoxic and ototoxic side effects
(214). Nephrotoxicity is usually reversible but ototoxicity, or the toxic effect on the inner
ear, is generally irreversible and can lead to hearing loss (215). Thus, aminoglycosides
should only be administered when no other antibiotic is deemed as effective, for instance
in the treatment of MDR organisms and of critically ill patients, and should be replaced
with less toxic agents as soon as the sensitivity profile of the organism is ascertained
(211). Combination therapy with aminoglycosides often includes amikacin or tobramycin
with either piperacillin, ticarcillin, ceftazidime, imipenem, meropenem or aztreonam
(189, 201).
Another option when considering therapy for P. aeruginosa infections, is the
combination of either an aminoglycoside or a β-lactam with ciprofloxacin (216, 217).
Ciprofloxacin belongs to a class of antibiotics known as fluoroquinolones (218).
Fluoroquinolones have a broad-spectrum of activity and act by preventing DNA
replication through the inhibition of the enzyme DNA gyrase (218). Ciprofloxacin has
great activity against P. aeruginosa and Gram-negatives and unlike the rest of above
antibiotics, the majority of which are for parenteral use or aerosolized, it is available for
oral administration (219, 220). It has been particularly good at treating respiratory
infections in CF patients but prolonged monotherapy can lead to resistance (219, 221224). Additionally, serious side effects, such as damage of young cartilage, tendonitis and
tendon rupture, hypoglycemia and arrhythmias, have been reported (225, 226). It is often
used in conjunction with inhaled antibiotics like the aminoglycoside tobramycin or the
polymyxin colistin (123, 227).
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Colistin was one of the first drugs to show good in vitro activity against P.
aeruginosa (228-230). It works by disrupting the structure of the outer membrane and
increasing cell permeability leading to cell lysis (231). Earlier studies however, reported
serious nephrotoxic and neurotoxic effects and thus its use was relegated to the external
treatment of eye and skin infections (232, 233). The emergence of MDR strains,
unresponsive to broad spectrum antibiotics but remaining susceptible to the drug, has
brought colistin back into the antimicrobial limelight (234, 235). Despite its earlier
reported toxicity, recent studies show its usefulness outweighs potential risks, which have
also been shown to be lower than originally reported, perhaps as a result of better dosing
strategies (236, 237). Although reported nephrotoxicity rates for intravenous use are up to
14%, in many cases a lack of better alternatives has redefined colistin as the last line of
treatment or salvage therapy (238, 239). For the treatment of respiratory infections, in
both CF and non-CF patients, colistin can be administered as an aerosol, which has the
advantage of a more direct higher dose delivery to the site of infection while limiting
toxicity (240-242). Colistin has also been shown to be effective against the inner structure
(core and stalk) of the P. aeruginosa biofilm suggesting this antimicrobial peptide can
penetrate this complex structure (243).
1.3

Mechanisms of intrinsic antibiotic resistance
P. aeruginosa can employ a number of mechanisms to evade, prevent or inhibit

the actions of antibiotics, the most common of which include restricted membrane
permeability, active efflux of antibiotics, alteration of drug targets, the formation of
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biofilm, and the expression of β-lactamases (Figure 1.8) (244-247). The following
sections will review some of these important mechanisms.

Figure 1.8. Mechanisms of antibiotic resistance in P. aeruginosa. P. aeruginosa employs
multiple mechanisms to inhibit the action of antibiotics including an intrinsically low
membrane permeability, expression of efflux pumps, modification of antimicrobial
targets and production of β-lactam-hydrolyzing enzymes. Reproduced from (248) with
permission from Elsevier.

1.3.1

Extrapermeability barrier
The cell wall of Gram-negative bacteria is composed of an inner membrane, a thin

peptidoglycan layer and outer membrane (OM) that serves as a selective permeation
barrier by restricting the passage of solutes across the membrane (Figure 1.9) (249, 250).
The OM is generally an asymmetric lipid bilayer with an inner leaflet of phospholipids
and a surface layer rich in lipopolysaccharide (LPS) (251, 252).
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Figure 1.9. Cell wall of Gram-negative bacteria. An inner phospholipid bilayer
containing mostly phosphatidylethanolamine (red lipids) with some phosphatidylglycerol
(light brown lipids) surrounds the cytoplasm of the bacterial cell. The periplasm, or the
space sandwiched between the inner and outer membranes, contains a thin peptidoglycan
layer; membrane-derived oligosaccharides (MDO) can also be present. The outer layer of
the OM is rich in LPS. Kdo, 3-deoxy-D-manno-octulosonic acid; (n) variable number of
O-antigen repeats; (PPEtn), pyrophosphoethanolamine (253).
(https://amit1b.wordpress.com/the-molecules-of-life/10-the-living-cell-gallery/)
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In order to reach their targets inside the cell, antibiotics must first cross the outer
membrane. Permeability of the OM is largely governed by the low fluidity structure of
the LPS layer and by the presence of channels or pores in the membrane known as porins
(250, 254). Generally, small, hydrophilic compounds, like β-lactams, are taken up by
porins, while lipid-mediated pathways are thought to be responsible for the uptake of
hydrophobic antibiotics like aminoglycosides and polymyxin (255-257).

1.3.1.1 LPS as a barrier and lipid-mediated uptake
LPS is one of the first barriers that solutes encounter when traversing the cell. It
is usually comprised of lipid A, the core sugars and the O antigen, and it is a very
strongly negatively charged structure (258, 259). Divalent cations such as calcium (Ca2+)
and magnesium (Mg2+) have a high affinity for LPS and help to neutralize some of these
negative charges while at the same time bridging neighboring LPS molecules (260-265).
Bridging of adjacent LPS molecules through divalent cations, as well as through
hydrogen bonding, promotes strong lateral interactions, stabilizes the structure and
creates a gel-like core of low fluidity in the lipid interior restricting the passage of solutes
and antibiotics across the membrane (266-268).
The low fluidity of the LPS structure is thought to restrict partitioning by
hydrophobic compounds and antibiotics (255, 269). Hydrophobic probes have been
shown to be excluded from the membranes of P. aeruginosa and Escherichia coli (270,
271). Similarly, P. aeruginosa and other Gram-negative bacteria intrinsically display
high MICs (minimum inhibitory concentration) against hydrophobic antibiotics such as
macrolides, novobicin, clindamycin and fusidic acid. (255, 272). Defects in efflux,
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however, have been shown to reduce the MICs of hydrophobic antibiotics. The intrinsic
resistance to hydrophobic antibiotics thus, is determined not only by the normal structure
of LPS but also by the ability of some of these compounds to be effluxed. LPS is
generally considered effective at slowing down the passage of hydrophobic antibiotics
and permeation rates through the outer membrane have been found to be 50-100 times
slower than through a simple lipid bilayer (273).
The structure of LPS, however, can be compromised by the presence of
polycationic compounds (274-276). Polycations, having sometimes a higher affinity for
LPS than divalent cations, can readily displace them from their regular binding sites in
the LPS, leading to disruptions in the membrane barrier and increasing permeability of
the outer membrane (271, 275). Specifically, the bulkiness of the polycations is thought
to create transient cracks in the structure of the LPS, thus allowing uptake of other
compounds such as hydrophobic antibiotics and of the polycations themselves in a
process known as self-promoted uptake. Examples of antibiotics that promote their own
entry into the cell by disrupting the normal structure of LPS via their cationic nature
include aminoglycosides, polymyxins, cationic detergents and polycationic peptides,
among others (256, 276-281). Permeabilization of the outer membrane with such
compounds can additionally sensitize the cells to permeation by other compounds and
antibiotics including lysozyme, β-lactams, and a number of hydrophobic antibiotics
(erythromycin, clindamycin, novobiocin, fusidic acid and cloxacillin) (274, 282-284).
Membrane permeabilizers, such as the metal chelator EDTA, have a similar effect and
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can enhance the uptake of a number of compounds and antibiotics that are not themselves
permeabilizers (285).
1.3.1.2 Porin-mediated transport
A major determinant of permeability is the presence of water-filled channels in
the outer membrane called porins. OprF is the major general porin in P. aeruginosa (286,
287). It is a non-specific channel for the passage of large substrates and has an exclusion
limit of about 3000 daltons in contrast to 600 daltons for OmpF, the general porin in E.
coli (287-289). Notwithstanding the large pore size and its abundance in the outer
membrane, OprF is considered a slow porin because of its slow rate of diffusion and low
permeability (289, 290). A study showed that the rate of arabinose influx was 50 times
slower through the P. aeruginosa OprF than through the E. coli OmpF channel (291). In
general, the rate of solute diffusion across the outer membrane of P. aeruginosa has been
at least two orders of magnitude lower than that of E. coli (287, 292).
The slow rate diffusion has been attributed to the conformation of the OprF
channel in P. aeruginosa. Various studies suggest that OprF can exist in two different
conformations, open or closed, and that only a minority of the channels are ever open,
thus accounting for the decreased permeability as compared to E. coli (291, 293-295).
While having the majority of channels closed may seem arbitrary, the periplasmic Cterminus of the closed conformer is predicted to interact with the peptidoglycan layer as a
way to stabilize the structure of the cell envelope (296-299). Thus, the closed conformer
of OprF appears to play a major structural role in P. aeruginosa besides that of
permeability, its absence leading to abnormal cell morphology and destabilization of the
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outer membrane (300, 301). However, even with only about 5% of the channels open at
any one time, OprF is still a major determinant of permeability in P. aeruginosa (293,
302).
Another porin affecting permeability and β-lactam resistance is the substratespecific porin OprD. OprD is specific for basic amino acids, dipeptides and carbapenems
(imipenem, meropenem, doripenem) (20, 21, 23, 34). In the clinical setting, exposure to
imipenem often leads to mutations, deletions or insertions in oprD and loss of the protein
resulting in impermeability and clinical resistance to imipenem (29-33, 38). Although
loss of OprD also increases the MIC against meropenem, it does not by itself usually lead
to clinical resistance (303-305), presumably because meropenem can also get inside the
cells via other routes (306-308). Additionally, both meropenem and doripenem are
subject to efflux by the MexAB system while imipenem is not (309-312). Thus, clinical
resistance to imipenem can happen with just the loss of OprD (313-315), while both
absence of OprD and upregulation of the MexAB pump are needed for meropenem and
doripenem resistance to occur (304, 309-311, 316).
As previously mentioned, OprD also mediates the uptake of basic amino acids
and peptides that structurally resemble carbapenems (Figure 1.10) (21, 23). The
positively charged residues at C2 of imipenem closely resemble a number of basic amino
acids such as histidine, lysine, arginine and ornithine that not surprisingly have been
shown inhibit imipenem transport through OprD (317). Small peptides containing lysine
have also been shown to inhibit transport, while addition of basic amino acids to different
media increased the resistance of different P. aeruginosa strains against carbapenems
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(22, 23, 36). Such finding could be of concern in the clinical setting as the empirically
demonstrated MIC might not reflect the real MIC in the blood or serum where the
presence of basic amino acids may reduce the efficacy of carbapenem treatment.
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Figure 1.10. Molecular structures of the β-lactam imipenem and of the amino acids Llysine and L-arginine.
Many other specific and gated porins, for uptake of a myriad of substrates
including iron and carbohydrates, exist in the outer membrane of P. aeruginosa (318). As
they have not been associated with resistance, they will not be further discussed here.
The porins involved in efflux are examined below.

1.3.2

Efflux pumps
Efflux pumps are ubiquitous in nature and have been recognized in both

prokaryotic and eukaryotic cells (319). They are membrane-bound pumps that transport a
variety of solutes such as dyes, antibiotics and toxic compounds to the outside of the cell
by using the energy of ATP hydrolysis or the energy derived from transmembrane
electrochemical gradients, such as the proton motive force (320, 321). Efflux pumps can
be substrate specific or they can transport a variety of structurally different compounds,
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including different classes of antibiotics (319). Pumps that are able to export a wide
range of antibiotics are often associated with multidrug resistance (319). Effluxdetermined resistance can be caused by an increase in expression of efflux proteins, often
as a result of mutations in efflux regulatory genes, or by mutations that enhance the
export capabilities of the pump itself (320).
Five different classes of efflux pumps have been described in bacteria: the major
facilitator superfamily (MFS), the small multidrug resistance (SMR) family, the
multidrug and toxic compound extrusion (MATE) family, the ATP-binding cassette
(ABC) family, and the resistance nodulation-division (RND) family (Figure 1.11). RND
efflux pumps are of particular interest in Gram-negative bacteria where they play a
crucial role in intrinsic and acquired resistance in synergy with the outer membrane
barrier (246, 322, 323). They are responsible for the export of a variety of substrates such
as toxic substances, dyes, detergents, antibiotics, as well as substances produced by the
host such as bile, hormones and antimicrobial peptides (324-328). RND pumps typically
have a tripartite arrangement comprised of an inner membrane transporter, a periplasmic
adaptor protein and an outer membrane channel that driven by the proton motive force,
work in concert to transport solutes across two membranes towards the extracellular
space (329, 330). Capture of solutes from the periplasm has also been reported in both E.
coli and P. aeruginosa (331-333).
Twelve RND efflux pumps have now been described in P. aeruginosa: MexABOprM (317, 334, 335), MexCD-OprJ (336, 337), MexEF-OprN (338), MexGHI-OpmD
(339, 340), MexJK (341), MexMN (342), MexPQ-OpmE (342), MexVW (343), MexXY
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(344, 345), TriABC-OpmH (346), MuxABC-OpmB (347) and CzrAB-OpmN (348).
Together they form a family of multidrug efflux pumps with an extensive substrate range
that

includes

aminoglycosides,

fluoroquinolones,

β-lactams,

tetracycline,

chloramphenicol and macrolides, among others (Table 1.1).

Figure 1.11. Family of efflux pumps found in bacteria and their substrates. Reproduced
from (319) with permission by the American Society for Microbiology.
RND efflux-encoding genes are organized into operons frequently in association
with an immediately upstream located transcriptional regulatory gene (320, 322, 349).
The first gene of the RND operon (mexA, mexC, mexE, and mexX) generally encodes a
membrane fusion protein connected to the cytoplasmic membrane and expanding through
the periplasm. The second gene (mexB, mexD, mexF, and mexY) encodes an inner
membrane transporter that moves the substrate across the cytoplasmic membrane into the
periplasm. An additional gene may be present in some operons (oprM, oprJ, and oprN).
This third gene encodes an OM protein that allows passage of substrates across the outer
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membrane into the extracellular space. Operons that do not code for the outer membrane
protein themselves, may instead use the OM protein from another pump. For instance, the
mexXY, mexJK, mexMN, and mexVW operons, lacking an OM-encoding gene, use the
OprM protein of the MexAB system as an outer membrane channel, MexJK can
additionally use OpmH (349).

Table 1.1: Substrate profile of RND efflux pumps described in P. aeruginosa (312, 323).
Efflux pump
Substrates
Fluoroquinolones, tetracycline, chloramphenicol, β-lactams
(except imipenem), β-lactamase inhibitors, novobiocin,
MexAB-OprM
macrolides, trimethoprim, tigecycline, triclosan, sulfonamides,
ethidium bromide, SDS, aromatic hydrocarbons,
thiolactomycin, cerulenin, acylated homoserine lactones
Fluoroquinolones, tetracycline, chloramphenicol, β-lactams
(except imipenem), novobiocin, macrolides, trimethoprim,
MexCD-OprJ
triclosan, ethidium bromide, SDS, aromatic hydrocarbons,
crystal violet
Fluoroquinolones, chloramphenicol, trimethoprim, aromatic
MexEF-OprN
hydrocarbons, triclosan
MexGHI-OpmD
Norfloxacin, vanadium
MexJK
Tetracycline, erythromycin, triclosan
MexMN
Chloramphenicol, thiamphenicol
MexPQ-OpmE
Fluoroquinolones, tetracycline, chloramphenicol, macrolides
Fluoroquinolones, tetracycline, chloramphenicol,
MexVW
erythromycin, ethidium bromide, acriflavine
Fluoroquinolones, aminoglycosides, tetracycline,
MexXY
erythromycin macrolides, chloramphenicol several β-lactams,
not imipenem,
TriABC-OpmH

Triclosan

MuxABC-OpmB

Aztreonam, macrolides, novobiocin, tetracycline

CzrAB-OpmN

Cadmium, zinc

30

MexAB-OprM is the major contributor of efflux-mediated intrinsic resistance in
P. aeruginosa (350). Although constitutively expressed, the MexAB-OprM pump
mediates resistance to varied antimicrobial agents having the widest substrate range of all
known RND P. aeruginosa pumps (317, 335). Recently, Yang et al. studied the promoter
activity of all 12 RND pumps found in P. aeruginosa (351). In agreement with previous
reports, mexAB-oprM had the highest activity in all conditions tested. mexJK, mexVW,
mexXY and muxABC-opmB were also constitutively expressed, but at much lower levels
than mexAB. Still lower, but detectable activity was observed for mexGHI-opmD,
mexPQ-opmE and mexMN, with no activity detected for the rest of the pumps.
These promoter expression studies are in agreement with previous reports that
show most pumps are either silent or constitutively expressed and that their contribution
to innate resistance is null (322, 350). In particular, disruptions of mexCD-oprJ and
mexEF-oprN were not previously shown to affect susceptibility, suggesting these two
pumps do not contribute to intrinsic resistance (338, 352). The MexXY system, on the
other hand, is thought to contribute to the intrinsic resistance of P. aeruginosa against
tetracycline, erythromycin, and gentamicin, as deletion of mexXY increases susceptibility
against these antibiotics (353). Not surprisingly, these compounds, but not other MexXY
substrates, were shown to induce expression of mexXY.
Although most pumps are silent or only weakly expressed, and likely not playing
a role in innate resistance, their contribution should not be discounted as it is often
mutations in their regulatory genes or regions (known and unknown), that lead to
overexpression and multidrug resistance. For instance, MexCD-OprJ is silent in wild-type
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but hyperexpression and variable levels of resistance have been attributed to in vitro and
in vivo mutations in its repressor-encoding gene, nfxB (336, 354). Such mutations have
also been reported in the regulatory genes for mexEF-OprN and mexJK, as well as for the
operons already providing intrinsic resistance, mexAB-oprM and mexXY (322, 349). Thus
collectively, the RND efflux pumps are a major determinant of efflux-mediated resistance
in P. aeruginosa.

1.3.3

Alteration and modification of penicillin-binding proteins
The peptidoglycan layer of Gram-negative bacteria consists of alternating

subunits of N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc), where
MurNAc bears a stem peptide often consisting of L-alanine, D-glutamic acid, L-lysine or
meso-diaminopimelic acid (meso-DAP), and D-alanyl-D-alanine (Figure 1.12) (355-358).
Cross-linking of the glycan chains, or transpeptidation, is carried out by essential proteins
known as penicillin-binding proteins, PBPs, and generally occurs between the third
amino acid (DAP) of a stem peptide and the fourth (D-Ala) of the next peptide chain
(Figure 1.12) (359). PBPs additionally catalyze other reactions in the later stages of
peptidoglycan synthesis and remodeling including polymerization of the nascent glycan
strand (transglycosylation), removal of the last D-alanine of the stem peptide
(carboxypeptidation), and hydrolysis of the peptide bond that connects the two strands
(endopeptidation) (360).
PBPs are generally classified as high molecular mass (HMM) and low molecular
mas (LMM) enzymes and are further subdivided into classes A and B (360-362). A class
C also exists for LMM PBPs. HMM class A PBPs are bifunctional with an N-terminal
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glycosyltransferase domain and a C-terminal transpeptidase domain, while class B
enzymes are only transpeptidases (Table 1.2). LMM class A and B PBPs are
carboxypeptidases, and class C can be carboxypeptidases and/or endopeptidases.

N-acetylmuramic acid
(MurNAc)

N-acetylglucosamine
(GlcNAc)

Direct cross-link

L-Ala
D-Glu
meso-dap or L-Lys
D-Ala
D-Ala

Figure 1.12. Structure of peptidoglycan. In Gram-negative bacteria the peptidoglycan
layer is made up of alternating subunits of MurNAc and GlcNAc. A 4-5 amino acid stem
peptide is attached to the GlcNAc subunits. Direct cross-linking can occur between the
fourth D-Ala of one PG molecule and the third meso-DAP residue of the next.

Table 1.2: Classification of penicillin-binding proteins
Category

Subclasses

High
Molecular
Mass

A

glycosyltransferase and transpeptidase

B

transpeptidase

A

carboxypeptidase

B

carboxypeptidase

C

carboxypeptidase/endopeptidase

Low
Molecular
Mass

In vivo function

Adapted from references (362) and (363).
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HMM PBPs are essential for survival whilst LMM enzymes are not. All PBPs,
however, have D-alanyl-D-alanine-peptidase (DD-peptidase) activity in their respective
DD-transpeptidase, DD-carboxypeptidase or DD-endopeptidase domains (360, 364). Not
surprisingly, this DD-peptidase domain is subject to inhibition by β-lactam antibiotics as
β-lactams resemble the natural substrates of PBPs, namely D-alanyl-D-alanine (Figure
1.13). This is in fact the role of β-lactam antibiotics, to target and inhibit PBPs.
β-lactams covalently bind the active site of PBPs and form long-lived acylenzyme complexes effectively acting as suicide inhibitors of the enzymes (362, 365).
Binding and inhibition of PBPs by β-lactams prevents the final crosslinking step of the
new peptidoglycan layer, thus disrupting cell wall synthesis and leading to cell death. To
successfully inhibit the action of PBPs, β-lactams rely on the specific binding to their
PBP target. PBP mutations that reduce the specific binding and lower the affinity with
which the β-lactam and its target bind, can render the drug ineffective and lead to
resistance.

Figure 1.13. Molecular structures of penicillin and D-alanyl-D-alanine (366).
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β-lactam resistance has been reported in P. aeruginosa following treatment of a
CF patient with high dosage of tobramycin and piperacillin in association with loss of/or
decreased binding to PBP3 (367). Similarly, β-lactam-resistant strains, selected in vitro
following growth on cefsulodin, did not express β-lactamase but did show reduced
affinity of PBP3 towards the two β-lactams tested, namely cefsulodin and carbenicillin
(368). Recently, a new mechanism of PBP-mediated resistance has been elucidated.
Specifically, in vitro and in vivo ampC overexpression and β-lactam resistance were
correlated to inactivation of a nonessential PBP4 in an ampD-independent manner (369,
370). It is not known how prevalent this mechanism of resistance is in the clinical setting,
but the phenotype was found to be reproducible upon deletion of PBP4.
Although modification of PBPs has also been previously reported in other Gramnegative bacteria, it is not currently considered a major cause of β-lactam resistance in
the clinical setting (365, 371). PBP-mediated resistance however, is a prevalent
mechanism in Gram-positive bacteria, particularly in Streptococcus pneumoniae,
methicillin-resistant S. aureus and the enterococci (371, 372).

1.3.4

Expression of β-lactamases
Expression of β-lactamases is one of the most efficient and common ways of

neutralizing the action of the commonly used β-lactam antibiotics (discussed in section
1.4) (373, 374). β-lactam-hydrolyzing enzymes can be chromosomal- or plasmid-encoded
and expressed constitutively or induced upon β-lactam challenge. Constitutive βlactamases are present at basal levels under normal conditions while inducible βlactamases are derepressed in the presence of antibiotics but maintained at low levels in
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their absence (375, 376). Synthesis of chromosomally encoded β-lactamases has been
found to be inducible in bacterial species having a specific transcriptional regulatory
system (375, 377, 378). In contrast, synthesis of chromosomally encoded β-lactamases is
constitutive in bacterial species lacking such regulatory systems. Derepression of the
chromosomally encoded β-lactamase AmpC is considered the most common mechanism
of β-lactam resistance in P. aeruginosa (379-382). The classes, mode of action and
genetics of β-lactamases will be discussed in section 1.5.

1.4

β-lactams
β-lactams are the most widely used class of antibiotics (204, 245, 383). They

contain a signature β-lactam ring composed of one nitrogen and three carbons that is
highly susceptible to hydrolysis by β-lactamases (Figure 1.14) (206). The major classes
of β-lactam antibiotics include penicillins, cephalosporins, carbapenems, monobactams,
and β-lactamase inhibitors (Figure 1.15).

β-lactam ring

β-lactamase

Penicillin

Penicilloic acid

Figure 1.14. Action of β-lactamases on the β-lactam ring. β-lactamases inactivate βlactam antibiotics by hydrolyzing the C-N bond present in the signature β-lactam ring.
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Figure 1.15. β-lactam classes. The major classes of β-lactams, penicillins,
cephalosporins, carbapenems, monobactams, and β-lactamase inhibitors, differ in the ring
structure fused to the four-membered signature β-lactam ring. Derivatives of each class
differ in the substituent at the R groups. Adapted from (248).

Penicillin has the distinction of being the first antibiotic discovered. In 1928 the
bacteriologist Alexander Fleming noticed that growth of the mold Penicillium notatum
lysed nearby growing Staphylococcus cells (384). Growth of a number of other
microorganisms including Pneumococcus, Gonococcus, Streptococcus pyogenes and
Streptococcus viridans were also inhibited by what Fleming concluded was an
antibacterial agent that was being produced by the fungus. He aptly named this
compound penicillin. Subsequent attempts to purify it were relatively unsuccessful, but in
1940 Chain et al. succeeded in purifying penicillin and in using it as a therapeutic agent
to treat mice infected with streptococci and staphylococci (385). In 1941, results from the
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first small clinical trial showing low toxicity and high efficacy were published (386). The
chemical structure of penicillin was finally elucidated by X-ray crystallography in 1945,
although the work was not published until 1949 (387).
A naturally occurring penicillin-like compound, termed cephalosporin C, was
later reported by Newton and Abraham (388-390). This compound was isolated from the
fungus Cephalosporium, now named Acremonium, and also possessed antibacterial
properties but contained a six-membered ring fused to the β-lactam structure, instead of
the five-atom structure normally seen for penicillins (Figure 1.15). The real breakthrough
came, however, with the discovery and synthesis of compounds containing only the βlactam nucleus without a side chain, namely 6-aminopenicillanic acid (6-APA) and 7aminocephalosporanic acid (7-ACA) (Figure 1.16) (391-393). It was possible to
chemically modify these compounds to produce new and improved antibiotics with
unusual side chains (394-399). Chemical additions or modifications of the side chains
allowed the development of a vast number of semi-synthetic penicillins and
cephalosporins with broad and extended-spectrum activity (Tables 1.3 and 1.4) (400403).

6-aminopenicillanic acid

7-aminocephalosporanic acid

Figure 1.16. Molecular structures of 6-aminopenicillanic acid and 7aminocephalosporanic acid. The 6-APA and 7-ACA compounds are useful structures
containing only the β-lactam nucleus without a side chain. The current semi-synthetic
penicillins and cephalosporins are derivatives of 6-APA and 7-ACA, where side chains
have been added and modified.
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Table 1.3: β-lactam antibiotics. I. Penicillins
Subclasses

Representatives

Natural Penicillins

Penicillin G
Penicillin V

Representative Structure

Penicillin G
Narrow
Spectrum
Penicillinaseresistant penicillins

Methicillin
Isoxozolyl penicillins
(oxacillin, cloxacillin,
dicloxacillin)
Oxacillin

Aminopenicillins

Ampicillin
Amoxicillin
Amoxicillin

Carboxypenicillins
Extended
Spectrum

Carbenicillin
Ticarcillin

Ticarcillin

Ureidopenicillins

Piperacillin
Azlocillin
Mezlocillin

Piperacillin
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Table 1.4: β-lactam antibiotics. II. Cephalosporins
Generations

1st

Representatives

Representative Structure

Cefazolin
Cefadroxil
Cefaloridine
Cefalotin
Cefalotin

2nd

Cefaclor
Cephamycins
(Cefoxitin
Cefotetan)
Cefoxitin

3rd

Cefotaxime
Cefsulodin
Ceftriaxone
Ceftazidime
Cefoperazone
Ceftazidime

4th

Cefepime
Cefpirome

Cefepime

5th

Ceftobiprole
Ceftaroline
Ceftobiprole
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A third class of β-lactams, termed carbapenems, were first discovered in species
of the genus Streptomyces (404). This genus is the source of a plethora of other natural
antibacterial compounds including tetracycline, chloramphenicol, aminoglycosides, and
cephalosporin C derivatives, among others (405-409). Specifically, thienamycin, the first
carbapenem, was discovered in the species Streptomyces cattleya which also produces
cephamycin C and penicillin N (404). Thienamycin was shown to be a very potent, broad
spectrum antimicrobial, generally resistant to degradation by β-lactamases. However, it
was also very unstable. Semisynthetic, stable alternatives of thienamycin have been
developed and include those approved for use in the US (imipenem, meropenem,
ertapenem, doripenem) (Figure 1.17), and in Japan (panipenem, biapenem, and
tebipenem) (207).

6
7

5
4

1

2
3

Meropenem

Imipenem

Doripenem

Figure 1.17. Structure of antipseudomonal carbapenems approved for used in the US.
Although very similar in structure to penicillins, position 1 of carbapenems has a carbon
atom instead of sulfur; the structure is also unsaturated at carbons 2 and 3.
Monobactam antibiotics are also known as monocyclic β-lactams since they do
not possess a ring fused to the β-lactam nucleus as seen for penicillins, cephalosporins
and carbapenems (Figure 1.15). The first monobactam discovered was nocardicin A,
produced by the bacterium Nocardia uniformis subsp. tsuyamanensis (410). Several other
natural monocyclic β-lactams have been identified in various other bacterial species
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including Pseudomonas acidophila, Agrobacterium radiobacter, Gluconobacter and
Acetobacter (411-414), the simplest of structures being produced by Chromobacterium
violaceum (413). Development of semi-synthetic alternatives was undertaken as naturally
occurring monobactams were shown to be very poor antimicrobials (415, 416). Currently,
aztreonam, a synthetic derivative based on the monobactam nucleus, is the only
monocyclic β-lactam approved for clinical use (Figure 1.18) (209, 210).

Figure 1.18. Structure of aztreonam, a monocyclic monobactam.

Aztreonam can be used to treat patients with allergies to penicillins and
cephalosporins and is considered a safer alternative to aminoglycosides as this β-lactam
does not cause ototoxic or nephrotoxic side effects (210). It is active against aerobic
Gram-negative bacteria including P. aeruginosa and most of the Enterobacteriaceae, but
it does not possess activity against Gram-positives or anaerobic Gram-negatives (417,
418). It is stable to most plasmid- and chromosomal-mediated β-lactamases of classes A
and D, and to all class B enzymes. Aztreonam, however, can be hydrolyzed by the class
A Klebsiella pneumoniae carbapenemases (KPCs) (419, 420). Additionally, it does not
induce expression of the chromosomal cephalosporinases from Citrobacter freundii,
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Enterobacter cloacae, Serratia spp. and P. aeruginosa but can serve as a powerful
competitive inhibitor of these enzymes as it is only slowly hydrolyzed by them (421424). Not surprisingly, it has been shown to enhance the antibacterial action of the βlactam cefepime by protecting it from degradation by the P. aeruginosa cephalosporinase
(425).
A final, important category of β-lactams are the β-lactamase inhibitors. Three are
currently commercially available: clavulanic acid from Streptomyces clavuligerus; and
sulbactam and tazobactam, semi-synthetic penicillin derivatives carrying sulfur dioxide at
position 1 (Figure 1.15) (426-428). Structurally they are very similar to conventional βlactams, having also a five-membered ring fused to the core β-lactam nucleus. Unlike
regular β-lactams, however, β-lactamase inhibitors have only weak antibacterial action
(423, 428). Nonetheless, they are good inhibitors of class A β-lactamases for which they
display high affinity, but generally they are poor inhibitors of the class B, C or D
enzymes (429-432).
Clavulanic acid, sulbactam and tazobactam are suicide inhibitors that irreversibly
inactivate the β-lactamases (423, 428). Since their main role is inhibitory and not
bactericidal, β-lactamase inhibitors must be co-administered with β-lactams to achieve
the desired antibacterial effect. A good inhibitor thus is one that can competitively bind
the enzyme, having a higher affinity for it than that of the co-administered β-lactam, so as
to provide protection to the antibiotic against destruction by the β-lactamase. The
currently approved β-lactam-inhibitor combinations are amoxicillin-clavulanic acid,
ticarcillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam (428). Studies
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have shown however, that none of these inhibitors adequately inhibit the chromosomal
cephalosporinase of P. aeruginosa and are thus deemed ineffective in the treatment of
AmpC-expressing isolates (433-435).

1.4.1

Mechanism of action of β-lactams
As described in section 1.3.4, β-lactams act by inhibiting the synthesis of the

peptidoglycan layer, a structure that is important for maintaining cell wall integrity and
stability (245). Early studies showed that radio-labeled penicillin covalently binds
enzymes that are involved in cell wall synthesis; hence these enzymes were named
penicillin-binding proteins (PBPs) (371). PBPs are found in almost all bacteria, but they
usually vary amongst species in their affinity for β-lactam antibiotics, number and size
(361).
There are about two to four essential PBPs in any given organism and their
inhibition can lead to cell lysis, death or growth arrest (361, 371). One of the most
important enzymatic activities associated with PBPs is the final transpeptidation step in
the synthesis of the peptidoglycan layer. The binding and inhibition of the PBPs by the βlactam antibiotics prevents the final crosslinking step of the new peptidoglycan layer,
thus disrupting cell wall synthesis (361, 371). It has been proposed that the structural and
conformational similarities between penicillins and the D-alanyl-D-alanine part of the
peptidoglycan (Figure 1.13) facilitates the binding of the β-lactam antibiotics to the active
site of the PBPs. Seven PBPs have been reported in the bacterium P. aeruginosa using
the techniques of polyacrylamide gel electrophoresis, but the number could be higher as
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evidenced by the sequencing of the parent strain, PA01, which yielded nine PBPs (361,
436).
1.5

β-lactamases
β-lactamases (EC 3.5.2.6), as defined by the Nomenclature Committee of the

International Union of Biochemistry and Molecular Biology, are a diverse group of
enzymes that specifically target and hydrolyze the C—N bond of the four-atom ring
found in β-lactam antibiotics (Figures 1.14 and 1.15). The first enzyme with penicillinase
activity was detected in E. coli by Abraham and Chain in 1940, before the actual
introduction of penicillin in the clinical setting (437). The widespread use of penicillin in
the 1940s saw the emergence of penicillin-resistant staphylococci and S. aureus strains
carrying penicillinase (438-441). Staphylococcal penicillinase-mediated resistance
became prevalent and of great concern through the 1950s (439, 442-445) until the advent
of semi-synthetic and more effective β-lactams in the 1960s led to the emergence and
spread of β-lactamases, especially of the plasmid-encoded types, in Gram-negatives (446449). Although β-lactamases can be found in a number of Gram-positive pathogens,
namely the staphylococci and Bacillus spp., these enzymes are more prevalent and
widespread in Gram-negative organisms where they remain a major determinant of βlactam resistance (373, 374, 450, 451). More than 850 β-lactamases have now been
identified.

A

comprehensive

list

can

be

found

at

the

Lahey

Clinic

(http://www.lahey.org/Studies/). Four main classes, A, B, C and D, are commonly
recognized based on amino acid homology (452, 453).
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1.5.1

Mechanism of action
Class A, C and D β-lactamases use a serine ester mechanism to disrupt the β-

lactam ring. Specifically, the β-lactam ring is attacked by the free hydroxyl of the serine
at the active site of the β-lactamase (Figure 1.19) (454, 455). The attack opens up the ring
producing a covalent acyl enzyme complex. Hydrolysis of the complex regenerates the
free, active enzyme and produces a hydrolyzed and inactive β-lactam. Class B enzymes,
on the other hand, usually have one or two zinc ions in the active site, which are
absolutely required for enzyme activity, hence they are known as metallo-β-lactamases
(MLBs) (456, 457). A zinc ion can recruit and activate a hydroxide to attack the carbonyl
carbon of the β-lactam ring leading to cleavage of the C–N bond and sometimes
protonation of the nitrogen (456).

Figure 1.19. Mechanism of action of serine β-lactamases. The β-lactamase first
associates with the β-lactam to form a non-covalent complex. A free hydroxyl from the
side chain of the active serine residue then attacks the β-lactam ring forming a covalent
acyl ester. The acyl-enzyme complex then undergoes hydrolysis to produce an inactive βlactam. Reproduced from (373) with permission by the American Society for
Microbiology.
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1.5.2

Classification
One of the first classification schemes for β-lactamases was proposed by Jack and

Richmond in 1970 with further updating in 1973 by Richmond and Sykes (458, 459).
This classification grouped β-lactamases according to the spectrum of activity, inhibitor
susceptibility, and the location of the gene coding for the enzyme (459). A major revision
was proposed by Bush in 1989 (460) that was later expanded by Bush and colleagues in
1995 (461). This scheme was based on functional similarities and took into account
inhibitor and substrate profiles (461).
The classification proposed by Bush recognized four major groups of βlactamases with multiple subgroups (460, 461). Group 1 are the cephalosporinases that
are poorly inhibited by clavulanic acid (462). Group 2 include the penicillinases,
cephalosporinases and broad-spectrum β-lactamases that are generally inhibited by βlactamase inhibitors (462, 463). Group 3 comprises the MLBs that can hydrolyze
carbapenems, penicillins and cephalosporins (463). Group 4 contains penicillinases not
inhibited by clavulanic acid (463).
Phenotypic classifications such as the one proposed by Bush and colleagues can
be faulty since point mutations can change the substrate and inhibitor profile for a given
enzyme (464). A classification scheme was thus proposed by Ambler based on amino
acid similarities rather than phenotypic characteristics (452). The Ambler scheme is
widely used today and, as previously mentioned, distinguishes four main classes of βlactamases: A, B, C, and D.
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1.5.2.1 Molecular class A
Class A enzymes are among the most common β-lactamases encountered in the
clinical setting and in the Enterobacteriaceae (373, 465). They are known as
penicillinases since they are mostly active against penicillin and penicillin-derived βlactams, but extended-spectrum class A β-lactamases with activity against cephalosporins
and carbapenems have also been reported (449, 461, 466). Most are well inhibited by the
commercially available β-lactamase inhibitors clavulanic acid, tazobactam, and
sulbactam (461, 467). The Class A β-lactamase-encoding genes are widely distributed in
bacteria and are generally plasmid-borne but have also been reported in the chromosomes
and integrons of Gram-negative bacteria (448, 468-472).
Common representatives include the TEM, SHV, PER and the TEM-, SHV-, and
PER-derived β-lactamases (Table 1.5). TEM-1, the first plasmid-encoded β-lactamase,
was reported in Greece in 1965 (473). It was originally identified in an E. coli isolate
from a patient named Temoneira (473). TEM-1 is currently one of the most commonly
reported β-lactamases in Gram-negatives being predominantly found in E. coli and in K.
pneumoniae but also identified in H. influenza and Neisseria gonorrhoeae (373, 446,
474). TEM-2, a less frequently reported point variant of TEM-1, has a more active
promoter than its progenitor, a different isoelectric point but the same hydrolytic profile
(475, 476).
A common group of class A enzymes are the SHV-type β-lactamases, named
after sulfhydryl variable, since it was thought that the inhibition of this enzyme by pchloromercuribenzoate varied according to the substrate used (477). The earliest
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representative of this group, SHV-1 is predominately found in K. pneumonia but plasmid
dissemination has occurred to other enterobacterial species including E. coli and Proteus
mirabilis (477-480). SHV enzymes are very structurally and functionally similar to TEM
enzymes, SHV-1 sharing as high as 68% of its amino acid sequence with TEM-1 (478,
481). TEM and SHV enzymes provide resistance against penicillins such as amoxicillin,
ampicillin, tircarcillin and carbenicillin and the narrow-spectrum cephalosporins (478).
Most class A extended-spectrum β-lactamases (ESBLs) are TEM-1, TEM-2- and SHV-1derived enzymes that differ from their precursors in as few as 1-4 amino acids (466, 482,
483). These point mutations increase the hydrolysis spectrum of the enzymes to include
extended-spectrum cephalosporins and monobactams (478).
Table 1.5: β-lactamase Ambler classification
Molecular class

Representatives

A

TEM, SHV, CTX-M, KPC, IMI, SME, GES, PER, VEB

B

IMP, VIM, SPM, GIM, SIM, NDM

C

AmpC, CMY, MIR, MOX, LAT, FOX, DHA, CFE, ACT

D

OXAs (OXA-10, OXA-23, OXA-40, OXA-48, OXA-50)

Another important group of class A β-lactamases are the CTX-M-types ESBLs.
These enzymes were first identified as non-TEM and non-SHV type ESBLs, exhibiting
only about 40% similarity with TEM- and SHV-types, and having distinct hydrolytic
activity against cefotaxime (484-487). They can occur in association with other TEM,
SHV and OXA enzymes and are frequently carried on transmissible plasmids that can
also carry blaTEM-1 (488-491). CTX-M-type enzymes are widely distributed among
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members of the Enterobacteriaceae family including E. coli, P. mirabilis, C. freundii, S.
marcescens, Salmonella, Klebsiella and Enterobacter spp., but have also been reported in
other non-enterobacterial species such as Vibrio spp. and Aeromonas hydrophila (485,
492-503).
Unlike the TEM- and SHV-derived ESBLs that arose by point mutations of their
precursors, the CTX-M enzymes appear to be the result of plasmid transfer from naturally
occurring chromosomal enzymes in the Kluyvera genus (504-506). Many CTX-M
enzymes have been reported to be identical or near identical to the CTX-M-like enzymes
KLUA and KLUC of the Kluyvera spp. (504, 505, 507), with others like KLUG-1 sharing
85-86% similarity with the CTX-M-1 enzymes (506). Additionally, the genetic regions
surrounding the acquired CTX-M enzymes have been shown to be 80-100% identical to
regions surrounding the corresponding β-lactamase-encoding gene in the Kluyvera
chromosome (504, 507-509). ISEcp1 or ISEcp1-like insertion sequences have been
detected upstream of many CTX-M-plasmid-encoded enzymes (490, 500, 504, 510, 511),
while some CTX-M enzyme are encoded in the class I integrons InS21, In35 and In60
(508-510, 512) further strengthening the case for horizontal gene transfer from the
Kluyvera chromosome.
A fourth relevant group of class A β-lactamases are the non-metallocarbapenemases. The chromosomally encoded representatives of this group include the
imipenem-hydrolyzing β-lactamase (IMI) and the non-metallo-carbapenemase (NMC-A)
described in E. cloacae (513-515), as well as the SME-types isolated from S. marcescens
(516-518). The spectrum of hydrolysis of these enzymes includes not only the
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carbapenems, but also penicillins, narrow-spectrum cephalosporins and aztreonam (519,
520). These chromosomally encoded non-metallo-carbapenemases however, do not
generally pose as much a threat as the TEM, SHV and CTX-M ESBLs, as they are only
infrequently reported.
Plasmid-borne representatives of class A non-metallo-carbapenemases include the
Klebsiella pneumoniae carbapenemase (KPC) and the Guiana extended spectrum (GES)
family of enzymes. The first KPC was detected in a K. pneumoniae isolate from North
Carolina in 1996 (521). KPCs remained relatively rare until the early 2000s when they
reemerged in the East Coast of the United States (522-525) causing multiple nosocomial
outbreaks in the New York area, sometimes through clonal spread (526-529).
Subsequently KPCs have been isolated in several European and South American
countries (530-538) as well as in Israel, China and Taiwan (539-541). The blaKPC genes
are usually carried on the plasmid-borne transposon, Tn4401, which undoubtedly
contributes to the ease of dissemination observed (521, 524, 532, 542, 543). Thus,
although most frequently observed in K. pneumoniae (544, 545), KPCs have also been
isolated from P. aeruginosa, E. coli, C. freundii, S. marcescens, as well as from
Salmonella and Enterobacter spp. (520, 522, 546, 547).
Similar to the TEM, SHV and CTX-M ESBLs, the KPC enzymes can hydrolyze
penicillins and cephalosporins (520). Unlike the ESBLs, however, KPCs can also
hydrolyze carbapenems to varying degrees (548). As carbapenems are often the first line
of defense against microorganisms that express ESBLs, the emergence of carbapenemresistant organisms, that are already resistant to penicillins and cephalosporins, severely
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limits treatment options. The dissemination of KPCs is thus of great concern. Hydrolysis
of carbapenems by KPCs, however, does not always lead to resistance, in some cases it
can mean a decrease in susceptibility, with intermediate to high level resistance also
being observed (523, 525).
GSE-1 was first reported in a K. pneumonia isolate from French Guiana (470).
Currently 15 GSE enzymes are recognized, five of which display carbapenemase activity,
albeit at low levels (520, 549). In every other sense they are typical ESBLs able to
hydrolyze penicillins and extended-spectrum cephalosporins (519, 520). The GSE
enzymes have been mostly identified in P. aeruginosa but have also been reported in
some enterobacterial species (469, 550-552). Although GSE β-lactamases are relatively
rare, nosocomial outbreaks have been reported in Korea, Portugal and South Africa (550,
553, 554).
Most of the class A enzymes, including the extended-spectrum PER- and VEBtypes, have been reported in P. aeruginosa (482, 549). Class B and D enzymes (discussed
below), however, are more prevalent in P. aeruginosa, whereas the class A enzymes are
widely distributed in the Enterobacteriaceae (448, 477, 555, 556).
1.5.2.2 Molecular class B
Class B or metallo-β-lactamases (MLBs) are often described as being a class apart
since unlike their serine counterparts they require Zn+2 in their active site in order to
hydrolyze β-lactams (456, 457). They have a broad hydrolysis spectrum that includes the
carbapenems and most often also penicillins and cephalosporins (456, 461, 463). MLBs
are resistant to inhibition by the commercially available serine β-lactamase inhibitors and
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are unable to hydrolyze the monobactam aztreonam (456, 557). The requirement for zinc
means they are sensitive to inhibition by EDTA, a known metal chelator (457, 461).
They are often carried on plasmid-borne transposons and integrons, but can also be
chromosomally encoded.
Chromosomally encoded MLBs are mostly found on environmental and
sometimes opportunistic pathogenic bacteria that are rarely a cause for concern, with the
notable exceptions of Bacillus anthracis and Stenotrophomonas maltophilia (457).
Chromosomal MLBs include CphA from A. hydrophila (558), BCII from B. cereus (559),
Bla2 from B. anthracis (560), SFH-1 from Serratia fonticola (561), FEZ-1 from
Legionella gormanii (562), TUS-1 and MUS-1 from Myroides spp. (563), and L1 from S.
maltophilia (564), among others. Frequently the MLBs are coproduced with
penicillinases and cephalosporinases and are induced upon β-lactam challenge. For
example,

A.

hydrophila

coordinately

expresses

two

β-lactamases,

CepH

(cephalosporinase) and AmpH (oxacillinase) in addition to the MLB CphA, also named
ImiH (565, 566). Coproduction of various β-lactamases is also observed in several other
Aeromonas species such as A. veronii, A. jandaei, A. caviae, and A. salmonicida (566568). Similarly, S. maltophilia produces two chromosomally encoded and inducible
enzymes, L1, a metallo-β-lactamase, and L2, a class A cephalosporinase (569-572).
The first occurrence of transferable imipenem resistance was reported in a P.
aeruginosa isolate from Japan (573). The identified enzyme, IMP-1, was encoded in a
conjugative plasmid that could be mobilized into other Pseudomonas strains. IMP-1 was
later identified in several S. marcescens strains from general hospitals in the nearby cities
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of Anjyo and Okazaki from the Aichi prefecture in Japan (574-576). An IMP-type
enzyme was also detected by DNA hybridization in fifteen P. aeruginosa clinical isolates
from three different geographical areas in Japan (577). DNA fingerprinting showed that,
for the most part, the strains were heterogeneous, while the blaIMP gene displayed little to
no variation, thus illustrating a plasmid-mediated proliferation that was not clonal in
nature (577). Further studies have shown that the IMP-1 enzyme and variants have
proliferated in Japan in the Enterobacteriaceae, including S. marcescens, E. coli, C.
freundii, K. pneumoniae, Enterobacter spp., as well as in non-enterobacterial species
such as P. aeruginosa, Pseudomonas putida, Achromobacter xylosoxidans and
Alcaligenes spp. (578-583).
PCR analysis of 42 strains carrying the blaIMP gene detected class 3 integron
sequences in 79% of them (579). A larger Japanese study involving 357 blaIMP-1-positive
strains that included P. aeruginosa, identified class I integron sequences in 99% of them
(580). Association of blaIMP with mobile genetic elements has likely facilitated the
dissemination of the enzyme in Japan. The IMP family of enzymes has also been reported
worldwide in places like Portugal (584), Italy (585), Canada (586), China (587, 588),
Australia (589, 590), England (591) and Korea (592, 593), among others. The current
data however, suggest that these are local occurrences rather than dissemination from the
alleles in Japan. Indeed, phylogenetic trees place IMP-1 in one of the later evolving
branches of the dendrogram (457, 594).
A second and also prevalent class of MLBs is the integron-borne VIM-type. The
first reported representative of this group, VIM-1 (Verona integron-encoded metallo-β-
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lactamase) was detected in Italy in 1997 in a P. aeruginosa β-lactam-resistant isolate
(595). Expression of the enzyme in a heterologous background conferred high level
resistance against penicillins (ampicillin, carbenicillin, piperacillin and mezlocillin) and
cephalosporins (cefoxitin, ceftazidime, cefoperazone and cefepime), while decreasing
susceptibility to the carbapenems (595). VIM-1 was found to be only distantly related to
other MLBs, sharing only 31% identity with IMP-1 (595). The blaVIM-1 gene was located
in the chromosome and encoded as part of a gene cassette carried in a class 1 integron,
which itself carried another gene cassette (aacA4) for aminoglycoside resistance (595).
Not surprisingly, a blaVIM-1 gene was subsequently reported in a plasmid from an A.
xylosoxidans isolate from the same hospital (596). A VIM-type enzyme, exhibiting a 90%
amino acid similarity with VIM-1, was reported in France in a P. aeruginosa isolate in a
nonconjugative plasmid (597). The variant, termed VIM-2, has since been found
throughout Europe and the rest of the world, and is often reported as the most detected of
acquired MLBs (598-604). A number of other VIM variants have also been reported
throughout the world and in a number of bacterial species including E. coli, K.
pneumoniae, E. cloacae, S. marcescens, C. freundii, Acinetobacter baumannii, P. putida
and P. aeruginosa; the latter being the most common host for these enzymes (457, 549).
Other noteworthy MLBs include SPM-1 (for Sao Paulo MLB), GIM-1 (for
German imipenemase) and SIM-1 (for Seoul imipenemase). SPM-1 was first detected in
1997 in a P. aeruginosa clinical isolate from Brazil (605). It was encoded in a plasmid,
but unlike the IMP and VIM enzymes that are regularly associated with class 1 integrons,
SPM-1 was associated with a novel transposable-like element with probable recombinase
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activity (606). Thereafter, P. aeruginosa SPM-1-producing strains have become prevalent
in Brazil and isolated from both clinical and environmental sources (607-610). To date,
SPM-1 has only been reported outside of Brazil in A. baumannii isolates from various
hospitals in Iran (611), and in a P. aeruginosa isolate from a Swiss man who had been
previously treated in a Brazilian hospital (612).
GIM-1 was first reported in five multidrug-resistant P. aeruginosa isolates from a
hospital in Dusseldorf, Germany (613). Subsequent reports identified more GIM-1producing P. aeruginosa isolates in hospitals within a 40 km radius from the location of
the original report (614). Although so far GIM-1 has not been reported outside of
Germany, it has however, spread to a number of enterobacterial species including
Acinetobacter pittii, E. cloacae, Klebsiella oxytoca, S. marcescens, E. coli, and C.
freundii (615-618).
SIM-1 was first detected in the chromosome of Acinetobacter clinical isolates
from Korea (619). Later, blaSIM-1 was also detected in two Acinetobacter (genomospecies
10) isolates that additionally carried blaIMP-1 or blaVIM-2 (620). To date, SIM-1 has not
been detected outside of Korea, except for an Acinetobacter baylyi clinical isolate
reported in China that additionally harbored OXA-23 in a large 360-kb plasmid (621).
Similar to the IMP and VIM enzymes, both GIM-1 and SIM-1, are carried in class I
integrons (613, 619). Although both SPM-1 and GIM-1 have been detected in P.
aeruginosa, the IMP- and VIM-types are the most commonly detected MLBs in this
pathogen and in the Acinetobacter spp. (549, 622).
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1.5.2.3 Molecular class C
Class C enzymes or AmpC β-lactamases are generally chromosomally encoded
but have also been reported in plasmids (623, 624). They can hydrolyze penicillins and
cephalosporins including the cephamycins (cefoxitin and cefotetan) and the oxyiminocephalosporins (cefotaxime, ceftriaxone, and ceftazidime), as well as the monobactam
aztreonam (625, 626). The increased rate of hydrolysis observed against some
cephalosporins as compared to penicillins, particularly the first generation cephalosporins
cefazolin, cephaloridine, cephalothin and cephalexin, has given rise to their common
designation of cephalosporinases (625). Although able to slowly hydrolyze some of the
later generation cephalosporins, such as cefotaxime and cefoxitin, these enzymes often
display high affinity for these substrates as evidenced by low Km values (625, 627). The
penicillins cloxacillin, oxacillin and carbenicillin act as transient inhibitors able to
efficiently form acyl-enzyme complexes but usually being very poorly hydrolyzed by the
class C enzymes (626). Additionally, the class A inhibitors are generally not good
inhibitors of the cephalosporinases, although tazobactam and sulbactam have been shown
to inhibit some class C enzymes (429, 430, 432).
Chromosomal class C enzymes are ubiquitous in Gram-negative bacteria and very
frequently encountered in the Proteobacteria including the Aeromonadales (Aeromonas
spp.) and the Pseudomonadales (A. baumannii, P. fluorescens and P. aeruginosa) (623).
They are particularly well represented in members of the Enterobacteriales, including
some commonly encountered species and pathogens such as C. freundii, E. aerogenes, E.
cloacae, E. coli, Morganella morganii, Providencia stuartii, S. marcescens, Shigella spp.
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and Yersinia enterocolitica, among others (555, 623). Some well-known members of the
Enterobacteria group such as K. pneumoniae, K. oxytoca, P. mirabilis, Salmonella spp.
and Yersinia pestis (623), however, do not carry a chromosomal class C enzyme,
although this does not preclude the possibility of carrying plasmid-borne AmpC.
In many of the species carrying a chromosomal ampC, including P. aeruginosa,
C. freundii and E. cloacae, ampC expression is constitutively low but induced upon βlactam challenge (377, 628). Induction is tightly controlled by the transcriptional
regulator AmpR and intricately linked to the recycling of the peptidoglycan layer (375).
On the other hand, in E. coli and Shigella spp. ampC does not respond to induction by βlactams and is only produced at very low levels (629, 630). Consequently the natural
AmpC expression in such backgrounds does not lead to resistance. The marginal levels of
AmpC β-lactamase observed in such species stem from the genetic environment
surrounding the structural β-lactamase gene. In species with an inducible system (e.g.,
AmpC of P. aeruginosa), ampR is frequently located upstream of ampC and divergently
transcribed; while species with a non-inducible system lack ampR and have a very weak
promoter (378, 631, 632). Additionally, an attenuator is located between the promoter
and the β-lactamase-encoding gene leading to the premature termination of the majority
of transcripts (633). Derepression and hyperproduction in species having a non-inducible
system, i.e., lacking ampR, can occur but often require mutations in the promoter and
attenuator regions and/or the combined effect of different mutation types in order to
provide any meaningful β-lactam resistance (634-638). Although such mutations have
been reported in both E. coli and in Shigella spp. (634, 639, 640), they are rarer than
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those leading to constitutive hyperexpression in species with an inducible system (376,
630). Mutational derepression or stable derepression of ampC, as it is also known,
however, has been reported as one of the most common mechanisms of β-lactam
resistance in species that have an inducible AmpC system such as P. aeruginosa, C.
freundii, E. cloacae, M. morganii, P. stuartii, Enterobacter and Serratia spp. (380, 446,
465, 641-645). The genetics of inducible class C β-lactamases will be covered in section
1.5.3.
Although chromosomal ampC-types are the predominant class C enzymes in
Gram-negative bacteria, dissemination into plasmids began to emerge in the late 1980s
and continued to spread worldwide (646-649). They are predominantly found in species
not usually known to possess chromosomal ampC, such as K. pneumoniae, K. oxytoca
and Salmonella spp., but have also been reported in E. coli (624, 649). Representatives
include MIR-1, MOX-1, LAT-1, FOX-1, ACT-1 and the CMY-types first reported in K.
pneumonia, as well as CFE-1 and DHA-1 first identified in E. coli and Salmonella
enteritidis, respectively (Table 1.5) (624, 649, 650). The original chromosomal enzymes
of Proteobacteria described above are the likely progenitors of these plasmid-borne
enzymes (649). For instance, CMY-2 and the closely related types LAT-1 and CFE-1,
appeared to have originated from the AmpC of C. freundii sharing 96, 95 and 99% amino
acid sequence with that enzyme, respectively (647, 651, 652). CMY-1-types, including
MOX-1, were originally thought to have descended from P. aeruginosa, but have since
been shown to be more closely related to the chromosomal enzymes of the Aeromonas
(646, 650, 653). The genetic support is usually an integron-based plasmid that often
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carries other resistance genes such as those coding for aminoglycoside and quinolone
resistance, or even other β-lactamase-encoding genes such as blaTEM-1, blaCTX-M-3 and
blaVIM-1 (649, 654-658). The hydrolysis spectrum remains the same as that of their
chromosomal-encoded counterparts (623, 649).
Although plasmid-encoded AmpC enzymes have been reported worldwide, they
are not as prevalent in the clinical setting as the ESBLs. They are most commonly
reported in K. pneumoniae isolates from patients that have had long hospital stays or
prolonged

care

at

the

ICU,

where

urinary

indwelling

catheters

and

an

immunocompromised system are predisposing factors (650, 659-662). Plasmid-encoded
AmpC enzymes have not so far been described in P. aeruginosa (549).
1.5.2.4 Molecular class D
Transferable drug resistance among Gram-negative bacteria started being reported
and characterized in the early 1960s (663-665). The agents mediating resistance were
dubbed resistance or R factors and later shown to be extrachromosomal pieces of DNA,
termed plasmids (666). Datta and Kontomichalou recognized two distinct penicillinaseencoding R-factors, RTEM and R1818, on the basis of substrate profile (473). The enzyme
from R1818, later renamed R46 (667), was able to hydrolyze methicillin and cloxacillin
more efficiently than the penicillinase from RTEM, which displayed only slight activity
against these substrates (473). Additionally the R1818 penicillinase was able to hydrolyze
cloxacillin almost as fast as it could hydrolyze penicillin (473). Later work showed that
the penicillinase from R1818 also hydrolyzed oxacillin faster than benzylpenicillin (668672). Other studies characterized several more R factors mediating expression of β-
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lactamases that resemble that of R1818 in the rapid hydrolysis of oxacillin and cloxacillin
(670, 671, 673).
Two different classes of oxacillin-hydrolyzing enzymes were then distinguished
on the basis of molecular weight and substrate profile (674). One group was characterized
by having low molecular weight (∼24,000) and high hydrolysis rate against methicillin,
while the other had high molecular weight (∼40,000) but relatively low hydrolysis of the
same compound. The lowest rate of hydrolysis, however, was around 40-fold higher than
that previously observed for the original TEM enzyme against methicillin (473).
Isoelectric focusing further divided the oxacillinases into three main subclasses that were
designated as OXA-1, OXA-2 and OXA-3 to reflect their preference for the isoxazolyl
penicillins such as oxacillin and cloxacillin (475).
The first oxacillinases described, particularly OXA-1 (675, 676), OXA-2 (447,
669, 677) and OXA-3 (671, 678, 679) from plasmids RGN238, R46, and R57b,
respectively, were characterized by their ability to degrade isoxazolyl penicillins and by
their sensitivity to inhibition by NaCl (674). As more OXAs were reported and
characterized, it became apparent that these were a diverse group of enzymes with a
heterogeneous substrate profile that in some instances did not include the oxacillin-type
β-lactams

(680).

More

than

350

oxacillinases

are

now

recognized

(http://www.lahey.org/studies/webt.asp) and they can be broadly divided into the narrowspectrum, extended-spectrum and the carbapenem-hydrolyzing types (680).
The plasmid-mediated narrow-spectrum OXA enzymes include the originally
characterized oxacillinases in E. coli (OXA-1), S. typhimurium (OXA-2), and K.
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pneumoniae (OXA-3), as well as a few others also first described in E. coli (OXA-4,
OXA-7), K. pneumoniae (OXA-9, OXA-47), A. baumannii (OXA-37) and P. aeruginosa
(OXA-5, OXA-6, OXA-10, OXA-20, LCR-1) (680). Generally they can hydrolyze
penicillins and sometimes early generation cephalosporins but not extended-spectrum
cephalosporins. The hydrolysis spectrum however, can vary greatly from enzyme to
enzyme. For instance, OXA-1 can generally hydrolyze amino- and ureidopenicillins,
narrow-spectrum cephalosporins (681), as well as the broad-spectrum cephalosporins
(675, 681), albeit weakly; whereas the P. aeruginosa OXA-5 can only hydrolyze
penicillins and cephalothin (682). Similarly the P. aeruginosa OXA-10, originally
categorized as a P. aeruginosa specific enzyme (PSE-2), hydrolyses carbenicillin and
oxacillin, as well as aztreonam and some of later generation cephalosporins like
cefotaxime and ceftriaxone, albeit slowly (683). The P. aeruginosa LCR-1 only
hydrolyzes penicillins including oxacillin (684).
The extended-spectrum class D enzymes are mostly point mutation variants of the
narrow-spectrum OXA-2 and OXA-10 enzymes (680, 685). These mutations extend the
hydrolysis spectrum to include the extended-spectrum cephalosporins. OXA-11, the first
reported OXA-10 variant, was identified in a P. aeruginosa isolate taken from the
bloodstream of a Turkish patient (686). It was carried on a plasmid and had two amino
acid substitutions (Asn146Ser and Gly167Asp). Several other OXA-10 variants,
including OXA-14 (687), OXA-16 (688), OXA-17 (689), and OXA-19 (690) were also
identified in P. aeruginosa isolates from both Turkey and France. Up to nine
substitutions were observed per variant (OXA-19, OXA-28, OXA-145, OXA-147), with
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OXA-14 having only one point mutation (http://www.lahey.org/Studies/). The
Gly167Asp substitution appears to be the common thread among the variants that are
very resistant to ceftazidime.
Unlike the OXA-10 ESBLs, the majority of which have more than one point
mutation, the seven currently known OXA-2 variants have each only one substitution.
OXA-15 (691) and OXA-36 have both a substitution at aspartate 149, to glycine and
tyrosine respectively (685, 691). Both OXA-10 and OXA-2 ESBLs are carried in
plasmid-borne class 1 integrons in association with aminoglycoside resistance cassettes
(680). ES-OXAs are not widely distributed and have been mostly reported in P.
aeruginosa (549).
A very important class of oxacillinases is comprised of the carbapenemhydrolyzing β-lactamases (CHDLs). The majority has been identified in plasmids from
the nosocomial and opportunistic pathogen A. baumannii, not usually in association with
integrons (622, 692). CHDLs can significantly hydrolyze carbapenems often leading to
decreased susceptibility or resistance towards meropenem and imipenem (685, 693).
They are also able to hydrolyze most penicillins and provide high-level resistance to the
aminopenicillins (ampicillin, amoxicillin) and the carboxypenicillins (ticarcillin) with
variable hydrolysis against the ureidopenicillins (piperacillin). CHDLs, however, do not
generally significantly hydrolyze cephalosporins or provide any meaningful resistance
against these compounds (519, 693). The notable exception is OXA-146 which
hydrolyses ceftazidime (694).
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OXA-23, the first OXA carbapenem-hydrolyzing β-lactamase identified, was
recovered from an A. baumannii isolate taken from a patient in Scotland (695). It was a
plasmid-borne enzyme that showed very weak relation to other β-lactamases. Nineteen
different variants have so far been reported for the OXA-23 group, the OXA-23 allele,
however, remains the most common of this group with a widespread prevalence (685,
693). The OXA-51 group, currently consisting of 95 variants, is naturally present in the
chromosome of A. baumannii (696, 697). These enzymes are not thought to play a major
role in the intrinsic resistance as their expression is unregulated and uninducible. The
blaOXA-51 gene however, has sometimes been reported in association with the upstreamlocated ISAba1 or ISAb9 (698-700). The promoters carried within these insertion
sequences have been shown to drive expression of blaOXA-51 in carbapenem-resistant
isolates (698-700).
Other important CHDLs include the OXA-40, OXA-48, OXA-58 and OXA-143
groups (701-703). Although most display low level of carbapenem hydrolysis, they have
often been reported in carbapenem- or multidrug-resistant strains, whereby their
transformation into E. coli or susceptible A. baumannii confers decreased susceptibility
or carbapenem resistance (703-707). CHDLs are predominant and widespread in A.
baumannii but relatively rare in P. aeruginosa (549, 685, 692, 693, 708, 709).

1.5.3

Genetics of inducible class C β-lactamases
The inducible expression of AmpC β-lactamase in the Enterobacteriaceae and in

P. aeruginosa is regulated by AmpR, a LysR-type transcriptional regulator (710-712).
The induction of ampC, however, also involves the interplay of several other amp genes
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and is coordinately linked to the recycling of the peptidoglycan layer (375, 713, 714). In
the Enterobacteriaceae model, ampG encodes a transmembrane protein that serves as a
permease for passage of the inducer (1,6-anhydromurapeptides) that results from
remodeling of the peptidoglycan layer during normal cell growth (715, 716). AmpG
transports 1,6-anhydromurapeptides into the cytoplasm where the amidase AmpD
hydrolyses them for murein recycling (717). It has been proposed that during normal
physiological growth, the muramyl peptides processed by AmpD maintain AmpR in an
inactive conformation that is unable to induce the expression of ampC (716, 718, 719).
In the presence of β-lactams, however, there is an excessive breakdown of murein
leading to an accumulation of 1,6-anhydromurapeptides in the periplasm and in the
cytoplasm (718, 720). Under these conditions, AmpD cannot keep up with the increased
concentration of 1,6-anhydromurapeptides in the cytoplasm. The high number of
muramyl peptides can then induce a conformational change in AmpR to promote the high
level expression of ampC (716, 721). AmpD can thus function as a negative regulator of
ampC expression in the absence of β-lactams. In fact, mutational inactivation of ampD,
in both Enterobacteriaceae and P. aeruginosa, leads to constitutive over-expression of
AmpC and consequently increased β-lactam resistance (722, 723). Recent work by Juan
and colleagues reveals that three ampD homologs in P. aeruginosa are responsible for a
stepwise ampC up-regulation mechanism that ultimately leads to constitutive
hyperexpression of this β-lactamase (643). Details of this intricate mechanism are further
discussed in Chapter 4.
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1.5.4

Genetics of class D β-lactamases
Oxacillinase-encoding genes have been reported in a multitude of bacterial

species including P. aeruginosa. Most of these and other β-lactamase-encoding genes
appear to be unregulated, with insertion sequences often providing strong promoters for
high-level expression of such genes (471, 698, 700, 724-728). To date, the only known
regulatory systems of chromosomal-encoded class D β-lactamases are that of Ralstonia
pickettii and Aeromonas spp. (567, 729, 730).
R. pickettii carries two inducible chromosomally encoded β-lactamases, OXA-22
and OXA-60, exhibiting a narrow-spectrum of hydrolysis that includes the penicillins
(731, 732). Induction requires the presence of the divergently transcribed ORF rp3 found
190 bp upstream of the OXA-60-encoding gene (730, 733). Imipenem was found to
increase the mRNA levels of blaOXA-22 and blaOXA-60 as well as that of rp3, suggesting
regulation by Rp3 occurs at the transcriptional level (733). Rp3 is thought to function as
an activator as a recombinant Rp3 was shown to bind tandem repeats upstream of both
OXA-encoding genes and to protect regions of ∼30 bps there (733). RP3 was not similar
to any known regulatory proteins. No significant similarities were found with P.
aeruginosa proteins either.
Aeromonas spp. can produce two–three inducible and unlinked β-lactamases (552,
696-698). For instance, Aeromonas jandaei AER 14, formerly known as Aeromonas
sobria AER 14, produces three chromosomally encoded β-lactamases, AsbA1 a class C
cephalosporinase, AsbB1 (OXA-12) an oxacillinase, and AsbM1, a metallo-β-lactamase
(734-736). Aeromonas veronii bv. sobria similarly produces a penicillinase (AmpS), a
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cephalosporinase (CepS) and metallo-β-lactamase (ImiS) (737, 738), with the homologs,
AmpH, CepH, and ImiH, also identified in A. hydrophila (565, 739).
The expression of all β-lactamases in A. hydrophila is coordinately regulated by a
two-component system (TCS), encoded by blrA and blrB, and located immediately
upstream of ampH, the oxacillinase-encoding gene (729). PCR analysis confirmed the
presence of the blrAB operon in other species of the Aeromonas genera, including A.
jandaei and A. veronii bv. sobria, where the TCS-encoding genes are also linked to the
blaOXA gene (729). Regulation by a TCS thus appears to be a common and effective
mechanism of coordinate β-lactamase expression in Aeromonas spp.

1.5.5

The pox operon
Previous work showed that ampC mutations do not completely abolish β-

lactamase activity in the P. aeruginosa PA01 strain (740). Furthermore, the susceptibility
profile of an ampC-deficient strain did not show an increase in sensitivity towards the
three β-lactam representatives tested, benzyl-penicillin, meropenem and cefotaxime, as
compared to the wild-type PA01 (740). In view of these results, the presence of a second
chromosomally encoded β-lactamase in P. aeruginosa was postulated. In silico analysis
revealed that ORF PA5514 encoded a putative β-lactamase with a signal peptide
sequence at the N-terminus. The presence of a signal peptide is consistent with what is
known about β-lactamases since they are localized to the periplasm and require a signal
peptide for translocation.
Analysis of the sequences around PA5514, termed poxB, revealed the presence of
an upstream ORF annotated PA5513, named poxA, 49 bp upstream. In the absence of
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promoter-like sequences in the intergenic region between PA5513 and PA5514, it was
proposed that poxA and poxB form a two-gene operon (Figure 1.20). PoxA displayed
high sequence similarity to hypothetical hydrolases and acyltransferases of yet unknown
function. The presence of transmembrane spanning domains, as suggested by its
hydrophobicity plot, and the absence of any signal sequence, indicate PoxA likely
localizes to the inner membrane.
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Figure 1.20. Restriction map of the pox operon.
PoxB, on the other hand, shows high sequence identity to class D β-lactamases
from A. baumannii and Fusobacterium nucleatum (740). Alignment of the PoxB
sequence with 26 conserved residues in class D β-lactamases revealed that 21 of the 26
amino acids were identical. Differences in four of the remaining five amino acids place
PoxB in a new branch of a dendogram (740). PoxB, thus appears to be a new kind of
oxacillinase, markedly different from other OXA enzymes (740).
Expression studies conducted in E. coli, where there is a naturally low basal level
of β-lactamase expression, confirmed the role of PoxB as a β-lactamase. Specifically,
Girlich et al. showed that introduction of poxB in an E. coli background yields βlactamase activity (741). Previous work in our lab also showed that both the poxB gene
and the poxAB operon are capable of producing high basal levels of β-lactamase activity
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in E. coli (740). The goal of this dissertation was to characterize PoxB and the poxAB
operon and determine their contribution to β-lactam resistance in the nosocomial and
intractable pathogen P. aeruginosa.
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Chapter 2

Characterization of a carbapenem-hydrolyzing enzyme, PoxB, in
Pseudomonas aeruginosa
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2.1 Abstract
Pseudomonas aeruginosa is an opportunistic pathogen often associated with
severe and life-threatening infections that are highly impervious to treatment. This
microbe readily exhibits intrinsic and acquired resistance to varied antimicrobial drugs.
Resistance to penicillin-like compounds is commonplace and provided by the
chromosomal AmpC β-lactamase. In the present work the contribution of a second,
recently discovered, chromosomally-encoded β-lactamase, PoxB, and its relation to
AmpC, were investigated. A single deletion of ampC surprisingly did not alter
susceptibility against most of the penicillins or cephalosporins tested, however its
overexpression provided resistance and/or decreased susceptibility against these βlactams.

Carbapenem

susceptibilities,

as

evidenced

by

minimum

inhibitory

concentrations (MICs), were mostly unaffected by the lack of AmpC. PoxB expression
decreased susceptibility against the carbapenems but did not affect susceptibility against
the penicillins or cephalosporins. Additionally, PoxB was only poorly inhibited by class
A inhibitors, but a novel non-β-lactam inhibitor, termed avibactam, was a slightly better
inhibitor of PoxB activity. Clinical concentrations of avibactam, however, failed to
produce a change in MIC against the carbapenems by E-test. In addition, poxB was found
to be cotranscribed with the upstream open reading frame, poxA, which itself was shown
to encode a 32-kDalton protein of yet unknown function.
Key Words: PoxB, OXA-50, AmpC, Oxacillinase, Class D β-lactamase
Abbreviations: Congo red, CR; Coomassie brilliant blue, CB; Isopropyl β-D-1thiogalactopyranoside, IPTG; Minimum inhibitory concentration, MIC; Open reading
frame, ORF; Sodium dodecyl sulfate-polyacrylamide gel electrophoresis, SDS-PAGE
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2.2. Introduction
Pseudomonas aeruginosa is a ubiquitous and versatile opportunistic pathogen
commonly affecting immunocompromised individuals such as those with severe burns,
AIDS and cancer (89, 92, 96, 99, 109, 202). In addition, it is a significant source of
nosocomial infections and the second most common cause of ventilator-associated
pneumonia in the hospital setting (72, 73). Most notably, P. aeruginosa is the primary
pathogen associated with lung deterioration and mortality in patients with cystic fibrosis
(CF), a deadly, autosomal, recessive genetic disorder affecting about 70,000 individuals
worldwide (122, 742). Treatment often proves challenging and ineffective as the
bacterium exhibits innate and acquired resistance to a broad range of antibiotics (246,
349, 743). In particular, resistance to the frequently used β-lactam-type antibiotics is
common and mediated by the expression and derepression of the chromosomally encoded
AmpC β-lactamase (379-381, 722).
The Ambler classification scheme distinguishes four different classes of βlactamases (classes A, B, C and D) on the basis of amino acid sequences (452). All four
classes have been reported in P. aeruginosa and are often transposon or plasmid-borne
(601, 744-747). In addition to the acquired β-lactamases, P. aeruginosa strains frequently
carry the chromosomal class C β-lactamase AmpC (711, 748). Derepression of ampC has
been identified as a common cause of moderate to high-level β-lactam resistance in P.
aeruginosa clinical isolates (379, 380, 643-645, 749).
A second chromosomally-encoded β-lactamase, termed PoxB (PA5514) or OXA50, has been reported in P. aeruginosa (740, 741). PoxB belongs to the class D β-
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lactamases, also termed oxacillinases, for the ability of some members of this class,
particularly, the earlier reported ones, to degrade isoxazolyl penicillins such as oxacillin,
methicillin, and cloxacillin (671, 674, 682, 750-752). The DBL numbering system is used
to correlate homologous residues and signature sequences across class D β-lactamases
that may otherwise be located at different amino acid positions (753). Differences in
these amino acid signature sequences place PoxB in a new branch of the oxacillinase
phylogenetic tree, suggesting it is only weakly related to other oxacillinases (740, 741).
For instance, class A and D enzymes commonly have a serine-threonine-phenylalaninelysine (STFK) motif at position 70 in the DBL numbering system, where serine, the
active site residue, and lysine are conserved in serine β-lactamases and in penicillinbinding proteins (753, 754). To our knowledge, however, PoxB is only one of two
oxacillinases where the traditional STFK motif of class D β-lactamases is replaced by
STYK (serine-threonine-tyrosine-lysine) (740, 741), the other being OXA-62 from
Pandoraea pnomenusa (755-757). Thus, PoxB appears to be a new kind of oxacillinase,
markedly different from other known OXA enzymes. In addition, previous in silico
analysis suggested poxB may form a two-gene operon with the upstream open reading
frame (ORF), PA5513, termed poxA (740), which is predicted to encode a putative
hydrolase or acyltransferase of yet unknown function. The role of poxA and its relation to
poxB is yet to be determined.
In the present work we examine the role of PoxB and its contribution to β-lactam
resistance by generating single in-frame deletions of both chromosomal β-lactamaseencoding genes, namely ampC and poxB. We also study the efficacy of class A enzyme
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inhibitors and of a novel non-β-lactam inhibitor termed avibactam, against PoxB.
Additionally, the hypothesis that poxA and poxB form an operon and the role of PoxA
were investigated.

2.3 Materials and Methods

2.3.1 Bacterial strains, plasmids and media. Bacterial strains, plasmids and primers
used in this study are shown in Table 2.1. Escherichia coli and P. aeruginosa were
cultured routinely in Luria-Bertani medium (LB; 10 g tryptone, 5 g yeast extract, and 5 g
NaCl, per liter). Cation-adjusted Mueller Hinton broth (CAMHB) and agar (BBL, BD)
were used for susceptibility testing using the broth microdilution method and E-test,
respectively. T-broth (10 g Bacto tryptone and 5 g NaCl, per liter) was used for pellicle
formation and Congo red (CR) binding assays. Antibiotics were used at the following
concentrations: ampicillin (Ap) at 100 µg/ml, and gentamycin (Gm) at 15 µg/ml for E.
coli; Gm at 75 µg/ml for P. aeruginosa.

2.3.2 Construction of poxA, poxB, and oprD deletion mutants. A single in-frame
deletion of poxA (PA5513) was constructed using overlap extension PCR and
homologous recombination as previously described (758). Briefly, sequences upstream
(816 bp) and downstream (773 bp) of the target deletion were amplified using primer
pairs CApoxAUF1-CApoxAUR1 and CApoxADF2-CApoxADR2, respectively (Table
2.1). The PCR products were then ligated through another round of PCR, cloned into the
suicide vector pEXG2 (759) and moved into P. aeruginosa PA01 for homologous
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recombination with the genome. Double-cross-over recombinants were selected for by
screening for Gm sensitivity and sucrose resistance. The deletion was confirmed by PCR
amplification of deletion product from the genome and sequencing. The strain is referred
to as PA0∆poxA henceforth. In-frame deletions of poxB (PA5514) and oprD (PA0958)
were generated in a similar manner using primer pairs DBpoxBUF1-DBpoxBUR1 and
DBpoxBDF2-DBpoxBDR2;

and

DZoprDUF1-DZoprDUR1

and

DZoprDDF2-

DZoprDDR2, respectively (Table 2.1). The poxB and oprD deletions were also
introduced into a previously generated ampC deletion strain (PA0∆ampC) (760) to create
PA0∆ampC∆poxB, PA0∆ampC∆oprD and PA0∆ampC∆poxB∆oprD.

Table 2.1: Bacterial strains and plasmids used in this study
Strains/Plasmids

Reference/
Source

Relevant phenotype and genotype

Escherichia coli
DH5α

F- Φ80lacZΔM15 Δ(lacZYA-argF)U169 deoR
-

+

New England
--

recA1 endA1 hsdR17 (rk mk ) phoA supE44 λ

Biolabs

thi-1 gyrA96 relA1
TOP10

F- mcrA Δ(mrr-hsdRMS-mcrBC)Φ80lacZΔM15

Life

ΔlacΧ74 recA1 araD139 Δ(ara-leu)7697 galU

Technologies

galK rpsL (StrR) endA1 nupG
BL21(DE3)

F- ompT hsdSB (rB-mB-) gal dcm (DE3)

(761)

Pseudomonas aeruginosa
PA01

Wild-type

(762)
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PKM119

PA0∆poxA, PA01 containing in-frame deletion

This study

of poxA
PKM120

PA0∆poxB, PA01 containing in-frame deletion

This study

of poxB
PKM201

PA0∆ampC, PA01 containing in-frame deletion

(760)

of ampC
PKM202

PA0∆ampC∆poxB, PA01 containing in-frame

This study

deletions of ampC and poxB
PKM121

PA0∆oprD, PA01 containing in-frame deletion

This study

of oprD
PKM203

PA0∆ampC∆oprD, PA01 containing in-frame

This study

deletions of ampC and oprD
PKM204

PA0∆ampC∆poxB∆oprD, PA01 containing in-

This study

frame deletions of ampC, poxB and oprD
Plasmids
pEXG2

GmR; pMB1ori sacB

pGEM-T Easy

ApR; TA cloning vector for PCR amplicons,

(759)
Promega

pUC origin, f1 ori
pCR2.1-TOPO

ApR, KmR; TA cloning vector for PCR
amplicons, pUC origin, f1 ori lacZα

pET15bVP

ApR; pBR322 origin, oriV, expression vector,

Life
Technologies
(756)

T7 promoter, His tag coding sequence
pMMB67EH-Gm

GmR; IncQ, RSF1010, lacIq Ptac expression

(763)

vector with ampR::aacC1 insertion at DraI
pDZ427

GmR; pET15bVP carrying an 891-bp XhoI and
BamHI poxA fragment
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This study

pAmpC

GmR; pMMB67EH-Gm carrying a 1297-bp

This study

fragment containing the ampC ORF
pPoxA

GmR; pMMB67EH-Gm carrying a 946-bp

This study

fragment containing the poxA ORF
pPoxB

GmR; pMMB67EH-Gm carrying an 835-bp

This study

fragment containing the poxB ORF
Primers
DZampCF

5’-GGAATTCAACGACAAAGGACGCCAATCCTC-3’

This study

DZampCR

5’-CGGGATCCATGGCACCATCATAGCCAGGACCGG-3’

This study

DZpoxAF

5’-GGAATTCTTACACTGCGCGCCGTACGAGGA-3’

This study

DZpoxAR

5’-CGGGATCCGATTCCCCACGGAAGGAGCGTT-3’

This study

RTpoxARev1

5’-AGGAGAAGGGCACTGAAGAGGAGA-3’

This study

RTpoxAFord2

5’-GACTTTCTCCTGCCCAATCCATGA-3’

This study

RTpoxARev2

5’-CACCAACCAGAAGTTATCCACA-3’

This study

DZpoxAFord4

5’-CTCGAGATGTCGCTATCCCCCTGGTTCC-3’

This study

DZpoxARev4

5’GGATCCTCATGGATTGGGCAGGAGAAAGTC-3’

This study

DZpoxBF

5’-GGAATTCAGGATGACCCCACAGGACCGAGCCAT-3’

This study

DZpoxBR

5’-CGGGATCCCAGAGCGTCAGGGCAGTATCC-3’

This study
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CApoxAUF1

5’-GGAATTCGATCGTATTGCCGGGTCTC3’

This study

CApoxAUR1

5’-GAGCATTCTAGCTAGCTAGAACCAGGGGATAGCGACAT-3’

This study

CApoxADF2

5’-CTAGCTAGCTAGAATGCTCCCAATCCATGAACGCTCCTT-3’

This study

CApoxADR2

5’-CGGGATCCAAGCCGTAGAGCCGCTCGTT-3’

This study

DBpoxBUF1

5’-GAATTCGGATTTCGACCTCTGGCTGTG-3’

This study

DBpoxBUR1

5’-GAGCATTCTAGCTAGCTAGCAGGAGAAGGGCACTGAAGAG-3’

This study

DBpoxBDF2

5’-CTAGCTAGCTAGAATGCTCTCAAGGCTCTC-GGGATACTG-3’

This study

DBpoxBDR2

5’-CGGGATCCACTGGGTGTGGTTGGAGAAT-3’

This study

DZoprDUF1

5’-GGAATTCCAAAGCGAACATACTGACCTCTC-3’

This study

DZoprDUR1

5’-GAGCATTCTAGCTAGCTAGACTTATAGCACGCAGTGTTTCTTG-3’

This study

DZoprDDF2

5’-CTAGCTAGCTAGAATGCTCCCTATAAAGGAAGGGCGTAGGTA-3’

This study

DZoprDDR2

5’-CGGGATCCCGGTGGAAAGCAGATACTGACTGGTA-3’

This study

2.3.3 PCR amplification and cloning of poxA, poxB and ampC. The P. aeruginosa
PA01 genome was used as the template for PCR amplification of the poxA (PA5513),
poxB (PA5514) and ampC (PA4110) ORFs with primer pairs DZpoxAF-DZpoxAR,
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DZpoxBF-DZpoxBR, and DZampCF-DZampCR, respectively (Table 2.1). The amplicons
were independently cloned into pCR2.1-TOPO and sequenced. Each insert was then
moved into the EcoRI-BamHI sites of the broad-host range expression vector
pMMB67EH-Gm (763) and propagated in E. coli TOP10 or DH5α. The plasmid carrying
ampC, (pAmpC), was subsequently introduced by electroporation into PA0∆ampC∆poxB
while pPoxA was introduced into PA0∆ampC, PA0∆poxA, and PA0∆poxB. The pPoxB
plasmid was introduced into PA0∆poxA, PA0∆poxB, PA0∆ampC, PA0∆ampC∆poxB and
PA0∆ampC∆poxB∆oprD.
For protein expression in E. coli BL21(DE3), the poxA ORF was amplified using
primers DZpoxAFord4 and DZpoxARev4, cloned into the pGEM-T Easy vector
(Promega, Madison, WI) and sequenced. The 891-bp fragment was then subcloned into
the XhoI and BamHI sites of the broad host range shuttle vector pET15bVP (756) and
propagated in E. coli TOP10 (Life Technologies, Grand Island, NY). The resultant
plasmid was then introduced into E. coli BL21(DE3) (761) for expression studies.

2.3.4 Protein expression and one-dimensional gel electrophoresis. To determine if
poxA is translated, the ORF was cloned into the expression vector pET15bVP and
introduced into E. coli BL21(DE3) as described in section 2.3.3. Stationary-phase
cultures were diluted to an OD600 of 0.02 in 25 ml of LB broth and incubated with
shaking at 37°C until the culture density reached an OD600 of 0.5. Cells were then
induced with 1 mM of isopropyl β-D-1-thiogalactopyranoside (IPTG) and reincubated at
37°C. One-ml samples were taken at the time of induction and every hour for a total of
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four hours for both IPTG-induced and non-induced samples. The cells were recovered by
centrifugation, resuspended in 100 µl of 4X SDS protein sample buffer and boiled for 10
minutes. Proteins were separated on a 12% SDS-PAGE gel and stained with Coomassie
brilliant blue (CB).

2.3.5 Analysis of PA01 mRNA. To determine if poxA and poxB are cotranscribed, RNA
was extracted from wild-type P. aeruginosa PA01, using the RNeasy mini kit (Qiagen).
cDNA was synthesized with Superscript III (Invitrogen) and an (NS)5 random primer
using standard methods (764). Two sets of primers were used to amplify the intergenic
between poxA and poxB plus 24 bp corresponding to the 3’ end of poxA and 53 or 486 bp
from the 5’ end of poxB. RTpoxAFord2 and RTpoxARev1 were designed to amplify 126bp product, while amplification with RTpoxAFord2 and with RTpoxARev2 would yield
a 559-bp product. RNA samples not treated with Superscript were also tested to ensure
no carryover DNA contamination resulted from the RNA isolation procedure.

2.3.6 β-lactamase assay. The β-lactamase assay was modified from a previously
published protocol (765). Briefly, stationary-phase cultures were diluted in 25 ml of LB
broth to an OD600 of 0.02 and incubated with shaking at 37°C. At an OD600 of 0.6, cells
were induced with 50 µg/ml of benzylpenicillin, while cells containing the expression
plasmid (pPoxB) were induced with 1 mM IPTG. In both cases induction was carried out
for an hour. Ten milliliter of cells were harvested by centrifugation and resuspended in
1000 µl of 1x BugBuster solution (Novagen, EMD Millipore, Billerica, MA) containing 1
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μl of benzonase (Novagen) and 1 KU of rLysozyme (Novagen). Lysate was rotated for 20
min at room temperature before centrifuging at 4°C for 15 minutes to collect the βlactamase-containing supernatant. A 2-µl aliquot of cell lysate was added to nitrocefin
(final concentration, 100 µM) in 250 µl of assay buffer. The reaction was incubated at
37°C

for

20

minutes

and

the

hydrolysis

of

nitrocefin

was

measured

spectrophotometrically at 482 nm. Total protein concentration was determined with
Bradford on the same supernatant. The activity was expressed as nmol of nitrocefin
degraded per minute per microgram of total protein.

2.3.7 Minimum inhibitory concentration (MIC). MICs were determined by the E-test
system according to the manufacturer’s instructions (bioMérieux, Marcy l’Etoile) or by
the broth microdilution method according to standard protocols (766, 767). E-test values
were often reported as a range or as two independent values to illustrate variation seen in
biological and technical replicates.

2.3.8 Colony morphology on Tryptone Agar containing Congo red. Plates containing
1% agar, 1% tryptone, 40 µg/ml of CR and 20 µg/ml of CB were spotted with 10 µl of
0.025 OD600 cells. Plates were also supplemented with 1 mM IPTG and 10 or 20 mM
NaNO3, when appropriate. Plates were incubated at room temperature or in an anoxic
chamber for 5-7 days and pictures were taken with the Epson Perfection V550 scanner
(Long Beach, CA).
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2.3.9 Pellicle formation and cell-surface interactions.

For pellicle formation, the

strains were grown in 6 ml of T-broth at room temperature without shaking for 7 days as
previously described (768). The tubes were inspected visually for formation of mats at
the liquid-air interphase. To assess cell-cell and cell-surface interactions, cells were
grown in borosilicate glass tubes overnight (O/N) with shaking at 37°C in T-broth in the
presence and absence of 1 mM IPTG and inspected visually the next day for aggregates
on the walls of the tubes (769).

2.3.10 Congo red binding assay. The CR-binding assay was performed as previously
described with minor modifications (770). Briefly, strains were grown in 2 ml of T-broth
at 37°C without shaking for 48 hours. Cells were harvested by centrifugation, and washed
with T-broth. The pellet was resuspended in 1 ml of T-broth containing 40 µg/ml of CR
and incubated with shaking at 37°C. After 90 minutes, the cells and the bound CR were
pelleted by centrifugation. The optical density of the supernatant was determined at 495
nm and the percentage of CR left in the supernatant was calculated.

2.4 Results and Discussion
P. aeruginosa infections are commonly treated with a combination of β-lactams
and aminoglycosides. Resistance to the β-lactam antibiotics is frequently observed in the
clinical setting and is commonly due to the expression of enzymes that can hydrolyze
these compounds, namely β-lactamases (645, 743, 771-773). P. aeruginosa clinical
isolates often harbor acquired β-lactamases particularly of the oxacillinase- (class D) and
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metallo-β-lactamase IMP- and VIM-types (class B) (549, 608, 610, 614, 747, 748, 774,
775). Additionally, P. aeruginosa expresses a chromosomal cephalosporinase, AmpC,
that provides intrinsic resistance and that can be expressed at high levels in the presence
of β-lactams (711, 712, 776). A second chromosomally encoded oxacillinase-type βlactamase, PoxB, has also been reported (740, 741). The aim of this study was to examine
the role of the class D β-lactamase PoxB in P. aeruginosa PA01.

2.4.1 poxA and poxB form an operon.

Previous in silico analysis revealed the

oxacillinase-encoding gene (PA5514) to be located 49-bp downstream of a putative ORF
annotated PA5513 (Figure 2.1A). Given the close proximity between PA5513 and
PA5514, the absence of promoter like sequences in the intergenic region, and the
presence of a potential ρ-independent terminator downstream of PA5514, we previously
hypothesized that poxA and poxB form a two-gene operon (740). To determine if in fact
these two genes are cotranscribed, RNA was extracted from the prototypic P. aeruginosa
PA01, cDNA was synthesized and two sets of primers (RTpoxAFord2-RTpoxARev1 and
RTpoxAFord2-RTpoxARev2) were used to amplify the intergenic region plus small
portions of the 3’ of poxA and the 5’ of poxB (Figure 2.1A). As expected, the first set of
primers yielded a 126-bp amplicon in both genomic DNA and cDNA templates (Figure
2.1B, lanes 1 and 2), with the second set yielding a 559-bp product in the same templates
(Lanes 5 and 6). In the absence of template DNA or reverse transcriptase, no
amplification was detected for both primer sets (Lanes 3, 4, 7 and 8). This work confirms
that these two genes are cotranscribed and that they form an operon.
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Figure 2.1. The poxAB operon. (A) The pox genes and the approximate location of
primers used to show PA5513 and PA5514 form an operon. Two sets of primers were
used to amplify the intergenic region as well as the 3’ end of poxA and the 5’ start of
poxB from wild-type cDNA. Primer pair RTpoxAFord2 and RTpoxARev1, denoted as F2
and R1 respectively, were used for amplification of a 126-bp product, while
RTpoxAFord2 and RTpoxARev2, denoted F2 and R2, were used to amplify a 559-bp
region. (B) A 126-bp amplicon was detected in wild-type genomic and cDNA samples
(Lanes 1 and 2) upon amplification with F2 and R1. Similarly, a 559-bp product was
observed upon amplification with F2 and R2 in wild-type genomic and cDNA samples
(Lanes 5 and 6). No amplification could be detected with either primer set in the absence
of reverse transcriptase or template DNA (Lanes 3, 4, 7 and 8).
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2.4.2 poxA is translated into a 32.4-kDalton protein. Since our present work indicates
poxA and poxB are cotranscribed, it is also expected that poxA mRNA is translated into a
protein with a function potentially related to that of PoxB. To confirm our prediction, the
poxA ORF was amplified and cloned into the expression vector pET15bVP (756) and
expressed in E. coli BL21(DE3) (761). Whole cell extracts were obtained from cells
carrying the poxA-overexpressing plasmid in the presence and absence of IPTG. Proteins
were visualized in an SDS-PAGE gel. A protein band corresponding to PoxA was
detected at around 32 kDalton an hour after induction with IPTG and thereafter (Figure
2.2, Lanes 3-6). The same band was also present but reduced in whole cell extracts from
uninduced cells that had been grown for 4 hours after induction (Lane 7). PoxA was
absent from the uninduced and induced conditions at the 0 time point (Lanes 1 and 2), as
well as from cells containing only empty vector (Figure 2.2, lanes 8-9). Thus the poxA
ORF codes for a protein.
Since both poxA and poxB are part of a single operon, they could potentially have
related functions. In silico analysis reveals that the nucleotide sequences composing this
operon are not found anywhere else but in P. aeruginosa. Sequences showing high
similarity to both the poxA ORF (73-82%) and the PoxA protein (66-78%) were also
identified in other Pseudomonas species such as P. denitrificans, P. entomophila, P.
monteilii, and P. putida, but were unlinked to any β-lactamase-encoding gene. Similar to
PoxA, these hypothetical proteins are classified as putative hydrolases or acyltransferases
of the α/β hydrolase superfamily. The α/β hydrolase fold is present in a varied number of
proteins that share little in terms of function or sequence homology but show structural
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(uninduced and induced) carrying only empty vector are also shown (Lanes

3-6). Uninduced cells grown for 4 hours (Lane 7) as well as cells

of induction and at the 1-,2-, 3-, and 4-hour mark of IPTG induction (Lanes

PoxA in the absence (Lane 1) and presence of IPTG (Lane 2) at 0 time point

extracts were obtained from E. coli BL21(DE3) cells carrying pET15bVP-

Figure 2.2. poxA is translated into a 32.4-kDalton protein. Whole cell

similarity (777, 778). Proteins carrying the canonical α/β fold include lipases, esterases,
proteases, peroxidases as well as transporters and hormone precursors. The role of PoxA
and its relation to PoxB are yet to be determined.

2.4.3 poxA and poxB deletions do not alter β-lactamase activity or β-lactam
susceptibility. To investigate the role of poxA and poxB in P. aeruginosa, single inframe deletions of each of the genes were generated. The β-lactamase and β-lactam
susceptibility profiles were compared with that of the parent strain PA01. An in-frame
deletion of poxB was also introduced into a previously generated PA0∆ampC strain
(760). Single deletions of poxA or poxB did not alter the β-lactamase or susceptibility
profiles of the strains as compared to the wild-type PA01 (Table 2.2 and Figure 2.3).
Since the AmpC β-lactamase was present in these backgrounds and potentially obscuring
the role of PoxB, the susceptibility and β-lactamase activity were also examined in strains
lacking ampC.
Little to no β-lactamase was detected in both PA0∆ampC and PA0∆ampC∆poxB
suggesting AmpC is responsible for the activity observed in wild-type and in deletion
poxA and poxB strains (Figure 2.3). Interestingly, a deletion of ampC alone significantly
increased susceptibility against the aminopenicillins (ampicillin and amoxicillin), but
produced only minor changes against the carbapenems (imipenem and doripenem), with
no effect observed against the cephalosporins and the rest of the penicillins (Table 2.2).
When overexpressed, however, AmpC was capable of restoring the phenotype and/or
increasing resistance against all penicillins and cephalosporins tested (Table 2.3), in most
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cases past clinical breakpoints, while having little to no effect on the carbapenems. These
results are in agreement with the known hydrolysis spectrum of AmpC that includes
penicillins and cephalosporins but rarely carbapenems (625, 626, 779, 780). Resistance
against penicillins and cephalosporins has been observed in the clinical setting and
correlates with different levels of AmpC derepression (379-381, 722, 781-783). Lastly,
deleting poxB from an already ampC-deficient background did not further alter
susceptibility suggesting either that PoxB plays no role in β-lactam resistance or that it is
not expressed under the tested experimental conditions (Table 2.2).

Table 2.2: Susceptibility profiles of poxA, poxB and ampC deletion mutants
Minimum Inhibitory Concentration (µg/ml)
β-lactam
Ampicillin
Ampicillin/sulbactam

PA01
>256
>256

∆poxA
>256
>256

∆poxB
>256
>256

∆ampC
16-24
16-32

∆ampC∆poxB
24
16-32

Amoxicillin

>256

>256

>256

8-12

16-24

Amoxicillin/clavulanate
Ticarcillin/clavulanate

>256
8-12

>256
12

>256
8-12

8
8

8
12

Piperacillin/tazobactam
Piperacillin

3-4
4-6

3
4

3
4

3

3-4

Aztreonam
Cefepime

1.5-3
1-1.5

2
1-1.5

2
1

1.5-3
0.75-2

2-3
1

Cefotaxime
Ceftazidime

4-6
1-1.5

6
1.5

6
1.5

4-6
1.5

4
1

Imipenem

1-1.5

1.5

1.5

0.25- 0.5

0.38-0.5

0.25-0.5
0.125-0.38

0.38-0.50
0.38

0.38
0.38

0.25-0.75
0.094

0.25- 0.38
0.094-0.125

4
4-6

Meropenem
Doripenem
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Figure 2.3. β-lactamase activity profile of pox and ampC deletion mutants. The βlactamase activities of PA0∆poxA, PA0∆poxB, PA0∆ampC and PA0∆ampC∆poxB were
quantified in the presence (blue bars) and absence (white bars) of the inducer
(benzylpenicillin at 50 µg/ml for 1h). Assays were carried out on cell lysate with 100 µM
of nitrocefin as chromogenic substrate. One milliunit of β-lactamase was defined as 1
nanomole of nitrocefin hydrolyzed per minute per microgram of protein. * p-value<
0.005 for β-lactamase activity in PA01 induced versus activity in PA01 uninduced; ** pvalue< 0.05 for β-lactamase activity in PA0∆poxA induced versus activity in PA0∆poxA
uninduced; *** p-value< 0.005 for β-lactamase activity in PA0∆poxB induced versus
activity in PA0∆poxB uninduced, as determined by paired t-test.
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2.4.4 PoxB is a carbapenemase. To determine the role of PoxB in P. aeruginosa, we
overexpressed poxB in a low-copy plasmid under the control of an IPTG-inducible
promoter in both PA0∆ampC and PA0∆ampC∆poxB. Overexpression of PoxB provided
little to no resistance against the penicillins and the cephalosporins (Table 2.3). There
was, however, a significant decrease in susceptibility (increase in MIC) against the
carbapenems, meropenem and doripenem, as determined by E-test (Table 2.3). A fourfold increase in MIC was also observed against meropenem (not tested against
doripenem) using the broth microdilution method (Figure 2.4). PoxB, however, did not
appear to alter susceptibility against imipenem in an ampC- or ampCpoxB-deficient
background suggesting PoxB may not be able to hydrolyze this carbapenem.
In carbapenems, the signature β-lactam ring, composed of one nitrogen and three
carbons, is fused to an unsaturated five-atom ring that binds sulfur at position C2 (Figure
2.5). The basic structural differences between the carbapenems (imipenem, doripenem,
and meropenem) are imparted by the varying side chains extending from the sulfur at C2.
Meropenem and doripenem have bulkier side groups than imipenem. Additionally, there
is a methyl group at C1, absent from imipenem that could be the basis for the lack of
activity of PoxB against this compound. However, beyond structural differences,
resistance/susceptibility to imipenem in P. aeruginosa must also take into account the
role of the outer membrane porin OprD.
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8-12

>256

3
3
1-1.5
6
1.5
1.5
0.38
0.38

Piperacillin/tazobactam

Piperacillin

Cefepime

Cefotaxime

Ceftazidime

Imipenem

Meropenem

Doripenem

12

8-16

>256

Amoxicillin
Amoxicillin/clavulanic
acid
Ticarcillin/clavulanic
acid

0.094

0.25-0.38

0.5

1

6

1.5

3-4

2-3

6-12

12

>256

Ampicillin/sulbactam

24

>256

Ampicillin

1.5

1.0- 1.5

0.5- 0.75

1

6

1-1.5

4

1.5- 2

8

12

16

16

24

ofPA0∆ampC
Table 2.3: Overexpression
AmpC and PoxB
PA01
PA0∆ampC
β-lactam
(vector)
(vector)
(pPoxB)

0.094-0.125

0.25-0.38

0.5-0.75

1

8

1-1.5

4

3

8

8-12

8-16

12-16

32

PA0∆ampC∆poxB
(vector)

1.5-2

1.5-2

0.5- 0.75

1-1.5

8

1.5

3

3

12

16

24

16

64

PA0∆ampC∆poxB
(pPoxB)

Minimum Inhibitory Concentration (µg/ml)

0.75

0.5

0.5

12-16

>256

4

>256

64

64

>256

>256

>256

>256

PA0∆ampC∆poxB
(pAmpC)

Figure 2.4. Determination of meropenem MIC in a PoxB-overexpressing background.
The MIC of meropenem was determined by the microbroth dilution method in
PA0∆ampC∆poxB (pPoxB) (blue square), PA0∆ampC∆poxB (vector) (grey triangles)
and in PA01 (vector) (light blue diamond). Cells were grown O/N in the presence of 1
mM IPTG with increasing concentrations of meropenem (0-3 µg/ml). The final cell
density measured at OD600 after 18 hours of growth is reported. * p-value< 0.0001 for
OD600 of PA0∆ampC∆poxB (pPoxB) versus optical density for PA0∆ampC∆poxB
(vector)

with

0.25

µg/ml

meropenem;

**

p-value=

0.0005

for

OD600

of

PA0∆ampC∆poxB (pPoxB) versus optical density for PA0∆ampC∆poxB (vector) with 1
µg/ml meropenem, as determined by unpaired t-test.
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Figure 2.5. Chemical structures of carbapenems: meropenem, imipenem and doripenem.
The positions of atoms in the core β-lactam ring and the carbapenem nucleus structure are
numbered and depicted in meropenem.

OprD is a substrate-specific porin that mediates the diffusion of basic amino acids
and imipenem into the cell (757, 784, 785). Imipenem remains a viable and powerful
treatment option against P. aeruginosa, however, mutations in or loss of oprD and
subsequent resistance to this β-lactam, often arise after imipenem treatment (313, 315,
786). In the absence of oprD, the MIC for imipenem increases to ∼8-16 µg/ml as the
antibiotic cannot penetrate the cell as fast as it could in the wild-type (305, 314, 315).
Imipenem will still enter the cell, most likely through other pores and porins, albeit at a
much lower rate (L. Silver, Personal communication). This slower rate of diffusion
makes imipenem a better substrate for the AmpC β-lactamase, which is active in the
periplasm of the cell. Thus, in an oprD-deficient background, the activity of imipenem is
determined by the expression of ampC and potentially poxB, but not by the mex efflux
system, as imipenem, unlike meropenem and doripenem, is not subject to efflux (312,
787, 788). If ampC is also removed from the equation, the activity of imipenem should
be determined by PoxB. Previous studies have shown PoxB has some affinity against
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imipenem (741), however, PoxB activity against imipenem has not been examined in an
oprD-deficient background. We thus set out to test the ability of PoxB to provide
resistance against imipenem in the absence of oprD.
As expected, deletion of oprD alone significantly decreased susceptibility of the
strains against the carbapenems, with the greatest increase in MIC observed for
meropenem followed by imipenem (Table 2.4). In such a background, the MIC is
presumably dictated by the action of AmpC and PoxB, along with efflux for meropenem
and doripenem. AmpC plays a major role in providing resistance here, since in its
absence, the strain becomes very susceptible to imipenem, but less so to meropenem and
doripenem (Table 2.4). This work corroborates previous studies where imipenem
resistance was found to be dependent upon both the loss of oprD and the expression of
AmpC β-lactamase (305). Similarly, in our study AmpC afforded greater protection
against imipenem in a less permeable background, e.g., loss of oprD (Table 2.4).
Specifically the loss of oprD raised the MIC from 1 to 8 µg/ml, with a further deletion of
ampC restoring susceptibility to that of wild-type levels (MIC = 1 µg/ml). Resistance
against meropenem and doripenem in our study, was found to be affected mainly by the
loss of oprD, with only minor changes observed upon deletion of ampC, suggesting these
two carbapenems are not good substrates for AmpC and/or they are efficiently effluxed.
In agreement with these results, our single ampC deletion mutant also showed a slight
increase in susceptibility against imipenem but no change against meropenem (Table
2.2).
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Doripenem

Meropenem

Imipenem

Carbapenems

0.38

0.38

0
1

0.50- 0.75

0.38- 0.75

1

0

1.5

1.5

0

1

(vector)

(mM)

1.5

0.75-1

6

6

8-16

8-12

(vector)

0.5-1

0.75

2-4

2-4

1

0.75-1

(vector)

Table 2.4: Susceptibility
oprD mutantsPA0∆ampC∆oprD
IPTG
PA01profile of
PA0∆oprD

1

1-1.5

6

4

0.75-1

0.75-1.5

PA0∆ampC∆poxB
∆oprD (vector)

Minimum Inhibitory Concentration (µg/ml)

8-12

1-1.5

16-32

6

4-8

0.75-1.5

PA0∆ampC∆poxB
∆oprD(pPoxB)

A further deletion of poxB from an ampCoprD-deletion mutant did not alter
susceptibility (Table 2.4). However, overexpression of PoxB in an oprDampCpoxBdeficient background significantly increased the MICs of all the carbapenems, including
imipenem (Table 2.4), showing that in fact PoxB can hydrolyze all of these β-lactams. In
particular, the increase in MIC observed for meropenem reached the CLSI clinical
resistant breakpoint for this carbapenem (≥ 8 µg/ml) (767). Determination of MIC by the
microbroth dilution method corroborated the E-test results (Figure 2.6 A-D).
Previous biochemical studies showed that the supposed preferred substrates of
oxacillinases, namely oxacillin and cloxacillin, were hydrolyzed very poorly, if at all by
PoxB (741). Additionally, PoxB exhibited very low affinity towards most of the
substrates tested, which included benzylpenicillin, ampicillin, piperacillin and
cephalothin. PoxB, however, did exhibit the highest affinity towards imipenem, although
its ability to hydrolyze it was low (741). Against meropenem, PoxB exhibited low
affinity and weak hydrolysis, while overexpression in trans did afford the cells a
decreased in susceptibility (increase in MIC) against meropenem but not imipenem (741).
Similarly, our work shows that PoxB does not significantly hydrolyze penicillin and
cephalosporin β-lactams. In contrast to previous work, however, we show PoxB is
capable of hydrolyzing not only meropenem but also imipenem and doripenem producing
a decrease in susceptibility (higher MIC) towards these β-lactams when overexpressed.
Although PoxB biochemically may not have the greatest affinity towards some of these
carbapenems, its expression does afford the cell greater protection against these βlactams. PoxB thus is a carbapenemase with a narrow spectrum of hydrolysis.
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A

B
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C

D

D
Figure 2.6. Determination of carbapenem MICs in P. aeruginosa oprD-deficient strains
by the microbroth dilution method. (A) MIC of imipenem in the presence of 1 mM IPTG.
(B) Optical density of cells grown O/N with increasing concentrations of imipenem (0-3
µg/ml) in the presence and absence of IPTG (1 mM). (C) MIC of meropenem in the
presence of 1 mM IPTG. (D) Optical density of cells grown O/N with increasing
concentrations of meropenem (0-3 µg/ml) in the presence and absence of IPTG (1 mM).
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2.4.5 Expression of PoxB does not alter efflux. It is expected that the significant
decrease in susceptibility against carbapenems observed above is caused by the
expression of PoxB and not by an increase in the activity of efflux pumps, especially as
imipenem is not the subject of efflux. Nonetheless, the activity of efflux pumps was
checked by examining the susceptibility of PoxB-overexpressing strains against known
efflux substrates. As expected, the MIC values did not significantly differ between wildtype and PoxB-overexpressing strains (Table 2.5), suggesting efflux systems were neither
enhanced nor compromised by the increased expression of PoxB. Thus, these results
clearly argue that the increase in carbapenem MIC (Tables 2.3 and 2.4) is provided by the
expression of PoxB.
Table 2.5: MIC in the presence of efflux substrates
Range (µg/ml)
PA01 vector

PA0∆ampC∆poxB
(vector)

PA0∆ampC∆poxB
(pPoxB)

Chloramphenicol

32

32

32

Trimethoprim

150

150

100

Novobiocin

512

512

512

Tetracycline

8

8

8

Ofloxacin

1

1.5

1

Norfloxacin

0.75

0.75

0.75

Ciprofloxacin

0.19

0.19

0.19

Levofloxacin

0.38

0.38

0.38

Antibiotic

2.4.6 Inhibitors of PoxB.

β-lactam antibiotics are often co-administered with β-

lactamase inhibitors to improve the efficacy of treatment against β-lactamase-expressing
pathogens (423, 428, 557). β-lactamase inhibitors are β-lactams themselves with only
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minor antibacterial activity (789-792) that can either reversibly or irreversibly inhibit the
β-lactamase thus preventing it from hydrolyzing the co-administered antibiotic (423, 793796). Currently, three irreversible β-lactamase inhibitors, clavulanic acid (797, 798),
sulbactam (426, 799, 800) and tazobactam (801, 802) are approved for clinical use. Their
activity is limited to most class A enzymes, being generally ineffective against classes B,
C and D β-lactamases (428, 467). PoxB has been shown to be only poorly inhibited by
these (741). A new β-lactamase inhibitor, termed avibactam, with a broader spectrum of
activity has been developed and is currently undergoing phase III clinical trials in
combination with ceftazidime (803-805). Unlike the aforementioned compounds,
avibactam is not a β-lactam, although its structure closely resembles one (804). The
ability of avibactam to inhibit PoxB activity was examined and compared to that of weak
inhibitors of oxacillinases, namely tazobactam, sulbactam and clavulanic acid.
Subinhibitory concentrations of imipenem (0.5 µg/ml) and meropenem (1 µg/ml)
that only allowed PA0∆ampCΔpoxBΔoprD to grow when PoxB was overexpressed
(Figure 2.6A and 2.6C) were used to examine the inhibitory action of tazobactam,
sulbactam and clavulanic acid against PoxB. A slight inhibition of growth was apparent
with tazobactam in the presence of imipenem, and to a smaller extent with sulbactam
(Figure 2.7). In the presence of clavulanic acid, growth either remained unaltered or was
slightly enhanced. Overall, as expected, the ability of PoxB-overexpressing strains to
grow on imipenem or meropenem was not significantly affected by the presence of these
inhibitors at the tested clinical concentrations, indicating these compounds did not inhibit
PoxB activity (Figure 2.7).
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Figure 2.7. Effect of tazobactam, sulbactam and clavulanic acid on PoxB activity. The
ability of PA0∆ampCΔpoxBΔoprD (pPoxB) to grow in the presence of subinhibitory
concentrations of imipenem (0.5 µg/ml) or meropenem (1 µg/ml) was examined in the
presence of the class A enzyme inhibitors tazobactam (A), sulbactam (B) and clavulanic
acid (C). OD600 readings after O/N growth with aeration at 37°C are reported.
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Similarly, the ability of avibactam to inhibit PoxB activity was tested by growing
PoxB-expressing strains in CAMH agar with IPTG in the presence and absence of
avibactam at a clinically used concentration (4 µg/ml). The presence of PoxB increases
the MIC against imipenem, meropenem and doripenem (as detailed in Section 2.4.4,
Table 2.4) since PoxB can hydrolyze these carbapenems. Inhibition of PoxB by
avibactam, should then produce a decrease in MIC against the carbapenems. Our results
show, however, that the MIC of PoxB-expressing cells was not altered in the presence of
this inhibitor (Table 2.6), suggesting avibactam does not significantly inhibit PoxB
activity.

Table 2.6: Effect of avibactam on carbapenem MIC
Minimum Inhibitory Concentration (µg/ml)
Carbapenems

Imipenem

Meropenem

Doripenem

CAMH

PA0∆ampC∆poxB
∆oprD (vector)

PA0∆ampC∆poxB
∆oprD(pPoxB)

Alone

0.25

0.75

IPTG
IPTG + AV

1.5
1.5

6
4, 6

Alone
IPTG
IPTG + AV

6
4, 6
6, 4

4
32
32

Alone

0.75-1

0.75-1

IPTG

0.75-1

8

1-1.5

8

IPTG + AV
AV- Avibactam at 4 µg/ml
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The inhibitory action of these compounds was also tested directly on cell lysate
from PoxB-overexpressing cells by quantification of the β-lactamase activity.
Concentrations as high as 700 µM of tazobactam failed to reduce the β-lactamase activity
in cell lysates from PA0∆ampCΔpoxB (pPoxB) cells, while only a minor reduction was
observed with 4000 µM of sulbactam (Figure 2.8A and 2.8B). A general downward trend
of inhibition was observed with clavulanic acid starting at 50 µM, but a 50% inhibition
was not reached even at high levels of the inhibitor (4000 µM). Avibactam decreased
PoxB activity by more than half (Figure 2.8C) at a concentration of 2000 µM (530.488
µg/ml), which is 75-fold higher than that of the highest concentration of avibactam used
in clinical studies (0.5-7 µg/ml) (806-808). Notwithstanding that avibactam produced
greater inhibition than the other tested inhibitors, the large quantities of the compound
needed to inhibit PoxB activity, makes avibactam a weak inhibitor.
Avibactam at a concentration of 4 µg/ml has proven sufficient and efficient at
increasing susceptibility and/or eliminating resistance against a number of β-lactams in a
large number of clinical isolates (809-811). For instance, in a study of 1466 Gramnegative isolates collected from patients hospitalized with pneumonia, bloodstream, intraabdominal and urinary tract infections, avibactam in combination with ceftazidime
effectively reduced MICs from 16 or 32 to 0.25 µg/ml in 90% of Enterobacterial isolates
(809). About 99.8% of such isolates exhibited an MIC of ≤4 µg/ml, the CLSI clinical
susceptible breakpoint for ceftazidime (809). Similarly, avibactam reduced the MIC
anywhere from 16 or 32 to 4-8 in 90% of P. aeruginosa isolates, with an average of
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Figure 2.8. PoxB β-lactamase activity in the presence of tazobactam, sulbactam,
clavulanic acid and avibactam. The β-lactamase assay was performed on lysate from
IPTG-induced (1 mM) PA0∆ampCΔpoxB (pPoxB) cells. Lysate was incubated for 20 min
with increasing concentrations of tazobactam (A), sulbactam (B), clavulanic acid (C), and
avibactam (D). Chromacef was used as a chromogenic substrate. One milliunit of βlactamase was defined as 1 nanomole of chromacef hydrolyzed per minute per
microgram of protein.
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96.8% of all isolates showing a ceftazidime/avibactam MIC of ≤8 µg/ml, the CLSI
susceptible breakpoint for ceftazidime in this organism (809).
Although avibactam has shown variable activity against class D enzymes, it
remains a more potent and effective inhibitor of class A (805-808, 812) and C (805, 807,
812, 813) enzymes, including the problematic class A Klebsiella pneumoniae
carbapenemases or KPCs (814, 815). A study found that avibactam potentiated the
activity of both ceftazidime and aztreonam against meropenem-nonsusceptible Gramnegative bacilli expressing multiple β-lactamases of the class A and C types (811).
Avibactam, however, was less successful at reducing the MIC of Acinetobacter
baumannii isolates carrying OXA-23-like genes (MIC90 fold reduction of 2-4 vs fold
reduction of 32-256 against class A, B and C enzymes in that particular study) (811).
Similarly, avibactam did not significantly improve the activity of cefepime, ceftazidime
or imipenem in A. baumannii isolates carrying PER-1, OXA-51 and OXA-58, with only a
minor increase in susceptibility (∽2-fold decrease in resistance) observed (816). The
efficacy of ceftazidime against an OXA-5-expressing P. aeruginosa clinical isolate was
also not improved by the presence of avibactam (817).
OXA-48 appears to be just one of a few class D enzymes against which avibactam
is active. A study showed that K. pneumoniae and E. coli isolates harboring the
carbapenemase OXA-48 exhibited significant reduction in the MIC of imipenem,
cefepime and ceftazidime when combined with avibactam, leading to susceptibility in
90% of isolates (816). In another study, the number of K. pneumoniae OXA-48producers showing resistance was eliminated and/or susceptibility was enhanced by the
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addition of avibactam (818). However, a kinetics study also found the rates of reaction of
avibactam with OXA-48 and OXA-10 to be much slower than that of the other tested
class A and C enzymes (804). The P. aeruginosa OXA-10 was actually found to be
poorly inhibited by avibactam (804). Although avibactam has not been tested against
very many OXA enzymes and while the structure and hydrolytic activities of
oxacillinases is wide and varied, the emerging trend suggests that avibactam is not a very
good inhibitor of class D enzymes. It is thus not surprising avibactam is only a weak
inhibitor of PoxB (OXA-50).

2.4.7 Inhibition by NaCl. Oxacillinases are known to be inhibited by NaCl in vitro
(669, 674, 682). This characteristic is commonly attributed to the presence of a Tyr
residue at position 144, with replacement by Phe leading to resistance to inhibition (703,
819). Inhibition is often showed directly by measuring enzyme activity (β-lactamase
assay), or indirectly by determining MIC changes (820). Previous work showed
inhibition of purified PoxB by NaCl (IC50, 50 mM), which not surprisingly carries Tyr at
position 144 (741). We here further test if the previously reported NaCl inhibition of
PoxB can translate into quantifiable changes that can affect the ability of PoxB to provide
resistance. To that end, PA0∆ampCΔpoxBΔoprD (pPoxB) was grown in the presence of
subinhibitory concentrations of imipenem (0.5 µg/ml) or meropenem (1 µg/ml) that only
allowed growth if PoxB was expressed. Growth was monitored O/N and inhibition of
growth was used as an indirect indicator of PoxB activity.
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NaCl produced a small, but steady increase in growth up to a concentration of 50
and 100 mM in the presence of meropenem or imipenem, respectively (Figure 2.9). A
slight growth decrease was detected in the presence of meropenem at NaCl
concentrations of 100 mM or higher. Concentrations of ≥200 mM decreased growth
below the level of untreated cells, suggesting NaCl was compromising PoxB-dependent
growth (Figure 2.9). In the presence of imipenem, growth never fell below that of
untreated cells, but the enhancement of growth seen with up to 100 mM was lost at NaCl
concentrations of 200 mM or higher, also suggesting that this higher range of solute was
affecting the ability of PoxB to hydrolyze the β-lactam.

Figure 2.9. PoxB activity in the presence of NaCl. Inhibition of PoxB by NaCl was
examined by growing PA0∆ampCΔpoxBΔoprD (pPoxB) O/N in the presence of
subinhibitory concentrations of meropenem or imipenem with IPTG (1 mM) and with
increasing concentrations of NaCl. The subinhibitory concentrations of meropenem and
imipenem selected were those previously shown to allow growth of only PoxBoverexpressing cells.
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Although small inhibition of growth is detected with NaCl, particularly at higher
concentrations, NaCl did not completely abolish growth of PA0∆ampCΔpoxBΔoprD
(pPoxB) in LB or CAMH broth containing meropenem or imipenem (Figure 2.9). In
short, PoxB activity did not appear to be inhibited by NaCl to levels significant enough to
prevent hydrolysis of the carbapenems and subsequently growth in media containing
these β-lactams. The slight decrease in growth observed, however, was determined to be
mostly unrelated to osmolarity, since cells grown in the presence of NaCl only lysed at a
concentration of 800 mM of solute (Figure 2.10). A concentration of 400 mM does
appear to slightly affect osmolarity leading to a <2-fold reduction in absorbance as
compared to growth in 200 mM of NaCl.

Figure 2.10. Determination of MIC for NaCl. The concentration of NaCl needed to lyse
cells was determined by growing PA01 (vector) and PA0∆ampCΔpoxBΔoprD (pPoxB)
O/N with increasing concentrations of NaCl in CAMHB media.
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Inhibition by NaCl, however, was apparent on cell lysate from PA0∆ampCΔpoxB
(pPoxB) cells (Figure 2.11). Specifically, β-lactamase activity decreased with increasing
concentrations of NaCl. The phenotype was readily observed in the absence of IPTG.
However, in the presence of IPTG, where the levels of PoxB are significantly higher,
NaCl inhibition could not be appreciated (Data not shown).

Figure 2.11. Inhibition of PoxB by NaCl. PoxB inhibition was measured in vitro as a
function of β-lactamase activity. The β-lactamase assay was performed on lysate from
IPTG-induced and uninduced (1 mM) PA0∆ampCΔpoxB (pPoxB) cells. Lysate was
incubated for 20 min with increasing concentrations of NaCl (0-800 mM). Only data for
uninduced lysate is shown. Nitrocefin was used as a chromogenic substrate. One milliunit
of β-lactamase was defined as 1 nanomole of nitrocefin hydrolyzed per minute per
microgram of protein.
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The CF lung is notoriously susceptible to bacterial infections and in particular to
colonization by P. aeruginosa (122, 123). The most widely accepted hypothesis of CF
pathobiology, the low volume hypothesis, states that mutations in the CFTR gene cause
an excessive intake of NaCl in the lung epithelium leading to surface airway dehydration
and impaction of mucus thus setting up the stage for the chronic and persistent bacterial
infections that are the hallmarks of CF lung disease (155, 177, 189). The CF lung, with its
imbalance of Na+ and Cl- ions transport, may confer an advantage to OXA-producing
organisms susceptible to inhibition by NaCl than otherwise provided by healthy lung. By
the same token, OXA-enzymes susceptible to NaCl inhibition may exhibit decreased
activity in the normal lung. However, it has been difficult to measure the salt content on
surface airway epithelium. Mice and epithelial culture studies, although substantiating the
low volume hypothesis, have not shown a difference in ion content between healthy and
CF models (174, 176, 821-823). Thus, it is difficult to ascertain the ramification of the
imbalance of Na+ and Cl- transport caused by CFTR mutations on the activity of OXAtype β-lactamases, if at all.

2.4.8 PoxA and Congo red binding phenotype. A Biolog microarray phenotypic assay
pointed to a growth defect for the PA0ΔpoxA mutant in the presence of 10 mM NaNO3.
Since P. aeruginosa is a facultative anaerobe capable of using NO3 as a terminal electron
acceptor (824), we investigated the colony morphology of poxA mutants on CR and CB
plates with NaNO3 in aerobic and anaerobic conditions. Interestingly, a phenotype was
observed in the presence of oxygen and in the absence of NaNO3 (Figure 2.12).
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Specifically, overexpression of PoxA produced colonies with an outer dark ring and a
darker inner ring, while the center of the colony remained white (Figure 2.12). The
observed red phenotype here is indicative of hyperbinding to CR and suggests enhanced
production of extracellular polysaccharides such as Pel or Psl (768, 770).

Figure 2.12. Colony morphology on CR. Fresh cultures were diluted to an OD600 of 0.05
and 10 μl of each were spotted on agar plates containing 1% tryptone and 1% agar
supplemented with 40 μg/ml CR and 20 μg/ml CB in the presence of gentamycin (75
μg/ml ) and IPTG (1 mM). Plates were incubated at 25°C in the dark for five days. The
colonies were imaged every 24 hours using an Epson scanner. Fifth-day colonies are
shown.

Non-mucoid P. aeruginosa strains can secrete two extracellular polymeric
substances, Pel (768, 825, 826) and Psl (769, 827) polysaccharides, that are known to
contribute to biofilm formation. Although the P. aeruginosa strain PA01 has all the genes
necessary for production of both Pel and Psl, the latter has been shown to play a bigger
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role in biofilm formation and maturation in this background (768, 769, 826, 827). The
PA14 strain, on the other hand, can only produce Pel due to a three-gene deletion in the
psl locus (768, 825, 826). Nonetheless, a recent study showed that both Pel and Psl
polysaccharides were involved in micro- and macrocolony formation and in
subpopulation interactions in the PA01 biofilms (828), while a PA01 psl mutant was able
to form biofilm after acquiring mutations that allowed it to overexpress Pel (829).
CR is known to bind polysaccharides containing β-1,3- or β-1,4-glycosidic
linkages (830), and thus has been used to detect the carbohydrates-rich components in the
extracellular matrices of a number of bacteria (831-833). CR is in fact routinely used to
detect the presence of the Pel and Psl polysaccharides in P. aeruginosa (768-770, 825). In
order to determine if hyperbinding to CR observed upon expression of PoxA (Figure
2.12), is the result of increased production of either Pel or Psl polysaccharides, pellicle
formation, autoaggregative properties and binding to CR were examined in liquid media.
All strains were able to form pellicle at the liquid-air interphase and there was no
difference by visual inspection in the amount of pellicle being formed (Figure 2.13).
Similarly, not much difference was observed in the ability of the pellicles to bind CR
(Figure 2.14) or in the ability of the strains to form aggregates on the walls of the tubes
(Data not shown).
Expression of PoxA thus, does not appear to contribute to an increased production
of Pel or Psl in liquid media. Thus, at first glance, the CR-binding phenotype observed in
Figure 2.12, does not appear to be the result of an increased production of Pel or Psl
polysaccharides. Clearly the surface attached biofilm growing on plates are able to bind
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CR there, but the basis for binding remains unknown. Given that CR is known to bind
polysaccharides, it is likely that the CR phenotype observed here is due to increased
production of a carbohydrate or polysaccharide. Alternatively, the surface attached
biofilms that grow on plates may be conducive to the production of Pel or Psl in plates
but not in liquid media. CR, however, has also been shown to bind non-cellulose material
of the extracellular matrix, such as the proteinaceous thin aggregative fimbriae and curli
polymers produced by Salmonella spp. and E. coli isolates, respectively (834-836).

Figure 2.13. Pellicle formation in PoxA-expressing cells. Stationary phase cultures were
diluted to an OD600 of 0.025 in T-broth and pellicle formation was monitored at room
temperature without shaking for seven days. Seventh-day cultures are shown.
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Figure 2.14. CR-binding assay. Two-day old cells were pelleted, resuspended in Tbroth containing CR (40 µg/ml) and grown with aeration at 37°C for 90 minutes. The
cells along with bound CR were pelleted by centrifugation and the OD495 of the
supernatant was used to calculate the percentage of bound CR.

2.5 Concluding Remarks
P. aeruginosa carries two chromosomal β-lactamases, AmpC, a penicillinase and
cephalosporinase; and PoxB, a carbapenemase. The role of AmpC and its contribution to
β-lactam resistance are well-established and evident here. In our study, AmpC expression
readily afforded protection against the cephalosporins and penicillins but not against the
carbapenems. PoxB, on the other hand, had a narrow spectrum of hydrolysis that mostly
included the carbapenems. Similar to other class D enzymes, PoxB was only poorly
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inhibited by the currently available inhibitors: clavulanic acid, tazobactam and sulbactam.
A novel inhibitor, avibactam, was slightly more effective at reducing PoxB activity but
clinical concentrations failed to decrease MIC of carbapenems by E-test. Additionally,
poxB was shown to form an operon with an upstream ORF of yet unknown function,
termed poxA. Expression of PoxA in trans enhanced CR-binding abilities suggesting the
production of a CR-binding substance likely rich in carbohydrates.
PoxB appears to be constitutively expressed, but its relevance in the clinical
setting is still unknown. Mutational derepression of AmpC is a common mechanism of
resistance. Thus, it is plausible that mutations in poxB regulatory genes may lead to
increased expression and carbapenem resistance in the clinical setting. Expression and
regulation of poxB are examined in Chapter 3.
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Chapter 3

Regulation of the poxAB operon encoding a class D β–lactamase in
Pseudomonas aeruginosa
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3.1 Abstract
Regulation of AmpC β-lactamase in Pseudomonas aeruginosa is a tightly
controlled process that involves the global transcriptional regulator AmpR and the
recycling of muramyl peptides of the peptidoglycan layer. AmpC is normally produced at
low basal levels, but β-lactams such as benzylpenicillin, cefoxitin and imipenem, can
induce its high level expression. A second chromosomally encoded carbapenemase,
PoxB, has been characterized in P. aeruginosa, but its regulation has not yet been
examined. Although expression of poxB appears to be constitutive, studies in a
heterologous host suggest AmpR could also be involved in its regulation. In the present
work regulation of poxB by AmpR was detected at the transcriptional level by RT-PCR.
Quantification of β-lactamase activity, however, did not show regulation at the protein
level. Further, AmpR failed to bind the pox promoter suggesting indirect regulation. A
global genetic screen for transposon insertions into pox regulators identified a possible
link between polyamine transport and pox promoter activity.

Key Words: PoxB, AmpR, β-lactamase regulation

Abbreviations: Electrophoretic mobility shift assay, EMSA; Open reading frame, ORF;
pox promoter, Ppox; RT-PCR, Real-time polymerase chain reaction; Transposon, Tn
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3.2 Introduction
Pseudomonas aeruginosa PoxB is a class D β-lactamase with a narrow spectrum
of hydrolysis that mostly includes the carbapenems (741, 837). It is poorly inhibited by
the clinically used class A enzyme inhibitors and by avibactam, a new non-β-lactam
inhibitor that is currently undergoing clinical trials (Chapter 2) (741). Additionally, PoxB
forms a two-gene operon with the upstream open reading frame (ORF), poxA, whose
function is still unknown. The pox operon appears to be constitutively expressed but its
regulation has not been investigated.
It is not uncommon for regulatory proteins to be encoded in the general vicinity of
the genes they regulate (730, 739). For instance, the transcriptional regulator AmpR is
encoded immediately upstream of, and divergently transcribed from, the ampC structural
gene that it regulates (711, 776). It was our previous hypothesis that a two-component
regulatory system encoded by mifSR, located immediately upstream of the pox operon
and divergently transcribed, could be involved in its regulation. The response regulator
MifR has recently been implicated in the formation of biofilm (838). Deletion of either or
both mifS and mifR, however, did not affect β-lactam and carbapenem susceptibility or
poxB expression (G. Tatke, Personal communication).
Previous work from our lab, however, seems to implicate AmpR as possible
regulator of pox expression (710). Specifically, expression of ampR in an Escherichia
coli heterologous host resulted in decreased PoxB β-lactamase activity (710). AmpR is an
interesting candidate for regulator of pox expression. As a LysR-type transcriptional
regulator, AmpR regulates ampC expression by binding to the promoter region in the
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presence and absence of β-lactam inducers in both the Enterobateriaceae and P.
aeruginosa (839, 840). In this manner, AmpR can accomplish either repression or
induction given the presence/absence of activating inducer. Recently, AmpR has been
redefined as a global regulator, differentially controlling expression of various other
genes involved in virulence, quorum sensing, biofilm formation as well as various
transcriptional regulators (841-844). The AmpR regulon is quite extensive and possibly
includes both direct and indirect interactions. It would thus not be surprising if AmpR
also regulates expression of the pox operon.
In the present work we analyze the role of AmpR as potential regulator of poxB
expression. Our findings suggest AmpR regulates poxB but does not directly interact with
the pox promoter (Ppox) which indicates indirect regulation. A P. aeruginosa transposon
library was constructed and screened for insertions into regulators of pox expression.
Two transposon mutants exhibiting increased Ppox activity carried insertions in genes
involved in the transport and uptake of polyamines, essential molecules implicated in a
wide range of cellular functions (845-847). Polyamines reduced the susceptibility of P.
aeruginosa towards various β-lactams but provided resistance only against the
carbapenems. The mechanism by which polyamines are able to induce carbapenem
resistance is not well understood but could be related to a decrease in cell permeability or
to the increased expression of the carbapenem-hydrolyzing β-lactamase PoxB.
Polyamines have, in fact, been shown to modulate gene expression through binding of
both DNA and RNA (848-851). Thus, polyamine-dependent regulation, although
unprecedented for β-lactamases, is plausible.
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3.3 Materials and Methods

3.3.1 Bacterial strains, plasmids and growth media. Bacterial strains and plasmids
used in this study are listed in Table 3.1. E. coli and P. aeruginosa were cultured
regularly in Luria-Bertani medium (10 g tryptone, 5 g yeast extract, and 5 g NaCl, per
liter) at 37°C. Antibiotics were used at the following concentrations: ampicillin (Ap) at
100, gentamicin (Gm) at 15 and tetracycline (Tc) at 20 µg/ml for E. coli; Gm at 75 and
Tc at 60 µg/ml for P. aeruginosa. For construction of PA0ΔampRΔpoxB, a previously
generated in-frame deletion of poxB was introduced into PA0ΔampR (843) using overlap
extension PCR and homologous recombination as previously described (758). The
presence of the deletion was checked by gene-specific PCR.

Table 3.1: Bacterial strains and plasmids used in this study
Strains/Plasmids

Reference/
Source

Relevant phenotype and genotype

Escherichia coli
DH5α

F- Φ80lacZΔM15 Δ(lacZYA-argF)U169 deoR
-

+

New England
--

recA1 endA1 hsdR17 (rk mk ) phoA supE44 λ

Biolabs

thi-1 gyrA96 relA1
TOP10

F- mcrA Δ(mrr-hsdRMS-mcrBC)Φ80lacZΔM15

Life

ΔlacΧ74 recA1 araD139 Δ(ara-leu)7697 galU

Technologies

galK rpsL (StrR) endA1 nupG
SM10λpir

KmR, thi-1, thr, leu, tonA, lacY, supE,
recA::RP4-2-Tc::Mu, pir
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Stephen Lory

Pseudomonas aeruginosa
PA01

Wild-type

(762)

PKM201

PA0ΔampC, PA01 containing in-frame deletion
of ampC

(760)

PKM315

PA0ΔampR, PA01 containing in-frame deletion
of ampR

(843)

PKM332

PA0∆ampR∆poxB, PA01 containing in-frame
deletions of ampR and poxB

PKM106

PA0attB::mini-CTX-lacZ; TcR

PKM117

PA0attB::PampC-lacZ; TcR

This study

PKM118

PA0attB::Ppox-lacZ; TcR

This study

PKM319

PA0ΔampRattB::mini-CTX-lacZ; TcR

This study

PKM335

PA0ΔampRattB::Ppox-lacZ; TcR

This study

This study
(852)

Plasmids
mini-CTX-lacZ

R

Tc ; Integration-proficient vector for single-

(853)

copy chromosomal lacZ fusion at the attB site
pMMB67EH-Gm

GmR; IncQ, RSF1010, lacIq Ptac expression

(763)

vector with ampR::aacC1 insertion at DraI
pBTK24

ApR, GmR; transposon delivery vector, ori R6K

pPoxA

GmR; pMMB67EH-Gm carrying a 946-bp

Stephen Lory
Chapter 2

fragment containing poxA ORF
pOC19

GmR; pMMB67EH-Gm containing His-tagged

(852)

AmpR at C-terminus
pDZ29

ApR; pCR2.1-TOPO derivative containing a

This study

217-bp EcoRI-BamHI pox promoter fragment
pDZ197

TcR; Ppox fused to the lacZ of mini-CTX-lacZ
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This study

3.3.2 Construction of promoter fusions. A ΦCTX-based system was used to construct
single-copy promoter fusions, where the expression of the promoterless reporter gene
lacZ is under the control of Ppox. Briefly, Ppox was amplified using primers
KM_PpoxAFov

(5’-GAATTCTCACAGGCCGCCGAGCAGCGGCAG-3’)

and

KM_PpoxARev

(5’-GGATCCCTCACCAGCCGCGCAGGGTGAAACC-3’).

The

amplicon was cloned into the TA cloning vector pCR2.1-TOPO, sequenced and
subcloned into the EcoRI-BamHI sites of the integrative vector mini-CTX-lacZ and
resequenced for fidelity. The transcriptional fusion was subsequently introduced into P.
aeruginosa PA01 and the isogenic mutant PA0∆ampR as a single copy at the attB site. A
previously generated PA0::PampC-lacZ was used as positive control for promoter-driven
expression of lacZ (710).

3.3.3 Quantification of poxB mRNA expression. Total RNA was extracted from P.
aeruginosa PA01 and a previously generated PA0∆ampR (843) in the presence and
absence imipenem (0.15 µg/ml) using the RNeasy mini kit (Qiagen). cDNA synthesis
was performed with Superscript III (Invitrogen) and the (NS)5 random primer as
previously described (764). qPCR was performed with the ABI 7500 cycler (Applied
Biosystems) using the Power SYBR Green PCR Master Mix with ROX (Applied
Biosystems). clpX (PA1802) was used as endogenous control and amplified with
DBS_qRT_clpXF (5'-TGCGATTACGATGTGGAGA-3') and DBS_qRT_clpXR (5'-CCCTCGATGAGCTTCAGCA-3') (843). DZRTpoxBFord1 (5’-AATCGGCCAGGTTGTGGATAA-3’) and DZRTpoxBRev1 (5’-GGAGCAGAAAGCGGGTCTGT-3’) were
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used for the real time amplification of poxB. Gene expression was normalized to that of
the PA01 uninduced value.

3.3.4 β-lactamase assay. The β-lactamase assay was performed as previously described
with some modifications (765). Briefly, stationary-phase cultures of PA01, PA0∆ampR
and PA0∆ampR∆poxB were diluted in 25 ml of LB broth to an OD600 of 0.01 and
incubated with shaking at 37°C. At OD600 of 0.6-0.8, cells were induced with 0.15 µg/ml
of imipenem and reincubated for 1 hour at 37°C. Ten milliliters of cells were harvested
by centrifugation and resuspended in 800 µl of 1x BugBuster solution (Novagen).
Benzonase (1 μl/ml of BugBuster used) (Novagen) and rLysozyme (1 KU (Novagen)
were then added and the mixture was rotated for 20 min at room temperature. The lysate
was centrifuged at 4°C for 15 minutes to collect the β-lactamase-containing supernatant.
A 2-µl aliquot of cell lysate was added to nitrocefin (final concentration, 100 µM) in 250
µl of 50 mM sodium phosphate buffer. The reaction mixture was incubated at 37°C for
20 minutes and the hydrolysis of nitrocefin was measured spectrophotometrically at 482
nm. The Bradford assay was used to determine total protein concentration of each
sample. β-lactamase activity was expressed as nmol of nitrocefin degraded per minute per
microgram of total protein.

3.3.5 β-galactosidase assay. The β-galactosidase activity was quantified as a measure of
Ppox activity as previously described (854). Briefly, fresh cultures of PA01 and
PA0∆ampR harboring Ppox-lacZ were grown at 37°C and induced with benzylpenicillin
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(50 μg/ml) at an OD600 of 0.5 for 1 hour. The assay was performed on 1-ml cell lysate
using ortho-nitrophenyl-β-galactoside (ONPG) as a chromogenic substrate and the
activity was expressed in Miller units. Assays performed as part of transposon screening
were routinely done in the absence of induction.

3.3.6 Electrophoretic mobility shift assay (EMSA). The pox promoter region was
amplified using P. aeruginosa PA01 genome as template with primers EM-PpoxAFor
(5'-CGATCAGGGTCTGCAGCGAGC-3') and EM-PpoxARev (5'-GGCTTGCCGCTCGGTTCGC-3') and the 335-bp amplicon was used to perform EMSA. Briefly, the
promoter fragment was radiolabelled at the 5’ end by incubation with T4 polynucleotide
kinase (NEB) and [γ-32P]ATP (3,000 Ci mmol-1; Perkin Elmer). The labeled fragment
was diluted to a final concentration 100 nM and unincorporated nucleotides were
removed by sephadex G-25 (Biorad, Hercules, CA) spin chromatography. DNA binding
reactions containing 50 fmol of

32

P-labeled DNA probe and varying amounts of total

protein membrane fractions were incubated for 20 minutes and loaded thereafter in a nondenaturating 5% PAGE. Protein membrane fractions were used as AmpR was shown to
be membrane-associated (852). Radioactive signals were detected by scanning a
phosphostorage cassette with the GE Healthcare Typhoon 9400 scanner.

3.3.7 Pilot experiment to construct transposon library. Before attempting to generate
a transposon library it was necessary to determine the conditions needed to obtain good
coverage over the PA01 genome. About 20,000 to 40,000 mutagenized colonies, which is
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roughly 5-7 times the number of genes (~5500) in PA01, are necessary. A pilot study was
thus conducted by setting matings between the donor E. coli SM10λpir (pBTK24) and the
recipient PA0ΔampR::Ppox-lacZ. PA0ΔampR::Ppox-lacZ was grown overnight (O/N) at
both 37°C and 42°C, while E. coli SM10λpir (pBTK24) was grown O/N only at 37°C.
The donor and recipient were then diluted (1/5) and grown at 37°C in LB for about 4
hours. The recipient strain that was grown O/N at 42°C was also diluted and incubated in
a dry bath at 42°C for 4 hours. When the cultures reached an OD600 of 2.5 or higher, after
approximately 4½ hours, 6 mls of both the donor and recipient were centrifuged at
13,000 rpm for a minute. After discarding the supernatant, the cells were washed in 1 ml
of LB broth, repelleted and resuspended again in 1 ml of LB broth. One set of matings
was set up using the recipient that was grown at 42°C (Matings A-C), while the others
were done with the recipient that had grown at 37°C (Matings D-E) (Table 3.2).

Table 3.2: Mating volumes used in pilot study
Pilot Matings (µl)
Strains

Controls (µl)

A

B

C

D

E

Recipient
(37°C)

Recipient
(42°C)

Donor

PA0ΔampR::PpoxlacZ at 37°C

-

-

-

200

400

400

-

-

PA0ΔampR::PpoxlacZ at 42°C

200

-

-

-

600

-

-

-

1000

600 400

E. coli SM10 λpir
1000 600 800 1000 800
(pBTK24)
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All mating mixtures were centrifuged, the supernatant discarded and the pellet
resuspended in 30 µl of LB. The suspensions were then spotted on LB plates and
incubated at 37°C for 4 hours. All spots were resuspended in 200 µl of LB. Fifty and 150
μl of each were plated on selective media (LB-PIA-Gm75). For the controls, only 100 µl
of each strain were plated (Table 3.3). The most efficient matings had the recipient grown
at 42°C at a 1:1 ratio of donor to recipient (Table 3.2 and 3.3).

3.3.8 Transposon mutagenesis and screening for regulators of the pox operon. The
reporter strains, PA0::Ppox-lacZ and PA0∆ampR::Ppox-lacZ, displaying distinctly different
levels of pox promoter activity, were each mutagenized on four different occasions.
Twenty matings were set-up each time with the objective of obtaining enough
transposon-mutagenized colonies to cover the entire PA01 genome. Matings were set-up
as described in the pilot study. Briefly, O/N cultures of recipients and donor grown at 42
and 37°C, respectively, were freshly diluted 1/5 in LB broth and grown for four hours at
42 and 37°C, respectively. At the four-hour time point, enough culture of both donor and
recipient strains were centrifuged at 13,000 rpm for one minute (1 ml culture/eppendorf
tube). The suppernatants were discarded and the pellets resuspended in 1 ml of LB.
Matings were set up in donor to recipient ratios of 5:1, 2:1, and 1:1 (Table 3.4). All
mating mixtures were centrifuged, the supernatant discarded and the pellet resuspended
in 30 µl of LB, which were then spotted on LB plates and incubated at 37°C for an
additional four hours. All spots were individually resuspended in 200 µl of LB and 50
and 100 µl were plated on selective media (LB-PIA-Gm75 or LB-PIA-Gm75-X-gal100).

127

128
50

290

Volume
plated
(µl)

Colony
count

A

625

150

592

50

B

895

150

437

50

C

480

150

Pilot Matings

1

50

D

6

150

Table 3.3: Approximate colony count obtained for pilot study

0

50

E

3

150

0

100

Recipient
(37°C)

0

100

Recipient
(42°C)

Controls

0

100

Donor

Table 3.4: Mating ratios used for generation of P. aeruginosa library
Matings
Strains

Controls

1-7

8-14

15-20

Recipient

Donor

PA01::Ppox-lacZ or
PA0ΔampR::Ppox-lacZ (µl)

200

600

400

600

-

E. coli SM10 λpir (pBTK24) (µl)

1000

600

800

-

1000

For the PA0::Ppox-lacZ library, colonies obtained with the 1st and 2nd mating
events, were all pooled and frozen into five 96-well plates since selection was done only
in LB-PIA-Gm75. Screening of these pools for dark blue colonies remains to be done on
LB-PIA-Gm75-X-gal100 (Figure 3.1). Colonies for the 3rd and 4th mating events were
directly selected on LB-PIA-Gm75-X-gal100. The blue colonies resulting from this
screening were individually frozen in 4 x 96-well plates and further analyzed as described
in later sections.
For the PA0ΔampR::Ppox-lacZ library, all colonies obtained were pooled and
frozen with 10% skim milk in 57 x 2-ml-vials (mating events 1-3) and in two 96-well
plates (4th mating event) (Figure 3.2). Screening for white colonies has so far been done
on 34 wells (A1-C10, Plate #1, mating event 4). The screening was done by inoculating a
scraping from a well into 10 ml of LB broth and growing at 37°C for 45 minutes. Each
culture was then serially diluted and the 10-5 and 10-6 dilutions were plated onto LB-PIAGm75-X-gal100. White to light blue colonies were selected for further analysis and
individually frozen on 10% skim milk.
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Figure 3.1. Selection and screening of the PA01 library

Figure 3.2. Selection and screening of the PA0ΔampR library
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3.3.9 Mapping of the transposon (Tn) insertion site. Insertion sites were mapped by a
two-round semi-random PCR (825) using either pure colony or purified DNA as
template. The first round of PCR was performed using the Tn-specific primer Round1BTK24 (5’-GTCGTAAATCACTGCATAATTCG-3’) and the random primer Round1Pa(1) (5’-GGCCACGCGTCGACTAGTACNNNNNNNNNNGATAT-3’) (855), that can
anneal anywhere on the genome and has a nonrandom tail. One microliter of purified
product from the first round of PCR was used as template for a nested PCR with primers
Round2-BTK24 (5’-GCACTCCCGTTCTGGATAAT-3’) and Round2-Pa (5’-GGCCACGCGTCGACTAGTAC-3’) (855). The products were gel-purified and sequenced with
another nested Tn-specific, outward-facing primer BTK24-seq (5’-GCGGATAACAATATAATGTGTGGA-3), that will read through the junction and into the genome. Mapped
insertions were subsequently confirmed by gene-specific PCR.

3.4 Results and Discussion

3.4.1 AmpR downregulates poxB expression. Previous work in an E. coli heterologous
background showed increased PoxB activity in the absence of AmpR suggesting the
transcriptional regulator normally acts to downregulate poxB expression (710).
Regulation of the pox operon, however, has not yet been examined in P. aeruginosa. The
expression of poxB was thus quantified in the presence and absence of β-lactams in an
ampR deletion strain (PA0ΔampR) by RT-PCR. In the absence of the inducer, equivalent
amounts of poxB mRNA were observed in both wild-type and PA0ΔampR (Figure 3.3).
In the presence of the inducer, however, significantly higher amount of poxB mRNA was
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detected in an ampR-deficient background. This finding confirms previous work done in
a heterologous host (710) and suggests AmpR negatively regulates pox expression in the
presence of β-lactams.

4
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Figure 3.3. Expression of poxB in the absence of AmpR. RNA was isolated from PA01
and PA0ΔampR in the presence and absence of imipenem (0.15 µg/ml), reversed
transcribed to cDNA and tested by qPCR with poxB specific primers, as described in the
Materials and Methods. Values were normalized to the expression of the wild-type
uninduced sample and represent the mean (±SD) of two experiments conducted in
triplicates. * p-value< 0.01 for poxB expression in PA0ΔampR induced as compared to
PA01 induced, as determined by unpaired t-test.
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3.4.2 PoxB β-lactamase activity. To determine if the differential RNA expression
observed in the absence of ampR actually translates into quantifiable changes at the
protein level, the β-lactamase activity of PA0ΔampR and PA0ΔampRΔpoxB strains was
measured in the presence and absence of the inducer. As expected, in the wild-type βlactamase levels are detectable and induced upon β-lactam challenge (Figure 3.4). This
activity could be due to either AmpC alone or AmpC and PoxB combined.
The β-lactamase activity did not significantly increase in the absence of induction
in PA0∆ampR, the levels being equivalent to that of wild-type uninduced. In the presence
of the inducer, however, deletion of ampR resulted in the loss of induction, suggesting the
activity observed is likely due to the constitutive expression of ampC, which requires
AmpR for induction. A further deletion of poxB from an already ampR-deficient strain
yielded β-lactamase levels similar to that of PA0∆ampR, with no inducibility being
detected upon exposure to β-lactams. A PA0ΔampCΔampR strain behaved similarly to an
ampC deletion strain characterized in Chapter 2, in that it produced negligible amounts of
β-lactamase. The activity of PoxB thus, appears to be very low and masked by the
expression of ampC. The inducibility of poxB observed at the mRNA level (Figure 3.3)
does not translate into a detectable difference in terms of β-lactamase activity in the
conditions tested.
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Figure 3.4. β-lactamase expression of PA01 and its isogenic mutants. The β-lactamase
activity was quantified for the wild-type strain PA01 and the isogenic mutants
PA0∆ampR, PA0∆ampR∆poxB, PA0∆ampC and PA0∆ampC∆ampR, in the presence and
absence of the inducer. Logarithmic-phase cultures were induced with 0.15 µg/ml of
imipenem for 1 hour before harvesting. Assays were performed in triplicates on
BugBuster and rLysozyme-treated lysate using nitrocefin as chromogenic substrate. One
milliunit of enzyme is defined as 1 nmol of nitrocefin hydrolyzed per minute per
microgram of total protein. * p-value= 0.0001 for β-lactamase activity in PA0ΔampR
induced versus activity in PA01 induced, as determined by unpaired t-test.
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3.4.3 AmpR does not bind Ppox. As a LysR-type transcriptional regulator, AmpR
regulates gene expression by binding to DNA with its canonical N-terminal HTH motif
(856). Binding to the ampC promoter has been found to occur in both the presence and
absence of β-lactams (839, 840, 852). An EMSA was thus performed to determine if
AmpR directly binds the pox promoter. A [γ-32P] ATP radiolabeled Ppox fragment was
incubated with increasing concentrations of total membrane fractions extracted from cells
overexpressing a C-terminal His-tagged AmpR that was previously shown to be
functional (852). Cell extracts were recovered in the presence and absence of
benzylpenicillin. A 193-bp fragment corresponding to the ampC promoter region was
used as positive control as it was been previously shown to bind AmpR (852).
As expected and previously shown, AmpR was able to shift PampC in the presence
and absence of the inducer (Figure 3.5, Lanes 16 and 18), indicating EMSA conditions
were working properly. AmpR, however, did not shift a 335-bp Ppox fragment in the
presence (Lanes 8-12) or absence (Lanes 2-6) of benzylpenicillin, indicating AmpR does
not bind the pox promoter. If AmpR is in fact regulating expression of poxB, as suggested
by previous work and by qPCR here, then this regulation is indirect. This hypothesis is
further substantiated by the absence of an AmpR-binding site in the pox promoter region.
Previous work from our lab has shown AmpR is global regulator controlling
expression of not just ampC, but also of various other genes including a number of
putative and characterized transcriptional regulators and sigma factors such as creB,
pprB, algB, algT/U and rpoS (710, 842, 843). Thus it is possible that AmpR regulates
poxB through these or other, as of yet, unidentified regulators.
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Figure 3.5. P. aeruginosa AmpR does not bind to Ppox. Fifty fmol of a 300-bp radio-labeled Ppox fragment (Lane 1)
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3.4.4 PoxA autoregulates its own promoter. Autogenous regulation is a common
regulatory mechanism in which a gene product regulates expression of the very gene that
encodes it (857). Autoregulation, especially negative autoregulation, is a common theme
among transcriptional factors and regulators, with over 40% of E. coli transcriptional
factors regulating their own synthesis (857-859). Autoregulation however, also occurs in
non-regulatory structural genes including those coding for enzymes involved in a myriad
of metabolic processes, often with the first gene regulating the expression of the rest of
the genes in that operon (857, 860).
Since the role of PoxA was unclear, we postulated that PoxA may autoregulate
the pox operon. In order to determine if this was the case, poxA was expressed in a lowcopy plasmid under an IPTG inducible promoter and introduced into PA01 carrying a
chromosomal Ppox-lacZ fusion. In the absence of induction, the pox promoter exhibited
high basal, constitutive levels in both the presence and absence of poxA in trans (Figure
3.6). After one hour induction with IPTG, a small but significant decrease in Ppox activity
was observed in the presence of poxA, suggesting PoxA at high levels can negatively
regulate its own transcription. The trend, although no longer statistically significant, was
also observed 2 hours after IPTG induction. In wild-type, PoxA may contribute to
maintaining low levels of PoxB. Indeed poxB mRNA levels are relatively low and appear
for the most part to be uninducible in PA01 (Figure 3.3). PoxA is a putative hydrolase of
yet uncharacterized function.
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Figure 3.6. Activity of the pox promoter in the presence of pPoxA. The activity of the
pox promoter activity was quantified in PA01 carrying a chromosomal lacZ fusion in the
presence and absence of PoxA in trans. Exponentially growing cultures were induced
with 1 mM IPTG for 1 or 2 hours before harvesting for quantification of β-galactosidase
activity. * p-value <0.05 for promoter activity of PA0::Ppox-lacZ (pPoxA) in the presence
of IPTG vs Ppox activity in the same strain in the absence of IPTG, as determined by
paired t-test.
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3.4.5 Approach to identifying regulators of the pox operon. To identify other possible
regulators of the pox operon we have taken a global approach that involves construction
of a P. aeruginosa mutant library with potential transposon insertions into regulators of
pox expression. In order to screen for desired insertions, two reporter strains, PA0::PpoxlacZ and PA0∆ampR::Ppox-lacZ, were constructed and the conditions needed for a
successful genetic screening were investigated by examining promoter activity in the
presence of X-gal or ONPG.
As expected from previous work, the pox promoter was found to be more active
in the absence of ampR as evidenced by the distinctly dark blue phenotype displayed by
PA0∆ampR::Ppox-lacZ on plates containing X-gal (Figure 3.7 B and D). PA0::Ppox-lacZ,
on the other hand, having an intact AmpR that can repress Ppox, displayed a greenish to
light blue colony phenotype (Figure 3.7 A and C). For subsequent selection and screening
of the mutant library, 100 µg/ml of X-gal was used, however, lower concentrations of 40
and 60 µg/ml of X-gal were also effective at showing color differences.
The promoter activity was also investigated by the β-galactosidase assay. In the
positive control PampC activity was detected in the absence of induction and induced 3fold upon β-lactam challenge (Figure 3.8). On the other hand, Ppox activity was detected
in both PA0::Ppox-lacZ and PA0∆ampR::Ppox-lacZ, with higher activity observed in the
absence of ampR upon induction with β-lactams (Figure 3.8). These findings are in
agreement with the mRNA study (Figure 3.3) and the visual analysis of Ppox activity
(Figure 3.7).
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Figure 3.7. Activity of the P. aeruginosa pox promoter. The 10-5 and 10-6 dilutions of
freshly grown PA01 (Panels A and C) and PA0∆ampR (Panels B and D) cells carrying
Ppox-lacZ were plated on LB agar plates containing 40 (data not shown), 60 or 100 µg/ml
of X-gal. The promoter activity was ascertained by visually inspecting colony color
phenotype after an O/N incubation at 37°C.

140

Figure 3.8. Ppox activity in the presence and absence of ampR. PA01 and PA0∆ampR
cells carrying Ppox-lacZ were grown at 37°C and induced with benzylpenicillin at an
OD600 of 0.5 for 1 hour. The assay was performed on cell lysate using ONPG as a
chromogenic substrate. β-galactosidase activity was quantified in Miller units in the
presence and absence of β-lactams. * p-value<0.05 versus uninduced PA0::PampC-lacZ; **
p-value<0.02 versus uninduced PA0∆ampR::Ppox-lacZ as determined by paired t-test.
3.4.5.1 Identifying negative regulators. Having an intact ampR, PA0::Ppox-lacZ
displays a light blue phenotype on X-gal (Figure 3.8). Thus we postulate that the dark
blue colonies resulting from the transposon mutagenesis of this strain are likely to have
insertions into negative regulators of pox expression (Figure 3.9). Alternatively, a falsenegative dark blue colony could result from insertions immediately upstream of lacZ such
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that transcription from the Tn drives expression of the β-galactosidase gene. Only
mapping can determine the exact Tn insertion site.

Strain

Colony
color on
X-gal

PA0::
Ppox-lacZ

White light blue

Transposon insertion

Resulting
phenotype

Ppox lacZ
Dark Blue

Regulator

Negative
False Negative

Ppox lacZ
ΔampR::
Ppox-lacZ

White-light
blue

Dark Blue

Positive
False Negative
False Negative

Figure 3.9. Predicted color phenotype before and after Tn insertion into putative
regulators of the pox operon. Blue triangles indicate transposon insertion sites; yellow
arrows denote any positive or negative regulator-encoding genes.

3.4.5.2 Identifying positive regulators. PA0∆ampR::Ppox-lacZ displays a
distinctly dark blue phenotype on X-gal (Figure 3.8). Upon Tn mutagenesis of this strain,
colonies that display a white to light blue color, indicative of a decrease in Ppox activity,
potentially have insertions in genes encoding positive regulators of pox expression
(Figure 3.9). There are, however, two other possible Tn insertions that can lead to
repression of lacZ resulting in a white phenotype: (a) Tn insertion into Ppox that controls
the transcription of lacZ, or (b) Tn insertion into lacZ itself. To determine where in the
genome the insertion occurred, Tn-specific primers will be used to sequence through the
transposon junctions and into the genome.
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3.4.6 Construction of mariner Tn library. A P. aeruginosa PA01 mutant library was
constructed by mutagenesis of PA0::Ppox-lacZ and PA0∆ampR::Ppox-lacZ with the Tn
delivery vector pBTK24 (Figure 3.10). This vector is derived from the pBT20
minitransposon (861) and like its predecessor, carries the Himar1 mariner transposase
element isolated from the horn fly Haematobia irritans (855, 862, 863).

IR

IR
Transposable
Element

Ptac

Figure 3.10. Plasmid map and features of the mariner transposon vector, pBTK24.
pBTK24 has an ori R6K origin for replication in E. coli and an ampicillin marker for
plasmid propagation. The transposase-encoding gene, mariner C9, is responsible for
excision and recombination of the transposable element. Inverted repeats depicted in blue
flank the transposon, which carries a gentamicin cassette for selection and an outwardfacing Ptac promoter for transcription of downstream genes.
The pBTK24 vector also carries an oriT origin for transfer into Pseudomonas, but
having only an E. coli origin of replication (ori R6K), is a suicide delivery vector that
cannot be propagated in a P. aeruginosa background. The mariner C9 transposase is
encoded on the plasmid backbone to promote transposition and to prevent transposase
integration into the genome. The transposable element itself is flanked by 29-bp inverted
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terminal repeats (ITRs), which are recognized by the transposase for transposition by a
cut-and-paste mechanism (861). Additionally, the transposable element contains a
gentamicin cassette for selection and an outward-facing Ptac promoter for transcription of
downstream genes to prevent polarity.

3.4.6.1 Generation of the transposon library.

Transposon libraries of

PA0::Ppox-lacZ and PA0ΔampR::Ppox-lacZ were obtained by mutagenesis with E. coli
SM10 λpir (pBTK24). Each recipient strain was mutagenized on four different occasions
(mating events), with a total of 20 matings per event, in order to generate a library with
coverage over the entire PA01 genome. A total of 163,266 colonies were obtained for the
PA0ΔampR::Ppox-lacZ library and more than 503,988 colonies were obtained for
PA0::Ppox-lacZ (Table 3.5).

Table 3.5. Approximate colony count after Tn mutagenesis
Strains

Mating Events

Colony Count

1

387,625

2

86,427

3

299,36

4

ND

Total

> 503, 988

1

973

2

3,329

3

19,766

4

139,198

Total

163,266

PA0::Ppox-lacZ

PA0ΔampR::Ppox-lacZ

ND-Not determined
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3.4.7 Mapping insertion sites and identification of regulators
3.4.7.1 PA0::Ppox-lacZ library. Mapping was first attempted on 44 blue colonies
obtained from the PA0::Ppox-lacZ library (3rd and 4th mating events, Plate # 8, Figure 3.
1). Out of these, 15 insertions could be confirmed by gene-specific PCR and were
selected for further analysis. The majority of the Tn insertions were mapped to genes and
operons involved in the biosynthesis of lipopolysaccharide (LPS) (Table 3.6). Often
insertions occurred twice in the same gene but at different positions within the ORF (e.g.,
wbpJ, wzt, wbpY, and rmlA). Two clones had a Tn insertion that mapped to the same
location within wzt, suggesting these two clones were siblings. Three different insertions
were found within the PA3488 ORF, coding for a hypothetical, unclassified protein.
Although these 15 colonies displayed a dark-blue phenotype on X-gal indicative
of increased lacZ expression, the promoter activity as determined by β-galactosidase
assay was equivalent to that of wild-type (Figure 3. 11 A and B). Thus, determination of
promoter activity by blue/white screening alone was deemed to be insufficient for
identification of regulators.
It is likely that disturbances in LPS created by Tn insertions in such genes, led to
porosity of the membrane and leakage of the enzyme where it could readily cleave X-gal.
Subsequently, all blue PA01 colonies frozen in the 4 x 96-well plates (Plates 8-11) from
the 3rd and 4th mating events (Figure 3.1) were further screened by assaying the level of
β-galactosidase activity before selecting for mapping. Colonies producing significantly
different levels of enzyme as compared to the control strain were selected for mapping.
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Table 3.6. Mapped insertions from PA01 library, Plate # 8
Well
Insertion
Insertion
Gene
Function
ID
Site
Coordinate
A4

PA3147

3530530

wbpJ

Glycosyltransferase

B4

PA3147

3530649

wbpJ

Glycosyltransferase

E1

PA5450

6140010

wzt

F1

PA5450

6140164

wzt

E9

PA5450

6140164

wzt

E11

PA5448

6137971

wbpY

Glycosyltransferase

H1

PA5448

6137221

wbpY

Glycosyltransferase

C1

PA5451

6141320

wzm

A1

PA5163

5812349

rmlA

E6

PA5163

5812475

rmlA

D3

PA4999

5616945

waal

O-antigen ligase

F7

PA0795

874014

prpC

Citrate synthase

B5

PA3488

3906941

-

Hypothetical protein

E4

PA3488

3906772

-

Hypothetical protein

F5

PA3488

3907035

-

Hypothetical protein

ABC subunit of A-band LPS
efflux transporter
ABC subunit of A-band LPS
efflux transporter
ABC subunit of A-band LPS
efflux transporter

Membrane subunit of Aband LPS efflux transporter
dTDP-glucose
pyrophosphorylase
dTDP-glucose
pyrophosphorylase

Screening did not reveal any noteworthy colonies in Plates 9 and 11, however, in
Plate 8, two colonies were identified, B6 and G7, as having 8-fold higher promoter
activity than the control (Figure 3. 12). These, however, turned out to be false negative as
mapping revealed the Tn inserted immediately upstream of the lacZ ORF and mapping
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Figure 3.11. β-galactosidase activity of Tn mutants. The β-galactosidase activities of 15
Tn mutants showing a dark-blue phenotype on X-gal were quantified in the absence of
induction as described in Materials and Methods. The pox promoter activity of the
mutants (panel A and B) was found to be similar to the unmutagenized parent strain
PA0::Ppox-lacZ (Control).
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revealed the Tn inserted immediately upstream of the lacZ ORF and downstream of the
cloned pox promoter, with the -35 and -10 sequences of the Tn inserted in the direction of
lacZ. Thus, the outward-facing promoter of the transposable element appears to be
driving the high level expression of lacZ observed in these clones.

β-galactosidase Activity (Miller units)

1600
1400
1200
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800
600

400
200
0

Control

B6

G7

Figure 3.12. β-galactosidase activity of Tn mutants. The β-galactosidase activities of 96
blue colonies from the PA01 library (Plate 8) were quantified in the absence of induction
as described in Materials and Methods. Only two colonies from plate 8, B6 and G7,
were identified as having significantly higher lacZ expression than the unmutagenized
control, PA01::Ppox-lacZ.
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Screening of Plate 10 revealed that colonies A3, A4, A5, A6, B8 and B11 had
both a darker blue and higher β-galactosidase activity than the control (Figure 3.13 K and
L). Similar to clones B6 and G7 above, colonies A3, A4 hat the Tn inserted immediately
upstream of the lacZ ORF and downstream of the cloned pox promoter. Colonies A6 and
A12 had insertions in the LPS genes wbpY and wbpL. As these two colonies only had
slightly higher β-galactosidase activity than control, they were not pursued further.
Clones A5 (DZ478) and B8 (DZ481) had insertions in PA0322 and in PA0301 (spuE),
respectively (Figure 3.14). The role of these two genes will be explored in a later section.
Although the data from Plate 8 failed to identify any regulators, these data serve
to validate the study and screening methods. In general, colonies displaying high lacZ
activity were also dark in color. On the other hand, having a dark blue phenotype does
not always correlate with increased lacZ expression. Specifically, disturbances in the LPS
layer can allow for the color phenotype to be enhanced as a leakier, more porous
membrane presumably allows escape of LacZ or uptake of X-gal (J. Goldberg, personal
communication). Lastly, the outward-facing promoter of the transposable element was
found to be very efficient at transcribing downstream genes, with expression of lacZ
increasing up to 8-fold when such promoter was located upstream (Figure 3.12). Thus
evaluation of potential clones must take into account not only the contribution of the Tndisrupted gene but also the transposon-driven expression of nearby genes.
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Figure 3.13. Qualitative and quantitative screening of PA0::Ppox-lacZ transposon
mutants. Twenty-four dark blue colonies from Plate 10, wells A1 through B12, were
patched onto an LB plate containing imipenem (0.15 µg/ml), Gm (75 µg/ml) and X-gal
(100 µg/ml) and incubated O/N at 37°C for qualitative determination of promoter activity
(Panel K). The β-galactosidase activities were also quantified in triplicates in the absence
of induction as described in Materials and Methods (Panel L). Rows D-E and G-H are
technical replicates of rows A-B. Wells C1-C3 and F1-F6 represent activity of the control
unmutagenized strain PA0::Ppox-lacZ. The promoter activity, as measured by βgalactosidase assay (Panel L), is consistent with the activity observed in X-gal plates
(Panel K). Colonies A3, A4, A5, A6, B8 and B11 have both a dark blue phenotype and
increased hydrolysis of ONPG as evidenced by the darker yellow color. Although
colonies A1 and A12 appear to have slightly more β-gal activity than then control (Panel
L), only data from A3, A4, A5, A6, B8 and B11 could be subsequently reproduced.
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Figure 3.14. Genomic localization of PA0322 and spuE. PA0322 and SpuE were
identified as possible regulators of the pox operon using genome-wide genetic screen.
spuE encodes a polyamine transport protein and is part of a transcriptional unit
containing two operons involved in the biosynthesis and transport of polyamines (Pannel
A). PA0322, is a probable amino acid transporter with homology to the E. coli amine
transport protein YcjJ, also implicated in a polyamine-utilizing pathway (Pannel B).
These two genes are about 25, 000 bp and 21 ORFs away from each other (Pannel C) and
localized in a clusters of genes mostly involved with polyamine transport, utilization and
metabolism.
3.4.7.2 PA0ΔampR::Ppox-lacZ library. Screening of PA0ΔampR::Ppox-lacZ
library has thus far identified 77 white to light blue colonies (Figure 3.15A), 14 of which
showed varying degrees of mucoidy. Additionally, 21 colonies displaying a dark blue
phenotype were selected for further analysis as they appeared to be darker than the
unmutagenized parent strain, PA0ΔampR::Ppox-lacZ (Figure 3.15B).

A

B

Figure 3.15. Screening of PA0ΔampR::Ppox-lacZ library. Colonies obtained after Tn
mutagenesis of PA0∆ampR were all pooled and frozen in 10% skim milk in vials and 96well plates. Screening was performed on a number of wells (A1-C10) from Plate #1 by
growing scrapings in LB at 37°C for 45 minutes. The 10-5 and 10-6 dilutions were plated
on LB-PIA-Gm75-X-gal100. Seventy-seven white (Panel A) and 21 darker blue (Panel B)
colonies were selected for further analysis.
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The 77 white to light blue colonies were further screened by patching them onto
LB-Gm75-X-gal100 plates. Ten of these colonies displayed a clear white phenotype, and
not surprisingly carried insertions within various positions of lacZ. The rest of the 77
colonies, ranging in color from light blue to the typical light green of P. aeruginosa, were
further analyzed by assaying β-galactosidase activity. Only two colonies, CR88 and 90,
were found to produce low β-galactosidase activity but similarly carried insertions in
lacZ.
The 21 dark blue colonies showing a darker phenotype than that of the
unmutagenized parental strain, were suspected of having the insertion immediately
upstream of lacZ, with the promoter from Tn likely responsible for intense blue color
observed. Alternatively, the intense blue color could be due to increased leakage from
the cell, as previously hypothesized. A region immediately upstream of lacZ was thus
PCR amplified to check for transposon insertion. All but six of these colonies had
insertions in the MCS of mini-ctx-lacZ, thus explaining the intense dark color observed.
The remaining six colonies were assayed for promoter activity, however all colonies
produced β-gal similar to that of the isogenic strain. Thus far, the PA0ΔampR library has
not yielded any potential leads, however, screening has not yet been completed for this
library.

3.4.8 Role of PA0301 and PA0322. Since colonies B8 and A5 (plate 8, PA01 library)
had increased lacZ activity, a darker blue phenotype and carried Tn insertions in spuE
and PA0322, respectively, we decided to further explore the role of these two genes and
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their possible link to β-lactam resistance. SpuE (PA0301) forms part of the
spuABCDEFGH gene cluster (Figure 3.14A) involved in the utilization and transport of
polyamines (putrescine, cadaverine, spermidine, spermine) (864). Polyamines are small
polycationic organic compounds having more than one primary amine ( ̶ NH2 group) and
ubiquitously found in prokaryotes and eukaryotes (Figure 3.16) (845, 865). They are
essential for growth and due to their cationic nature they are able to interact with
polyanionic molecules such as nucleic acids (848, 866-868). They have also been shown
to stabilize and condense DNA (869-871). Their ability to bind DNA and RNA translates
into a range of pleiotropic effects such as modulation of protein-DNA interaction,
transcription and translation among many others (846, 849-851, 872-874). They have also
been reported to affect the activity of a number of ion channels such as the inwardly
rectifying potassium channel and to decrease outer membrane permeability in E. coli
(875-877).

Figure 3.16. Structures of some commonly encountered polyamines
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Besides their synthesis and catabolism, bacteria are able take up polyamines from
the environment (847, 878). P. aeruginosa can use polyamines as sole source of carbon
and nitrogen (864, 879). Two main ABC-transporter-type polyamine uptake systems have
been reported in E. coli: the PotA/B/C/D or the spermidine-preferential pathway, and the
PotF/G/H/I or the putrescine-specific system (880-882). A homologous system has been
found in P. aeruginosa encoded by the spuABCDEFGH gene cluster, where spuD and
spuE encode the periplasmic polyamine binding proteins for putrescine-preferential and
spermidine-specific binding, respectively (864, 883). SpuG and SpuH are the poreforming permeases in the inner membrane and SpuF is the ATPase for energy-driven
transport. SpuA, B and C encode putative enzymes for the utilization of polyamines.
Previous work showed that polyamines decreased expression of T3SS secretions
and virulence genes in PA01 (884). Polyamines were also shown to increase resistance in
P. aeruginosa against aminoglycosides, with resistance against quinolones and cationic
peptides being mediated by the expression of the oprH-phoPQ operon (885). In contrast,
polyamines significantly increased susceptibility of P. aeruginosa against a number of βlactams including the penicillins ampicillin, carbenicillin, piperacillin and ticarcillin, and
the third generations cephalosporins ceftazidime, cefoperazone and ceftriaxone (886).
This reduction in resistance was not linked to a decrease in expression of ampC or to
disruption of the outer membrane as expected of polycationic ions which are known to be
outer membrane disorganizers (886). Similarly, A. baumannii clinical and lab strains
were shown to be more susceptible to the β-lactams aztreonam, carbenicillin, piperacillin
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and ticarcillin when treated with spermine and spermidine, but only a slight to moderate
effect was observed against ceftazidime or meropenem (887).
PA0322 also encodes a probable amino acid transporter sharing 61% homology
with the E. coli YcjJ (PuuP) enzyme, which coincidently is a putrescine importer (888890). The Puu system is one of several putrescine utilization pathways reported in E. coli
besides the Pot system. Not much is yet known about the role of PA0322 as it still
remains uncharacterized. PA0322 does appear to form a putative operon with the
upstream ORF PA0321, which displays 67% similarity to an acetylpolyamine
aminohydrolase from Mycoplana ramosa involved in putrescine catabolism (891).
While identifying two targets that involve polyamine transport/utilization is
promising, the range of pleiotropic effects these molecules have can obscure the real
connection to the pox promoter. The observed phenotype may simple be an indirect effect
with no actual connection to Ppox. Additionally, membrane perturbations cannot be ruled
out as the main cause of the observed phenotype.
Increased poxB expression has been shown to decrease susceptibility against the
carbapenems (Chapter 2). In order to see if carbapenem susceptibility was altered in these
clones and if polyamines can affect susceptibility towards these β-lactams, the MIC
against carbapenems was determined in the presence and absence of the polyamine
spermidine. Addition of 1 mM of spermidine produced little to no change in
susceptibility across strains and β-lactams, while a concentration of 20 mM spermidine
was bactericidal to all strains tested (Table 3.7).
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Table 3.7. β-lactam MIC in the presence of spermidine
Polyamine
(mM)

PA0::PpoxlacZ

PA0::Ppox-lacZ
PA0322::Tn

PA0::Ppox-lacZ
spuE::Tn

Meropenem

0
1
5
10

1.5
1.5
>32
>32

1.5
2
>32
>32

1
1.5
>32
>32

Doripenem

0
1
5
10

0.19
0.25
0.75
2

0.19
0.25
1
2

0.19
0.50
1
2

Imipenem

0
1
5
10

0.75
1.5
6
>32

1
1.5
8
>32

1
1.5
12
>32

Ceftazidime

0
1
5
10

1.5
1.5
2
8

1.5
1.5
1.5
8

1.5-2
1.5
2
8

Piperacillin

0
1
5
10

4
4
4
12

3
3
4
12

4
3
4
12

Ticarcillin/
Clavulanate

0
1
5
10

12
12
6
8

12
12
8
8

12
8
8
8

Aztreonam

0
1
5
10

2
2
1
1.5

2
1.5
1
1.5

1.5
1.5
1
1.5

β-lactam
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The presence of 5 or 10 mM of spermidine rendered all strains very resistant
towards meropenem (MIC >32 µg/ml). This change however, occurred in both the
unmutagenized and mutagenized strains and thus is likely unrelated to altered Ppox
activity in Tn mutants. Similarly, spermidine at 5 mM produced a significant increase in
MIC against imipenem, with 10 mM leading to resistance against this β-lactam in a
strain-independent manner (MIC >32 µg/ml). A smaller but significant decrease in
susceptibility was also produced against doripenem that, although not leading to
resistance, raised MIC values 4-5-fold and 10-fold in the presence of 5 and 10 mM of
spermidine, respectively. Spermidine also produced a 2-3-fold increase in MIC against
ceftazidime and piperacillin, while having no effect on aztreonam. Overall, although
spermidine was able to alter the MIC values against various β-lactams tested, the most
dramatic increase in MICs were produced against the carbapenems, leading to resistance
against meropenem and imipenem. This experiment does not reveal if poxB expression is
altered or enhanced by the presence of polyamines, merely that polyamines significantly
raise the MIC values against the carbapenems and other β-lactams.
The mechanism by which carbapenem MIC is raised is not clear but it could be
related to a decrease in cell permeability. Previous studies in E. coli have shown that
polyamines decrease outer membrane permeability to the β-lactam cephaloridine by
inhibiting permeation through the porin channels OmpF and OmpC (875, 877).
Similarly, the polyamine cadaverine induced closing of liposome-reconstituted porins in
E. coli and was proposed to be a modulator of porin activity in vivo (876). Under
conditions of oxidative stress, polyamines also increased resistance in E. coli against
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fluoroquinolones, antibiotics that are known to traverse the cell via porins (892). Thus a
decrease in outer membrane permeability could account for the decrease in susceptibility
to carbapenems that is observed in the presence of polyamines in the current study.
However, other studies show that polyamines can sensitize E. coli, S. aureus, Salmonella
and P. aeruginosa to most β-lactams effectively increasing susceptibility against these
and other drugs (886, 893). The reduction in MIC suggested that any possible decrease
in permeability, caused by polyamine inhibition of porin transport, did not play a major
role or was not enough of a factor to generate resistance against most β-lactams in those
studies (886, 893).
Porins blockage by polyamines in P. aeruginosa does appear to be a factor
contributing to resistance at least against imipenem (886). Kwon and Lu showed that
while polyamines increased susceptibility against most β-lactams (decreased MIC), the
MIC against imipenem is increased in the presence of polyamines (886, 893). This
increase appeared to occur by blockage of the OprD porin. Inhibition of OprD activity
may explain the results of the present work showing that the MIC against all
carbapenems tested is increased in the presence of polyamines. However, MICs of
various other non-carbapenem β-lactams such as ceftazidime and piperacillin, were also
slightly altered in this study. These β-lactams, however, are not known to use the OprD
porin for passage into the cell. Thus, if polyamines affect susceptibility by blocking of
porins, they may be able to block more than one type of porin besides OprD. In the
present study, spermidine however, appears to be more effective at blocking OprD than
other porins, since it is the carbapenem MIC that is mostly altered. Alternatively,
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although permeability may be an issue contributing to resistance, other polyamine
intracellular effects may be responsible for the increase in MIC observed. Future studies
may elucidate on the expression of poxB in the presence of polyamines and the
mechanism by which polyamines are able to induce resistance against the carbapenems.

3.5 Concluding Remarks
Regulation of class D chromosomal β-lactamases has only been previously
described in Ralstonia pickettii and Aeromonas spp. (567, 730). In R. pickettii, the
induction of two chromosomally encoded β-lactamases, OXA-22 and OXA-60, requires
the regulatory element Rp3 encoded upstream of blaOXA-60 and divergently transcribed
(730). Aeromonas spp. can produce two–three inducible and unlinked β-lactamases, one
of which is an oxacillinase (566, 734-736). Expression of all is coordinately regulated by
a two-component system, BlrAB, encoded immediately upstream of the blaOXA gene
(567, 739). Unpublished studies from our lab showed a two-component system, MifSR,
encoded upstream of poxAB and divergently transcribed, played no role in poxB
expression or carbapenem resistance.
Previous work suggested the transcriptional regulator AmpR may be involved in
the regulation of the pox operon (710). Our transcription studies reveal poxB mRNA
levels increase in the absence of AmpR. The increase in pox mRNA levels, however, do
not translate into quantifiable changes at the protein levels as measured by PoxB βlactamase activity. Additionally, binding of AmpR to the pox promoter was not detected
indicating a possible indirect regulation by AmpR. As genes can often regulate their own
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synthesis and that of the operon they are encoded in, the activity of Ppox was investigated
in the presence of PoxA. PoxA was found to decrease Ppox was activity when expressed in
trans from an IPTG inducible promoter. This finding suggests PoxA is capable of
regulating the expression of the pox operon. Autoregulation by PoxA may account for the
low PoxB activity that is normally observed.
Interestingly, this work has unexpectedly connected the role of the small, essential
molecules polyamines with carbapenem resistance. Specifically, a genome search for pox
regulators identified Tn insertions in two polyamine transport genes leading to increased
Ppox activity. Although the link between polyamine transport and pox expression is not yet
clear, polyamines were found to drastically raise MICs against carbapenems leading to
clinical resistant phenotypes. Whether or not the polyamine-induced carbapenem
resistance is connected to enhanced pox expression, polyamine research may be a new
and worthwhile area of study in the lab.
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4.1 Abstract
Pseudomonas aeruginosa is a dreaded pathogen in many clinical settings. Its
inherent and acquired antibiotic resistance thwarts therapy. In particular, derepression of
the AmpC β-lactamase is a common mechanism of β-lactam resistance among clinical
isolates. The inducible expression of ampC is controlled by the global LysR-type
transcriptional regulator (LTTR) AmpR. In the present study we investigated the genetic
and structural elements that are important for ampC induction. Specifically, the ampC
(PampC) and ampR (PampR) promoters and the AmpR protein were characterized. The
transcription start sites (TSSs) of the divergent transcripts were mapped using 5’ rapid
amplification of cDNA ends-PCR (RACE-PCR), and strong σ54 and σ70 consensus
sequences were identified at PampR and PampC, respectively. Sigma factor RpoN was found
to negatively regulate ampR expression possibly through promoter blocking. Deletion
mapping revealed the minimal PampC extends 98-bp upstream of the TSS. Gel shifts using
membrane fractions showed AmpR binds to PampC in vitro whereas in vivo binding was
demonstrated using ChIP-qPCR. Additionally, site-directed mutagenesis of the AmpR
helix-turn-helix (HTH) motif identified residues critical for binding and function (Ser38,
and Lys42), and critical for function but not binding (His39). Amino acids Gly102 and
Asp135, previously implicated in the repression state of AmpR in the enterobacteria,
were also shown to play a structural role in P. aeruginosa AmpR. Alkaline phosphatase
fusion and shaving experiments suggest that AmpR is likely to be membrane associated.
Lastly, in vivo cross-linking study shows that AmpR dimerizes. In conclusion, a potential
membrane-associated AmpR dimer regulates ampC expression by direct binding.
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Key Words: β-Lactam resistance, LysR-type transcriptional regulator, AmpC βlactamase

Abbreviations: EMSA, electrophoretic mobility shift assay; HTH, helix-turn-helix;
LTTR, LysR-type transcriptional regulator; PG, peptidoglycan; RACE-PCR, rapid
amplification of cDNA ends-PCR; TSS, transcriptional start site
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4.2 Introduction
Pseudomonas aeruginosa, a Gram-negative opportunistic pathogen, causes severe
and life-threatening infections in susceptible individuals. This pathogen is primarily
associated with morbidity and mortality in patients with cystic fibrosis, a deadly genetic
disease (742). The bacterium’s innate ability to counteract the action of antibiotics often
complicates treatment strategies. Intrinsic resistance is conferred by its low membrane
permeability, the expression of efflux pumps and hydrolyzing enzymes, the alteration of
antimicrobial targets and the ability to form biofilm (246, 436, 781). In particular,
resistance to β-lactam antibiotics is mediated by the expression and overproduction of a
chromosomally-encoded class C β-lactamase AmpC (379-381).
Ambler class C β-lactamases were first described in members of the
Enterobacteriaceae family where expression is either constitutively low or inducible (375,
376, 630, 894). In species where expression is inducible, such as Citrobacter freundii
and Enterobacter cloacae, the induction requires β-lactam challenge and the presence of
a transcriptional regulator AmpR (375, 712, 895, 896). AmpR is a member of the LysR
family of transcriptional regulators and as such is a DNA-binding protein with a
predicted helix-turn-helix (HTH) motif at the N-terminus and an inducer-binding domain
at the C-terminus (856, 897). Comprehensive studies in the Enterobacteriaceae have
established the critical role of AmpR as the regulator of ampC expression and the
paradigm of β-lactamase induction.
In the Enterobacteriaceae, ampC inducibility is intimately linked to the recycling
of the peptidoglycan (PG) of the murein sacculus (713, 716, 718, 721). During normal
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physiological growth, N-actylglucosaminyl-1,6-anhydromuropeptides (GlcNAc-1,6anhydro-MurNAc tri, tetra, and pentapeptides) are continuously being released from the
murein sacculus due to remodeling (716, 718). The permease, AmpG, transports the
metabolites into the cytoplasm where the glycosidase NagZ removes the GlcNAc moiety
and the amidase AmpD removes the stem peptides from either the incoming GlcNAc-1,6anhydro-MurNAc-peptides or from the NagZ-processed product (716, 717, 719, 898901). The resulting muramyl peptides are recycled back into the PG biosynthetic pathway
to form the PG precursor UDP-MurNAc-pentapeptide (902). It has been proposed that
during normal cell growth, the cytosolic concentrations of UDP-MurNAc-pentapeptide
maintain AmpR in an inactive conformation that represses the expression of ampC (716,
718). In the presence of β-lactams, however, there is an excessive breakdown of murein
leading to accumulation of 1,6-anhydromuropeptides in the cytoplasm, which in turn
overwhelm the hydrolytic activity of AmpD (714, 716, 718, 903). The increased number
of AmpD-unprocessed muramyl peptides presumably displaces the repressor UDPMurNAc-pentapeptide from AmpR and induce a conformational change in the protein to
promote expression of ampC (714, 718, 903).
All amp gene homologs (ampC, ampR, ampD and ampG) have been identified
and studied in P. aeruginosa (643, 710, 711, 776, 782, 904-906). Whether a similar
induction mechanism is employed by P. aeruginosa is not yet known, however, recent
work illustrates significant departures from the classical enterobacterial induction system.
In particular, there are three ampD homologs in P. aeruginosa that are responsible for a
stepwise up-regulation mechanism leading to constitutive β-lactamase hyperexpression
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(246, 643, 904). Additionally, P. aeruginosa harbors two AmpG homologs, PA4218
(AmpP) and PA4393 (AmpG) that appear to be required for induction of ampC (837,
906). Further, our lab has shown that P. aeruginosa AmpR is a global transcriptional
regulator involved in the control of amp and various other genes (710, 842-844).
AmpR exhibits high sequence identity with its counterparts in C. freundii and E.
cloacae, and as in the Enterobacteriaceae, ampR is located immediately upstream of
ampC and divergently transcribed (711, 776). Such similarities suggest a common
regulatory mechanism among the species, however, the P. aeruginosa ampR-ampC
intercistronic region bears little resemblance to that of the enterobacteria. In vitro studies
using crude extracts have shown P. aeruginosa AmpR binds to this region, but the exact
binding site and the identity of the amino acids involved in the interaction have not yet
been determined (776). In essence, not much is known about the structural elements that
are critical to the functioning of P. aeruginosa AmpR as regulator of β-lactamase
expression.
In the present work, we define some of the genetic elements in the ampR-ampC
intergenic region including the ampR and ampC transcriptional start sites, as well as, the
minimal length of the ampC promoter needed for induction of the ampC system. We
further show AmpR specifically binds to the 193-bp PampC fragment identified by
promoter mapping as being required for induction. We also identify amino acids in the
AmpR HTH motif that are critical for the interaction with the promoter. Additionally, we
examine the role of two amino acids, Gly102 and Asp135, previously implicated in the
repression state of AmpR from the Enterobacteriaceae. Lastly, we show that P.
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aeruginosa AmpR likely functions as dimers as previously seen for C. freundii and is
potentially a membrane protein.

4.3 Materials and Methods

4.3.1 Bacterial strains, plasmids and media. Bacterial strains, plasmids and primers
employed in this study are shown in Table S1 of the Supplemental Material. E. coli and
P. aeruginosa were routinely cultured in Luria-Bertani medium (10 g tryptone, 5 g yeast
extract, and 5 g NaCl, per liter). Pseudomonas Isolation Agar (Difco) was used with LB
at a 1:1 ratio in triparental mating experiments. Antibiotics were used at the following
concentrations (per milliliter): ampicillin (Ap) at 100 µg, tetracycline (Tc) at 15 µg, and
gentamycin (Gm) at 15 µg for E. coli; Gm and Tc each at 75 µg for P. aeruginosa.
PA0ΔampC and PA0ΔampR strains used in this work were previously constructed using
overlap extension PCR and homologous recombination (760, 843).

4.3.2 PampC promoter deletions. To characterize the minimal promoter necessary for full
activity, 5’-end deletions of PampC were constructed and transcriptionally fused to a
promoterless lacZ. Briefly, 352-, 193-, 171-, 151-, 130-, 111-, 90-, 70-, and 51-bp
fragments were generated by PCR with the following primer pairs respectively:
SBJ03ampCRFor-OCPampCRevBc,
OCPampCRevBc,

OCPampCFor193-OCPampCRevBc,

OCPampCFor151-OCPampCRevBc,

OCPampCFor111-OCPampCRevBc,

OCPampCFor173-

OCPampCFor131-OCPampCRevBc,

OCPampCFor91-OCPampCRevBc,

OCPampCFor71-

OCPampCRevBc, and OCPampCFor51-OCPampCRevBc (Table S1, Supplemental material).
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The fragments were sequenced, then cloned into the EcoRI-BamHI sites of the integrative
vector mini-CTX-lacZ and integrated into PA01.

4.3.3 Construction of His-tagged AmpR. Primers OCAmpR-His-For and OCAmpRHis-Rev (Table S1) were used to amplify PA01 genomic ampR. The 933-bp amplicon,
carrying a His6 sequence at the 3’-end was cloned into pBluescriptSK(+) and sequenced
(Table S1). The fragment was subsequently subcloned into the EcoRI-BamHI sites of
pMMB67EH-Gm, a broad-host range expression vector (763). His-tagged AmpR was
shown to be functional by β-lactamase assay and E-test (Text S1 and Table S2,
Supplemental material).

4.3.4 Expression and purification of AmpR-His6. AmpR-His6 was purified according
to standard protocols. Briefly, stationary-phase cultures of PA0ΔampR (pAmpR-His6)
were diluted to an OD600 of 0.02 in 2 liters of LB broth and incubated with shaking at
37°C until the culture density reached an OD600 of 0.2. Cells were then induced with 1
mM of isopropyl β-D-1-thiogalactopyranoside (IPTG) and incubated for an additional six
hours before harvesting. The cells were recovered by centrifugation at 6,000 X g for 10
minutes at 4°C and resuspended in 25 ml of lysis buffer (20 mM HEPES pH8, 0.5 M
NaCl, 10% glycerol, 1 mM PMSF, 2 pellets of EDTA-free protease inhibitor cocktail
tablets complete, 100 μl of 0.1 mg ml-1 of lysozyme and 5 μl of DNase1). Following
disruption of the cells on ice with sonication (20-s pulse ON and 20-s pulse OFF for 20
minutes, amplitude 50%), the cell lysate was centrifuged at 10,000 X g for 10 minutes at
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4°C. The supernatant was further ultracentrifuged at 36, 000 rpm for 1 h at 4°C.
Membranes pellets were resuspended in 20 ml of solubilization buffer (20 mM HEPES
pH8, 0.5 M NaCl, 10% glycerol, 5 mM imidazole, 1 mM PMSF, 2 pellets of EDTA-free
Protease Inhibitor cocktail tablets complete, and 2 % of CHAPS) and loaded onto a
HisTrap FF 1 ml column. AmpR-His6 was eluted with buffer B (20 mM HEPES pH8,
0.5 M NaCl, 10% glycerol, 500 mM imidazole and 0.6% of CHAPS) by using an FPLC
chromatograph (Akta, Amersham Biosciences). About 20 ml were recovered and
dialyzed to remove imidazole. This AmpR preparation was used to make AmpR-specific
antibodies.

4.3.5 Construction of P. aeruginosa AmpR HTH and point mutants. Site-directed
mutagenesis was used to replace various amino acid residues in AmpR. Briefly, Ser38,
His39, Lys42, Ser43, and Glu46 were replaced with Ala; Gly102 and Asp135 were
replaced with Glu and Asn, respectively. Substitutions were constructed by PCR using
the following primer pairs: AmpRSer38AlaFor-AmpRSer38AlaRev, AmpRHis39AlaForAmpRHis39AlaRev,

AmpRLys42AlaFor-AmpRLys42AlaRev,

AmpRSer43AlaFor-

AmpRSer43AlaRev, AmpRGlu46AlaFor-AmpRGlu46AlaRev, AmpRGly102GluForAmpRGly102GluRev, and AmpRAsp135AsnFor-AmpRAsp135AsnRev (Table S1,
Supplemental material).
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4.3.6 Membrane fraction purification. Preliminary studies showed pAmpR-His6
expression and β-lactamase induction were achieved with a 2-hour incubation at a 1 mMIPTG concentration. Thus, PA0ΔampR (pAmpR-His6) cells at OD600 of 0.2 were induced
with 1 mM of IPTG and incubated for two hours before harvesting for membrane
fractionation. For β-lactamase induction, cells were further treated with 200 µg ml-1 of
penicillin G an hour after IPTG addition. Cells were recovered by centrifugation at 6,000
X g for 10 minutes at 4°C and resuspended in 50 ml of lysis buffer (20 mM HEPES pH8,
0.1 M NaCl, 1 mM EDTA, 1 mM PMSF, and 50 μl of DNase1). Following disruption of
the cells on ice with sonication (15 cycles of 10 second pulse ON and 30 S pulse OFF,
amplitude 40%), the cell lysate was centrifuged at 5,000 rpm for 10 minutes at 4°C. The
supernatant was ultracentrifuged at 36,000 rpm (Rotor Ti70) for one hour at 4°C and the
pellets were resuspended with 2 ml of membrane buffer (25% sucrose, 20 mM Tris pH8,
and 0.5 mM PMSF). Two-hundred milliliters of membrane fractions were aliquoted and
stored at -80°C.

4.3.7 Electrophoretic mobility shift assay (EMSA). The 193-bp PCR fragment
containing the ampR-ampC intergenic region plus a small part of ampR ORF was used to
perform EMSA.

Ten pmol of this fragment were radiolabelled at the 5’ end by

incubation with T4 polynucleotide kinase (NEB) and [γ-32P]ATP (3,000 Ci mmol-1;
Perkin Elmer). The labeled fragment was diluted to a final concentration 100 nM and
unincorporated

nucleotides

were

removed

by sephadex

chromatography. DNA binding reactions containing 50 fmol of
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G-25
32

(Biorad)

spin

P-labeled DNA probe

and varying amounts of total protein membrane fractions were incubated for 20 minutes
and loaded thereafter in a non-denaturating 5% PAGE.

Radioactive signals were

detected by scanning a phosphostorage cassette with the GE Healthcare Typhoon 9400
scanner.
For competition assays, 50 fmol of the 193-bp 32P-labeled probe were mixed with
the unlabeled 193-bp fragment in 10-, 100- and 500-fold molar excess in the EMSA
assay. For nonspecific assays, 50 fmol of the 193-bp 32P-labeled probe were mixed with
a PCR-amplified 233-bp fragment (alg44) in 10-, 100- and 500-fold molar excess in the
EMSA assay.

4.3.8 5’ RACE PCR. The ampC and ampR TSSs were mapped using a classical 5’
RACE-PCR on total mRNAs extracted from PA01, PA0ΔampR and PA0ΔampC (907).
Stationary-phase cultures of PA01, PA0ΔampR and PA0ΔampC were diluted to an OD600
of 0.02 and incubated with shaking at 37°C until the cultures reached an OD600 of 0.6.
The cultures were then induced with 200 µg ml-1 of penicillin G for one hour and
subsequently blocked on ice for 15 minutes with 1/5th of the final culture volume in 5%
acidic phenol-95% ethanol, pH 4. One milliliter of the cells were recovered by
centrifugation and resuspended with 3 mg ml-1 of lysozyme (Tris EDTA, pH 8). RNA
was then extracted according to the RNeasy mini kit protocol (Qiagen), treated with 10 U
of RQ1 DNase (Promega) for one hour, extracted with phenol/chloroform/isoamyl
alcohol (25:24:1) and chloroform, precipitated and dried. Superscript III (Invitrogen) was
then used to reverse transcribe 10 µg of RNA as previously described (907) using primers

172

5RA-PampC233 and 5RA-PampR229 for determination of the ampC and ampR TSS,
respectively. In the first round of PCR amplification (Pfu, Stratagen), primers Q t, Q0, and
5RA-PampC154 were used for ampC TSS determination, while Qt, Q0, and 5RA-PampR169
were used for determination of the ampR TSS. In the second round of PCR amplification
(Pfu, Stratagen), primer pairs Qi-5RA-PampC113, and Qi-5RA-PampR99 were used for
ampC and ampR TSS determination, respectively (Table S1). PCR products were cloned
into TOPO (Invitrogen), blue colonies were selected for screening and clones were
sequenced.

4.3.9 qPCR analysis of ampR and ampC mRNAs. Total RNA was extracted from
PA01, PA0ΔrpoN and PA0ΔrpoN (pRpoN) in the presence and absence of the inducer
(0.2 µg ml-1 imipenem) using the RNeasy mini kit (Qiagen).

RNA was reverse

transcribed into cDNA with Superscript III (Invitrogen) and an (NS)5 random primer
using standard methods (764). For qPCR, the ABI 7500 (Applied Biosystems) cycler was
used with Power SYBR Green PCR Master Mix with ROX (Applied Biosystems). The
reading was normalized to clpX (PA1802), whose expression remains constant in all the
samples and conditions tested. Melting curves were generated to ensure primer
specificity. Gene expression of each sample was normalized to PA01 uninduced value, to
see the effect of induction and mutation at the same time. Primer pairs
DBS_QRTAmpRFwd-DBS_QRTAmpRRev and qRT_ampCF-qRT_ampCR were used
for the real time amplification of ampR and ampC, respectively.
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4.3.10 Construction of VSV-G-tagged AmpR. A 540-bp fragment corresponding to the
3' end of ampR, minus the stop codon, was amplified using primers DB_ampR3’_F and
DB_ampR3’_R. The amplicon was cloned into pP30ΔFRT-MvaT-V (908), a replicationincompetent vector in P. aeruginosa, such that the 3’ end of ampR was fused in frame
with three alanines and the VSV-G tag (YTDIEMNRLGK). The construct was then was
introduced into PA01 as single copy by mating and clones were selected for gentamycin
resistance.

4.3.11 Chromatin immunoprecipitation quantitative PCR (ChIP-qPCR). Cells
harboring the VSV-G-tagged AmpR were harvested after sub-MIC β-lactam exposure
(843) and treated with formaldehyde to cross-link proteins with DNA as previously
described (908). DNA was sheared by sonication to an average length of 0.5-1.0 kb and
AmpR was immunoprecipitated with anti-VSV-G agarose beads (BETHYL Laboratories,
Inc.). ChIP-qPCR was performed using Power SYBR Green PCR Master Mix (Applied
Biosystems) with primers DBS_ChIP_ampCF and DBS_ChIP_ampCR. Fold enrichment
was normalized to clpX (PA1802).

4.3.12 Protein cross-linking. PA0ΔampR (pAmpR-His6) was grown to an OD600 of 0.3
and induced with 1 mM IPTG for 2 hours. Cells were grown for two additional hours in
the presence and absence of β-lactam antibiotics (0.1 µg ml-1 of imipenem). Cultures
were then treated with 0.1% formaldehyde for 20 and 40 minutes at room temperature.
Crude extracts containing 10 µg of total protein were separated on an SDS-
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polyacrylamide gel and AmpR was visualized using anti-His antibody. The blot was
subsequently stripped and reprobed using anti-σ70 antibody (NeoClone).

4.3.13 Polyclonal anti-AmpR-His6 antibody production. Purified AmpR-His6 was
used as antigen to raise anti-AmpR-His6 rabbit polyclonal antibodies (Covance,
Princeton, NJ). AmpR-His6 antibody was affinity-purified as previously described (909).

4.3.14 Western Blotting and EMSA of HTH mutants. Concentration of purified
AmpR-His6 was determined by the bicinchoninic acid (BCA) method (910).

A

calibration Western blot was generated using FujiFilm LAS-3000 imager to correlate
intensities with the concentration of purified AmpR-His6. Membrane fractions were
purified from PA0∆ampR pAmpR-HTH mutants and their concentrations were
determined using the BCA method, whereas the exact quantity of AmpR was deduced
from Western blotting.

Preliminary gel shifts with increasing concentrations of

membrane fractions of AmpR-HTH mutants showed that a 0.4 mg ml-1 is sufficient to
shift the 193-bp PampC PCR fragment (Data not shown). For a second gel shift, a 0.4 mg
ml-1 of total membrane fraction (8.44 ng of AmpR), recovered from PA0ΔampR
overexpressing AmpR HTH mutants in the presence and absence of 200 µg ml -1
penicillin G, was hybridized with the 193-bp PCR fragment spanning the ampC-ampR
intergenic region (Fig. 7). As this concentration was not enough to visualize AmpR, a
higher quantity (33 ng) was used for Western blotting of the HTH mutants to show that
the amount of AmpR-His6 is equivalent under all conditions and thus in the EMSA
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experiment (Data not shown). Further, the stability of AmpR-His6 mutants was verified
by Western using equal amounts of total protein with AmpR-specific antibodies (Figure
4.8). Sigma70 (NeoClone) was used as control to show the same amount of total protein
was loaded per sample. All Western blots were developed according to standard
protocols.

Briefly, proteins were transferred to a PVDF membrane (Bio-Rad) and

blocked with TBST (TBS 0.1 % Tween) and 5 % non-fat dry milk at 4°C overnight or for
four hours, followed by rinsing with the same solution and probing with rabbit antiAmpR antibody (1:3000). Membranes were subsequently washed with TBST, incubated
with goat anti-rabbit IgG (H+L)-horseradish peroxidase-conjugated antibody (1:5000)
(Bio-Rad), rinsed and developed using Enhanced Chemiluminescence Western Blotting
Substrate (Pierce).

4.3.15 β-galactosidase assay. β-galactosidase assays were performed as previously
described (854).

4.3.16 AmpR-LacZ and -PhoA fusion construction and analysis. The topology of
AmpR was investigated using phoA and lacZ fusions. The plasmid pSJ01 (710) carrying
a 1220-bp fragment containing ampR was digested at HindIII, HincII and PstI,
corresponding to the amino acid positions, Gln15, Val134 and Gln186, respectively (Fig.
S2A). The resultant fragments were ligated in-frame upstream of phoA and lacZcontaining plasmids, pTrcphoA and pTrclacZ (Table S1, Supplemental material), (911).
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The phoA and lacZ activities were qualitatively determined in E. coli according to
standard protocols (854).

4.3.17 Protease protection (shaving) assay. A stationary-phase culture of PA0ΔampR
(pAmpR-His6) was diluted to an OD600 of 0.02 and incubated with shaking at 37°C until
the culture reached an OD600 of 0.4. The cells were then induced with 1 mM IPTG for
four hours and chloramphenicol (500 µg ml-1) was added 30 minutes prior to harvesting
to stop protein synthesis. The cells were harvested by centrifugation and resuspended in
40 mM Tris-Cl pH 8.0, 0.5 M sucrose. Spheroplasts were obtained by adding 1 mg ml-1
of lysozyme and 4 mM EDTA for 10 minutes in a 30°C water bath followed by the
addition of 20 mM MgCl2. The formation of spheroplasts was monitored by light
microscopy. Spheroplasts were harvested by centrifugation at 4,000 X g for 10 minutes
and resuspended in 40 mM Tris-Cl pH 8.0, 0.5 M sucrose. Proteinase K (10 µg ml-1) was
added to 1 ml aliquot of the spheroplasts and incubated in a 30°C water bath. Samples
were taken at different time points and added to 2 mM PMSF and 4X SDS PAGE Sample
Buffer.

Samples were then boiled for 5 minutes and ran in a 4-20% SDS-PAGE

(Criterion Biorad). Proteins were transferred to a nitrocellulose membrane (Biorad) and
identified using AmpR (Covance), σ70 (NeoClone) and His-tag (Qiagen) antibodies. The
immunoblot was developed using SuperSignal West Pico Chemiluminescent Substrate
(Thermo Scientific).
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4.4 Results and Discussion

4.4.1 Analysis of the P. aeruginosa ampC-ampR regulatory region. P. aeruginosa
AmpR shares high identity with its homologs in C. freundii and E. cloacae (58.3 and
62.5%, respectively), as well as, the same gene organization, with ampR located upstream
of ampC and divergently transcribed (711, 776). The P. aeruginosa ampR-ampC
intercistronic region, however, shares no significant similarities with that of C. freundii
and E. cloacae, with the exception of an inverted 38-bp sequence that in C. freundii is
protected by AmpR (711, 840). The lack of conservation in the promoter region could
point to different sigma factor requirements and/or different regulatory mechanisms. To
elucidate the transcriptional regulatory elements of P. aeruginosa ampC and ampR, their
148-bp intergenic region was characterized.
The transcriptional start sites (TSS) were determined using 5’ RACE-PCR on
total mRNAs isolated from PA01, PA0ΔampR and PA0ΔampC (Figure 4.1). A strong
similarity to RpoN (σ54) sigma factor sequences was detected at -12 and -24 positions of
the ampR TSS, whereas strong σ70 promoter sequences were observed at the -10 and -35
positions of ampC. Alignment of the C. freundii, E. cloacae and P. aeruginosa intergenic
region reveals a fair conservation for the ampC -10 and -35. However, there is a
downstream shift in the P. aeruginosa ampR TSS that could contribute to the change in
sigma factor control observed here (Figure S1, Supplemental material).
The presence of putative -12 and -24 recognition sequences in the ampR promoter
(PampR) suggested that its expression might be RpoN or σ54-dependent. Quantitative realtime PCR was used to validate this hypothesis. Total RNA was extracted from β-lactam
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Figure 4.1. Intergenic region of P. aeruginosa ampC and ampR. A 148-bp region
separates ampR from ampC. The ampR and ampC transcriptional start sites are indicated
with a blue and green +1, respectively, whereas the colored arrows designate the
beginning of the ORFs. Strong σ54 (blue) and σ70 (green) sequences are observed in the
ampR and ampC promoter regions, respectively. The underlined bases correspond to
conserved sequences. The Shine-Delgarno sequences or ribosome binding sites (RBS) are
marked by asterisks. A putative AmpR-binding site was identified based on sequence
homology and is indicated by the AmpR-box. Orange arrows denote palindromic
sequences in close proximity with the ampC and ampR RBSs indicative of hairpin
formation for regulating translation through blocking of ribosome binding.

induced and uninduced PA01, PA0ΔrpoN and PA0ΔrpoN (pRpoN) strains and reverse
transcribed into cDNA using standard methods (764). In the wild-type, exposure to βlactams increased ampR and ampC expression approximately 100-fold over the
uninduced samples (normalized to 1) (Figure 4.2). A further, significant increase in
expression of both genes was observed in PA0ΔrpoN upon β-lactam challenge that could
be rescued by pRpoN. In the absence of β-lactams, a small, but significant reduction in
expression was observed in the PA0ΔrpoN that could not be complemented.
In spite of the presence of a probable binding site on PampR, σ54 is not required for
ampR expression. The significant increase in the absence of rpoN and in the presence of
the β-lactams suggests σ54 negatively impacts ampR expression. RpoN may exert this
negative effect indirectly by enabling transcription of a negative regulator or directly by
competing for the RNA polymerase holoenzyme with another sigma factor.
Alternatively, P. aeruginosa RpoN can directly repress transcription by blocking
promoter access to a different sigma factor in a phenomenon referred to as σ-factor
antagonism as previously reported (912). Specifically, σ54 has been shown to repress σ22dependent transcription from PalgD by directly binding to the overlapping promoter
sequences in the absence of an external stimulus (912). Similarly, σ-factor antagonism
has also been reported in E. coli, where mutagenesis of a σ54-dependent promoter created
a new TSS with σ70 requirement that exhibited decreased transcriptional activity in the
presence of σ54 (913).
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Figure 4.2. RpoN downregulates P. aeruginosa ampR expression in the presence of βlactams. RNA was isolated from PA01, PA0ΔrpoN and PA0ΔrpoN(pRpoN) in the
presence and absence of β-lactams, reversed transcribed to cDNA and tested by qPCR
with ampC (grey bars) and ampR (black bars) specific primers, as described in the
Experimental Procedures. Values were normalized to the expression of the wild-type
uninduced sample and represent the mean (±SD) of two experiments conducted in
triplicates. * p-value< 0.001 for both ampR and ampC expression in induced PA01
versus expression in uninduced PA01, ** p-value< 0.005 for ampR and ampC expression
in induced PA0ΔrpoN versus expression in PA01 induced as determined by unpaired ttest.
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A model of repression by σ54 through promoter blocking is conceivable, where in
the absence of some external stimuli, in this case β-lactams, σ54 binds PampR and prevents
access and thus transcription by the sigma factor.

In the presence of the inducer,

however, σ54 may be partially or completely displaced by the sigma-RNA polymerase
complex to promote ampR transcription. Thus, the loss of rpoN leads to complete derepression of ampR expression in the induced condition.
Lastly and very interestingly, the expression of ampC followed a pattern similar
to that of ampR in all backgrounds. Previously, ampR expression in P. aeruginosa was
shown to be low and not significantly induced upon exposure to the β-lactam
benzylpenicillin (710). Similarly, expression from the C. freundii ampR promoter in E.
coli was found to be constitutive in the presence and absence of the inducer (6aminopenicillanic acid) (840). In E. cloacae, induction with cefoxitin significantly
increased transcription of ampC but had no effect on ampR expression (895). Recent
work from our lab however, showed that in the presence of very powerful known
inducers, namely imipenem and meropenem, expression of both ampC and ampR is
equally and very significantly induced in wild-type P. aeruginosa (760). In light of such
results, it is not surprising that our current data shows that wild-type P. aeruginosa has
similar ampC and ampR mRNA levels in the presence of imipenem. Similar induction
profiles in the absence of rpoN suggest that the ampC and ampR promoters can reach
their full induction potential upon removal of the restricting negative effect imposed by
RpoN. It is not clear how exactly RpoN, or its absence, can accomplish this, but it is
worth noting that in the ampC and ampR TSSs, the -12 sequence of ampR overlaps the -
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10 sequence of ampC. Thus, if σ54 is in fact blocking promoter access to RNA
polymerase, it could be blocking access to both the ampR and ampC promoters until such
time as inducers lead to its partial or complete displacement from the intergenic region.
Further studies are needed to elucidate the mechanism of ampC and ampR
downregulation by RpoN.

4.4.2 Mapping of P. aeruginosa PampC. To map the minimal promoter needed for AmpRdependent activity, a series of 5’-end deletions of PampC were transcriptionally fused to
the promoterless lacZ gene of the integrative vector mini-CTX-lacZ (853). The activity
of each promoter deletion was then analyzed in PA01 by assaying β-galactosidase
activity in the presence and absence of 200 µg ml -1 of penicillin G. The minimum length
of the promoter needed for full PampC activity is 193-bp (Figure 4.3). This fragment
consists of the full ampR-ampC intergenic region plus small parts of the ampR (22 bp)
and ampC (23 bp) ORFs. The high activity seen with the 193-bp fragment in the absence
of β-lactams as compared to the wild-type may be the result of the partial or complete
removal of the repressor-binding site. Subsequent loss of a 22-bp ampR fragment from
the 5’ end of the 193-bp segment resulted in a 2-fold decrease in induction likely
indicating partial removal of the activator-binding site. This 22-bp fragment
corresponding to the beginning of the ampR ORF seems to be necessary for full induction
of PampC. In silico analysis reveals that this segment is very well conserved among other
species but has no real identifiable features. Induction was abolished with a further 20-bp
deletion (151-bp fragment). Thus, the 42-bp region (denoted red in Figures 4.1 and 4.3),
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Figure 4.3. Mapping of the minimal P. aeruginosa ampC promoter. 5’-end deletions of
PampC were constructed and transcriptionally fused to a promoterless lacZ gene in the
integrative vector mini-CTX-lacZ as described in the Materials and Methods. Constructs
were introduced into PA01 for integration at the attB site to generate single-copy
promoter fusions. Promoter activities are expressed in Miller units. The +1 denotes the
ampC transcriptional start site. The 42-bp segment, missing from the 151-bp construct,
that appears to be necessary for activator binding, is depicted in red at the 5’ end of the
193-bp fragment. * p-value< 0.05 as compared to uninduced PA0attB::PampC352-lacZ; **
p-value< 0.05 versus uninduced PA0attB::PampC171-lacZ as determined by unpaired t-test
using ANOVA.

present at the 5’ end of the 193-bp fragment but deleted from the 151-bp construct,
demarcates the outer bounds of the functional promoter needed for activation of PampC.
Since this 42-bp fragment includes the AmpR box, an in silico derived putative AmpRbinding site (Figure 4.1), this region could be critical for activator binding.

4.4.3 P. aeruginosa AmpR binds to PampC. Previously, P. aeruginosa AmpR has been
shown to bind PampC using AmpR-overexpressing E. coli whole cell extracts (776).
Similarly, crude preparations of C. freundii AmpR were also shown to retard a radiolabeled ampR-ampC intergenic region (840). Since preliminary work from our lab
suggested that P. aeruginosa AmpR is likely to be a membrane-associated protein (See
Localization studies of P. aeruginosa AmpR section below and Figure. S2), we tested the
ability of PA01 membrane fractions to bind PampC. EMSA was performed using AmpRHis6 enriched membrane fractions and a [γ-32P] ATP radiolabeled PampC fragment. Shift
was observed with increasing concentrations of total membrane protein up to 0.4 mg ml -1
(Figure 4.4). The binding was competed-out by mixing labeled DNA with unlabeled
promoter DNA in 100-fold molar excess confirming AmpR binding to PampC (Figure 4.4).
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Additionally, competition with a nonspecific, unlabeled fragment (233-bp alg44 PCR
fragment) mixed in 10-, 100-, and 500-fold molar excess with the labeled PampC fragment,
failed to displace AmpR-His6 from PampC illustrating the binding specificity.

Figure 4.4. P. aeruginosa AmpR binds PampC. Fifty fmol of a 193-bp radio-labeled
PampC fragment (Lane 1) spanning the ampC-ampR promoter region were mixed with
increasing concentrations of AmpR-His6 enriched membrane fractions extracted from
PA0ΔampR (pAmpR-His6 ) in the presence of 200 µg ml-1 of penicillin G (Lanes 2 to 6).
Competition assays were carried out with the cold PampC fragment in 10- (Lane 7), 100(Lane 8) and 500-fold (Lane 9) molar excess. To characterize the binding specificity, a
nonspecific fragment (233-bp alg44 PCR fragment) was mixed in 10- (Lane 10), 100(Lane 11) and 500-fold (Lane 12) molar excess with the radio-labeled reaction mix. Lane
13 is the control showing the 193-bp radio-labeled PampC fragment in the presence of
membrane fractions extracted from PA0∆ampR containing the plasmid backbone alone.
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To determine if AmpR interacts with PampC in vivo, ChIP-qPCR was employed
(908). A functional VSV-G-tagged AmpR (Table S3, Supplemental material) was
introduced into PA01 as single copy and then immunoprecipitated with anti-VSV-G
antibody. Sequence-specific primers were used to detect the presence of PampC DNA with
qPCR. Promoter occupancy was detected in the presence and absence of β-lactams as
expected of LTTRs (856) (Fold enrichment over clpX control- Uninduced: 10.6±1.73,
Induced: 13.3±4.63; Fold enrichment for negative control target aprX- Uninduced:
1.30±0.02, Induced: 1.34±0.22). AmpR thus binds PampC in vivo in the presence and
absence of the inducer.

4.4.4 HTH is important for AmpR function. The majority of prokaryotic DNA-binding
proteins, including LTTRs, use the HTH motif to interact with DNA (897, 914). In
LTTRs, this domain is often found at the N-terminus (856, 897). The canonical HTH
motif is comprised of three helical bundles where the second and third helices interact
with the DNA, and the third makes the essential contacts with the major groove to
provide recognition (897, 914, 915). A multiple alignment of the AmpR family HTH
motif shows the highest degree of conservation is found in the first two helices, with the
most variation in the third helix that provides specificity (Figure S3, Supplemental
material). Although P. aeruginosa AmpR has been shown to bind the ampR-ampC
intercistronic region (776), the amino acids involved in the interaction have not been
identified.
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An amphipathic wheel of the third helix (residues Gln34 to Leu48), generated
using DNASTAR Protean, identified polar and charged amino acids potentially facing the
major groove of the DNA (Figure 4.5). Point mutations corresponding to these residues
were generated by site-directed mutagenesis of AmpR-His6. Residues Ser38, His39,
Lys42, Ser43, and Glu46 were thus replaced with alanine and the mutants were
overexpressed in PA01 and PA0ΔampR strains carrying the chromosomal PampC-lacZ
fusion (Figure 4.6). The PampC activity observed in PA01 is the result of both ampR
alleles, from the chromosome (ampRchr) and from the plasmid (ampRpls), whereas in
PA0ΔampR only ampRpls contributes.

Figure 4.5. Analysis of the third helix of the P. aeruginosa AmpR HTH motif. An
amphipathic wheel of the third helix (residues Q34 to L48) was generated using
DNASTAR Protean in order to identify polar and charged amino acids likely facing the
major groove of the DNA. The AmpR residues Ser38, His39, Lys42, Ser43, and Glu46,
were identified as amino acids likely to interact with the DNA and were thus targeted for
mutagenesis. They are indicated by the black arrows and denoted as S5, H6, K9, S10 and
E13 in the helical wheel, respectively. The N-terminal sequence of P. aeruginosa AmpR
illustrates the HTH motif and the location of the above amino acids (in red) in the third
helix of AmpR.
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Figure 4.6. Functional analysis of the P. aeruginosa AmpR HTH motif. Site-directed
mutagenesis was used to replace Ser38, His39, Lys42, Ser43, and Glu46 with Ala in
AmpR-His6. The mutant proteins were overexpressed in PA01 and PA0ΔampR strains
carrying a single copy of the PampC-lacZ fusion integrated at the attB site. β-galactosidase
activity was quantified in the presence and absence of β-lactams. * p-value< 0.05 versus
uninduced PA01 vector control; ** p-value< 0.005 versus induced PA01 vector control
as determined by unpaired t-test using ANOVA.

Alanine substitutions at Ser43 and Glu46 did not affect the ability of AmpR to
activate PampC in PA0ΔampR (Figure 4.6). In addition, both AmpRSer43Ala and
AmpRGlu46Ala were able to bind PampC in the presence and absence of β-lactams (Figure
4.7). These two findings suggest Ser43 and Glu46 are not critical for AmpR function.
However, expression of AmpRSer43Ala and AmpRGlu46Ala in PA01 that carries AmpRchr,
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significantly increased PampC activity by more than 2-fold in the presence of inducers
suggesting a possible interaction between chromosomal encoded AmpRchr and the
variants (Figure 4.6). In particular, the Ser43Ala substitution increased basal levels in the
absence of inducers, while leading to hyperinduction in the presence of β-lactams.
Similarly, significant activation of PampC in PA01 in the presence of AmpR-His6 further
strengthens the idea that AmpR functions as a multimer.

Figure 4.7. Electromobility shift assay of P. aeruginosa AmpR HTH mutants. A 50
fmol of the 193-bp radio-labeled PampC fragment (Lane 1) were mixed with membrane
fractions recovered from PA0∆ampR in the absence (Lanes 2 to 8) and presence of βlactams (Lanes 9 to 15) and carrying pMMB67EH-Gm (Lanes 3 & 10), pAmpR-His6
(Lanes 2 & 9), pAmpR-His6(His39Ala) (Lanes 4 & 11), pAmpR-His6(Ser38Ala) (Lanes 5 &
12), pAmpR-His6(Lys42Ala) (Lanes 6 & 13), pAmpR-His6(Ser43Ala) (Lanes 7 & 14), and
pAmpR-His6(Glu46Ala) (Lanes 8 & 15).
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AmpR mutant proteins failed to activate PampC when Ser38, His39, or Lys42 were
substituted with alanine. These three residues are thus essential for AmpR activity and are
presumably involved in the binding to PampC. A multiple alignment reveals Ser38 and
Lys42 are well-conserved in members of the AmpR family as expected of amino acids
that play a critical role in the functionality of a protein (Figure S3, Supplemental
material).
The loss of PampC activity in AmpRSer38Ala, AmpRHis39Ala and AmpRLys42Ala could
be attributed to the destabilization of the proteins. Their expression was thus analyzed
using Western blotting with anti-AmpR antibody (Figure 4.8). Interestingly, not only are
these three mutant AmpR proteins made, it appears that they, and in particular
AmpRSer38Ala and AmpRLys42Ala, are made in large quantities. These amino acid
substitutions, therefore, appear to stabilize rather than destabilize the proteins. Thus, we
argued that the loss of PampC activity may be due to their inability to bind DNA. Gelshifts revealed that AmpRSer38Ala failed to bind to PampC while AmpRLys42Ala bound very
poorly correlating well with the loss of PampC transcriptional activity (Figure 4.7).
Surprisingly, the His39Ala substitution did not prevent AmpR from binding to PampC in
the presence or absence of β-lactams, although it clearly prevented it from activating
transcription from PampC (Figures 4.6 and 4.7). AmpRHis39Ala is thus a positive control
mutant that can bind DNA but cannot activate transcription from the promoter to which it
binds.
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Figure 4.8. Stability of P. aeruginosa AmpR mutant proteins. Total protein extracts
were recovered from AmpR HTH and point mutants after a 1½-hour incubation with 1
mM of IPTG. The stability of each mutant was verified by Western blotting using
AmpR-specific antibodies. Equal amounts of total membrane protein were loaded per
well; σ70 was used as a loading control and detected with anti-σ70 antibody.

Positive control (pc) mutants are proteins that are defective in transcriptional
activation but retain the ability to bind DNA. The pc phenotype is caused by the
disruption of favorable protein-protein interactions between the activator protein and the
RNA polymerase (916-918). Several pc mutants of other proteins have been
characterized with mutations in or near the DNA-binding domain (916-921). Mutations
away from this region have also been reported (922). In particular, mutations in the
DNA-binding region have been mapped to the second helix of the HTH motif and to the
junction between the second and third helix of the same domain in the activator proteins
λ cI, 434 cI, and P22 c2 (916-919). AmpRHis39Ala is different from previously reported pc
mutants in that its mutation is found in the helix of the DNA-binding domain that is
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thought to directly interact with the major groove of the DNA (helix 3), and not in the
helix which usually lies across the major groove (helix 2), and makes contacts with the
DNA backbone. Although it is not clear whether this third helix can contact the RNA
polymerase, it may interact with other sites in the nearby helix to indirectly affect
transcription. Our work here does not reveal how the disruption of His39 affects
activation of transcription, but merely that it is required for it.
In the present work we show that the highly conserved residues Ser38 and Lys42
(not conserved in Klebsiella pneumoniae), in the HTH motif are critical for binding and
function of AmpR. The less conserved His39 is also necessary for promoter activation
but not for binding to the DNA.

4.4.5. Gly102 and Asp135 are critical for AmpR function. Previous work identified C.
freundii ampR mutants that constitutively express β-lactamase (839, 923). Specifically, a
change in Gly102 to Glu (Gly102Glu) resulted in high constitutive β-lactamase
expression in an inducer-independent manner, while a Gly102Asp substitution yielded a
similar but less pronounced phenotype (839, 923). In addition, Asp135 was also found to
play a role in the function of C. freundii and E. cloacae AmpR (923, 924). The
expression of C. freundii AmpRAsp135Tyr led to constitutive β-lactamase hyperexpression
in an ampG mutant background. In E. cloacae AmpR Asp135 substitutions to Val or Asn
resulted in higher β-lactamase activity in the presence and absence of inducers and
contributed to increased β-lactam resistance in two different E. coli backgrounds (923,
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924). Gly102 and Asp135, thus appear to play important roles in the activation/repression
state of AmpR in, at least, the Enterobacteriaceae.
To investigate the role of these amino acids, P. aeruginosa AmpR Gly102 and
Asp135 were replaced with Glu and Asn, respectively. The two mutant AmpR proteins
were overexpressed in PA01 and PA0ΔampR strains carrying PampC-lacZ (Figure 4.9).
Unlike in C. freundii, in P. aeruginosa the Gly102Glu substitution resulted in the loss of
PampC activity in the presence and absence of β-lactams. The loss of activity is due to
destabilization of the protein (Figure 4.8), suggesting a structural role for Gly102 in P.
aeruginosa AmpR.
On the other hand, the Asp135Asn substitution led to an inducer-independent
increase in PampC transcriptional activity in both PA01 and PA0ΔampR with no
concomitant increase in the amount of protein being made (Figures 4.8 and 4.9). Thus,
we postulate that the Asp135Asn substitution in the effector binding domain appears to
stabilize the active conformation effectively turning AmpR into a constitutive activator of
ampC transcription. The Asp135Asn substitution has also been reported in AmpR from a
P. aeruginosa clinical variant that exhibited hyper-constitutive β-lactamase expression
and high resistance to β-lactams (722). The importance of Asp135 corroborates the
previous work in E. cloacae and C. freundii (923, 924). Gly102, on the other hand,
clearly plays different roles in the P. aeruginosa and C. freundii AmpR proteins.
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Figure 4.9. Activity of the P. aeruginosa ampC promoter in the presence of AmpRHis6(Gly102Glu) and AmpR-His6(Asp135Asn) mutants. Site-directed mutagenesis was used to
replace Gly102 and Asp135 of P. aeruginosa AmpR with Glu and Asn, respectively.
Mutant AmpRs were expressed in wild-type PA01 and PA0ΔampR strains carrying
PampC-lacZ. β-galactosidase activity was quantified in the presence and absence of βlactams and is represented in Miller units. * p-value<0.01 versus induced PA0∆ampR
pAmpR-His6; ** p-value<0.01 versus induced PA0attB::mini-CTX-lacZ; *** pvalue<0.001 versus induced PA0∆ampR pAmpR-His6 as determined by unpaired t-test
using ANOVA.

4.4.6 Cross-linking studies suggest P. aeruginosa AmpR dimerizes. The PampC activity
in the presence of both ampRchr and ampRpls is always considerably higher than that in
PA01 and PA0∆ampR (ampRpls) (Figure 4.6). These findings suggest a possible
interaction between the wild-type and His-tagged AmpR. This is not surprising as LTTRs
exist and/or function as dimers or tetramers (856, 897, 925-929). To determine if in fact
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P. aeruginosa AmpR can dimerize, proteins from PA0ΔampR (pAmpR-His6) were crosslinked and AmpR was visualized with anti-His antibody. The detection of a 64-kD and a
32 kD species in cross-linked and non-cross-linked samples, respectively, suggests that
AmpR dimerizes in vivo (Figure 4.10). Only the monomeric form of σ70 was detected
after stripping and reprobing the blot. Our findings corroborate previous work in C.
freundii where both AmpR and its effector binding domain were shown to dimerize in
solution and in the crystallized form, respectively (930, 931).

Figure 4.10. P. aeruginosa AmpR appears to dimerize in vivo. A fresh culture of
PA0ΔampR strain harboring pAmpR-His6 was treated with 0.1% formaldehyde for 20
and 40 minutes at room temperature to achieve protein cross-linking. Crude extracts
containing 10 µg of total protein were separated on an SDS-polyacrylamide gel and
AmpR was visualized using anti-His antibody. The blot was later stripped and reprobed
using anti-σ70 antibody. Monomeric AmpR is detected in non-cross-linked samples at
zero time point, while AmpR dimeric entities (64KDa) are detected 20 and 40 minutes
after protein cross-linking.
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4.4.7. Localization studies of P. aeruginosa AmpR. Although it is generally accepted
that AmpR is a cytoplasmic protein, our bioinformatics analyses suggested that AmpR
may be membrane associated. More specifically, a Kyte-and-Doolittle hydrophobicity
plot (932) and the topology prediction softwares TopPred2 (933), DAS (934), MEMSAT
(935), TMpred (936), and SCAMPI (937) suggested the presence of a transmembrane
domain somewhere between amino acids 92 and 114 of P. aeruginosa AmpR. The
crystal structure of C. freundii AmpR, however, reveals this segment is near the proteinprotein interface of the dimer and thus unlikely to traverse the membrane (930).
In order to localize AmpR, phoA and lacZ were fused in-frame at amino acid
positions Glu15, Val134 and Gln185 (Figure S2A, Supplemental material). Fusions at
Glu15 were LacZ-positive and PhoA-negative, whereas fusions at Val134 and Gln185
were PhoA-positive and LacZ-negative suggesting AmpR may traverse the inner
membrane with the N and C termini in the cytoplasm and periplasm, respectively (Figure
4.11). Since this data is only qualitative, localization of P. aeruginosa AmpR was further
investigated with a protease protection assay using a C-terminal His-tagged AmpR that
was shown to be functional (Table S2, Supplemental material). Full length AmpR (32
kDa) was detected in whole cell extracts, as well as, in spheroplasts preparations treated
with Proteinase K (0-min incubation) that were immediately processed for
immunoblotting (Figure S2B, Supplemental material). Incubations with Proteinase K of 5
minutes or longer resulted in the visible reduction of full length AmpR and the
appearance of the degradation product (10-kDa fragment). However, slight degradation
of σ70 was observed. The evidence provided here is suggestive of AmpR being an inner
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membrane-associated protein. If confirmed, this would be an important finding and could
have major implications regarding the regulation of two ampD amidase homologs that
have now been localized to the periplasm (938, 939). The identity of the muramylpeptides that are important for regulating AmpR will further confirm its localization and
is the subject of ongoing work in the lab.

Figure 4.11. AmpR model. A three-dimensional structure of AmpR was generated using
RasMol (http://www.umass.edu/microbio/rasmol/). The topology of AmpR was
investigated by introducing phoA and lacZ fusions at amino acid positions Glu15,
Val134, and Gln185. Fusions at Glu15 were LacZ positive but PhoA negative, whereas
fusions at Val134 and Gln185 were PhoA positive and LacZ negative.

Although the majority of purified LTTRs appear to be soluble cytoplasmic
proteins, the nodulation factor, NodD, from Rhizobium species appears to be a peripheral
membrane protein associated with the inner leaflet of the cytoplasmic membrane (940). A
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few membrane-bound non-LTTRs have also been reported, such as the Salmonella
enterica serovar Typhimurium acid-sensing CadC, the streptococcal CpsA involved in
regulation of capsule production, and the Vibrio cholera toxin activator, ToxR (941-943).
Since these proteins act as both signal sensor and response regulator, they form a simple
but sophisticated form of transmembrane signaling system.

4.5 Concluding Remarks
The role of AmpR as regulator of ampC expression has been clearly established in
both the Enterobacteriaceae and P. aeruginosa. Our recent work has further redefined
AmpR as a major global regulator, playing an important role in acute infections through
its regulation of virulence, biofilm formation, quorum sensing and non-β-lactam
resistance (710, 841-844). Regulation of ampC, however, remains one of its most critical
roles, as AmpC derepression is a prevalent mechanism of β-lactam resistance in P.
aeruginosa.
In the present work we characterize some of the genetic and structural elements
necessary for induction of ampC and important for the functioning of AmpR as regulator
of AmpC β-lactamase expression. The presence of strong σ54 consensus sequences in the
ampR promoter led us investigate its possible involvement in the regulation of ampR.
However, contrary to what was expected, RpoN was not required for ampR expression in
the conditions tested. Instead, RpoN was found to downregulate expression of both ampR
and ampC, although the exact mechanism is yet unknown.
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Like other LTTRs, AmpR has two important regions critical for its functioning as
activator/repressor of ampC expression: the HTH motif for binding to DNA and the
effector binding domain for ligand interaction. Analysis of polar and charged amino acids
on the AmpR HTH revealed two residues, Ser38 and Lys42, important for binding of
AmpR to the promoter region and consequently for ampC promoter activation. A third
residue, His39, was shown to be important for function but not for binding to P ampC. In
the effector binding domain, we examined the role of two amino acids, Gly102 and
Asp135, previously shown to be important for maintaining AmpR in an inactive
conformation in the enterobacteria. In P. aeruginosa, Gly102 appears to be responsible
for maintaining a stable structural conformation, while Asp135 is responsible for keeping
AmpR in an inactive state that represses ampC expression. Additionally, our work
suggests that AmpR dimerizes and that it is likely to be membrane associated. This is the
first comprehensive look at the P. aeruginosa AmpR and the promoter elements that it
regulates.
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Chapter 5

General Discussion and Summary
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5.1 Overview
The Infectious Diseases Society of America classified Pseudomonas aeruginosa
as one of the troublesome ESKAPE1 pathogens that, along with Enterococcus faecium,
Staphylococcus

aureus,

Klebsiella

pneumoniae,

Acinetobacter

baumannii,

and

Enterobacter spp., causes the majority of nosocomial infections and effectively evades
the action of antibiotics (944, 945). The intractability of P. aeruginosa is owned to its
intrinsic low membrane permeability, the presence of multidrug efflux pumps that can
export more than one type of antimicrobial, and the expression of β-lactamases, enzymes
which can hydrolyze and inactivate the commonly used β-lactam antibiotics (246, 270,
317, 549, 946). In addition, P. aeruginosa can evolve resistance after treatment with
antibiotics through mutations in resistance genetic determinants or their regulatorencoding genes (247, 313, 336, 749, 947-949).
P. aeruginosa also has an innate ability to acquire resistance genes from the
environment and is often a natural reservoir of multiple plasmid-encoded β-lactamases
(549, 950). Chromosomally, P. aeruginosa carries AmpC, a class C β-lactamase that
plays a major role in intrinsic resistance against penicillin- and cephalosporin-type βlactams (711). Mutational derepression of this enzyme, whereby AmpC is produced at
high levels irrespective of the presence or absence of β-lactams, is currently one of the
most common mechanisms of β-lactam resistance in the clinical setting (379, 380, 722,
749).

1

ESKAPE is an acronym for the six pathogens, Enterococcus faecium, Staphylococcus aureus, Klebsiella
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp., which are
currently a major problem in the hospital setting.
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This dissertation delved into the role of a second chromosomally encoded βlactamase in P. aeruginosa termed PoxB. This work established PoxB is an oxacillinasetype β-lactamase with a narrow spectrum of hydrolysis that includes the carbapenems
imipenem, meropenem and doripenem. The currently available β-lactamase inhibitors did
not significantly affect PoxB activity as commonly seen for class D enzymes. In addition,
PoxB was shown to form a two-gene operon with the upstream open reading frame poxA,
whose expression exerted negative control on the pox promoter. The transcriptional
regulator AmpR negatively impacted pox expression but this regulation did not occur by
binding to the promoter. A mutant transposon library, constructed to screen for regulators
of pox expression, identified two clones with insertions in genes involved in polyamine
transport. Polyamines coincidently were shown to provide resistance against imipenem
and

meropenem.

In

summary,

two

chromosomal-encoded

β-lactamases

with

complementing hydrolytic spectrums have the potential to provide P. aeruginosa with
resistance against most classes of β-lactams including the penicillins, cephalosporins and
carbapenems.

5.2 PoxB is a chromosomal-encoded class D carbapenemase. Class D β-lactamases are
predominantly found in P. aeruginosa and in A. baumannii, but have also been reported
in Escherichia coli, K. pneumoniae, and Proteus mirabilis, among others (606, 685).
Three distinct oxacillinase categories are now recognized: the narrow-spectrum, the
extended-spectrum and the carbapenem-hydrolyzing oxacillinases (680). Carbapenemhydrolyzing class D β-lactamases (CHDLs), are widespread in the nosocomial pathogen
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A. baumannii but have also been occasionally reported in K. pneumoniae and
Acinetobacter spp., as well as and in a few of the Enterobacteriaceae (680, 685). CHDLs
are less common in P. aeruginosa and to date only three CHDLs have been reported
there: OXA-40, OXA-198 and, of course, OXA-50 or PoxB (549, 740, 741, 951, 952).
Specifically, a plasmidic carbapenemase was detected in two unrelated imipenemresistant P. aeruginosa isolates from northern Spain where OXA-40-producing A.
baumannii were found to be common (951, 953, 954). The nucleotide sequence in fact
showed 100% identity to the previously described blaOXA-40 from an A. baumannii isolate
endemic to this area (951). Thus, one of the first OXA-type carbapenemases detected in
P. aeruginosa was termed OXA-40 (954). Similarly, OXA-198 was identified in the
imipenem-resistant clinical isolate PA41437 (952). OXA-198 was encoded in a plasmidborne integron but was not closely related to other OXA enzymes. Biochemically, OXA198 behaved similarly to other CHDLs, exhibiting a strong affinity for carbapenems but
low rate of hydrolysis (952). Its expression in a heterologous host provided resistance
against ticarcillin and decreased susceptibility against piperacillin, cefepime, and the
carbapenems and but not against aztreonam and extended-spectrum cephalosporins (952).
Although the clinical strain PA41437 was resistant to imipenem and displayed a high
minimum inhibitory concentration (MIC) against meropenem (12 µg/ml), OXA-198
expression in trans only decreased susceptibility against these drugs, suggesting other
mechanisms of resistance were operating in the PA41437. Sequencing of oprD revealed a
number of mutations and an 88-bp deletion in this strain (952).
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To our knowledge PoxB (OXA-50), is the first carbapenem-hydrolyzing class D
β-lactamase reported in P. aeruginosa (740, 741). Similar to OXA-198, OXA-50 is only
weakly related to other class D enzymes, displaying 43-47% homology to CHDLs from
the OXA-23 and OXA-229 group found in A. baumannii and Acinetobacter spp. Unlike
the other two OXA enzymes reported in P. aeruginosa, OXA-50 is carried on the
chromosome and ubiquitously found in environmental and clinical P. aeruginosa isolates
(740). The goal of this dissertation was to characterize the naturally occurring class D βlactamase PoxB and determine its contribution to intrinsic resistance in P. aeruginosa.
Since the class C, chromosomal encoded AmpC β-lactamase is known to play a
major a role in both the intrinsic and acquired resistance against β-lactams in P.
aeruginosa, the role of PoxB was investigated in strains carrying clean deletions of the βlactamase-encoding genes (PA0∆ampC, PA0∆poxB and PA0∆ampC∆poxB). This work
clearly showed AmpC confers protection against penicillins and cephalosporins.
Specifically, an ampC deletion rendered strains susceptible to the aminopenicillins
(ampicillin and amoxicillin) but produced only a small decrease in MIC for imipenem
and doripenem (Chapter 2, Table 2.2). Overexpression of AmpC in PA0∆ampC restored
resistance against the aminopenicillins and additionally provided resistance or
significantly increased MICs (decreased susceptibility) against the cephalosporins and the
rest of the penicillins (Chapter 2, Table 2.3). A slight decrease in susceptibility was also
observed against doripenem but not against imipenem or meropenem suggesting the
carbapenems are not good substrates of the AmpC β-lactamase.
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The role of PoxB, on the other hand, was not readily observed in the natural
background. For instance, a poxB deletion failed to alter susceptibility in the presence or
absence of ampC (Chapter 2, Table 2.2). Similarly, the amount β-lactamase activity
produced by a poxB deletion strain (PA0∆poxB) was comparable to that of wild-type
PA01 (Chapter 2, Figure 2.3). PA0∆ampC, on the other hand, failed to produce any
detectable β-lactamase activity in the presence or absence of chromosomal poxB. This
suggests that the activity detected in wild-type and poxB deletion strains was due to the
presence of AmpC. PoxB thus appears to be expressed at very low, marginal levels in the
lab strain PA01 under the tested experimental conditions.
Expression of poxB from an IPTG-inducible promoter in an ampC-deficient strain
(PA0∆ampC) or in an ampCpoxB deletion strain (PA0∆ampC∆poxB), however, increased
the MIC, thereby decreasing susceptibility, against the carbapenems doripenem and
meropenem, but produced little to no change against the penicillins and cephalosporins
(Chapter 2, Table 2.3). It is well-documented that clinical strains can develop resistance
to imipenem after treatment with said carbapenem (304, 313, 314, 955). Mutations,
deletions and insertions usually occur in oprD, encoding an outer membrane porin
specific for the uptake of imipenem, and result in impaired/lost function of the porin
(313, 315, 947, 955). Similarly, in our studies loss of the outer membrane porin, OprD,
specific for the uptake of imipenem, extended the hydrolysis spectrum of PoxB to include
imipenem and enhanced the carbapenem-hydrolyzing phenotype leading to clinical
intermediate and resistant phenotypes (Chapter 2, Table 2.4). Thus, PoxB is a
carbapenem-hydrolyzing class D β-lactamase.
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In agreement with our studies, previous work by Girlich et. al examining the
biochemical properties of PoxB, failed to detect hydrolysis of oxacillin, cloxacillin,
cefepime, cefotaxime, ceftazidime and aztreonam, among others (741). Hydrolysis of
various other penicillins and cephalosporins, however, was detected, as well as of
nitrocefin, meropenem and imipenem. PoxB, however, displayed low affinity, high Km,
for most β-lactams tested, with the exception of imipenem and nitrocefin for which Km
values of 20 and 200 µM were obtained, respectively (741). Hydrolysis of both imipenem
and meropenem, nonetheless, was very low, with meropenem exhibiting even weaker
hydrolysis than that of imipenem. PoxB expression did afford the cell decreased
susceptibility against meropenem in the previous and present study (741). In the current
work, PoxB expression additionally increased MIC against doripenem, and in the absence
of OprD against imipenem. Protection against imipenem was not previously detected in
the work of Girlich et. al despite PoxB exhibiting high affinity for this β-lactam, as
experiments were conducted in oprD+ strains.
The current study further tested the effect of class A β-lactamase inhibitors,
tazobactam, sulbactam and clavulanic acid, on the activity of PoxB (Chapter 2, Figures
2.7 and 2.8). These compounds did not significantly affect PoxB activity and thus were
considered poor inhibitors and likely also poor substrates of the enzyme. That OXA-50 is
resistant to inhibition is not surprising as in general, class D enzymes are not significantly
inhibited by clavulanic acid, sulbactam, and tazobactam (428, 467). Exceptions include
OXA-53 (956), OXA-18 (957) and OXA-45 (958) all inhibited by clavulanic acid, OXA-
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12 (735) inhibited by both clavulanic acid and tazobactam, and OXA-2 and its point
mutant OXA-32 that are susceptible to inhibition by tazobactam (959).
Avibactam, a new non-β-lactam-type inhibitor, was also a poor inhibitor of PoxB
(Chapter 2, Table 2.6). Avibactam has been shown to successfully inhibit class A and C
enzymes, but has generally lacked activity against A. baumannii isolates expressing
OXA-type β-lactamases (804, 805). Significant activity has been observed against the
CHDL OXA-48, but a kinetics study showed that the rate of inhibition was lower than
that for class A and C enzymes (805, 816). Thus inhibition of class D enzymes still
remains a problem in the clinical setting where the commercially available inhibitors are
not generally active against OXA enzymes. In this respect, OXA-50 is a typical class D
β-lactamase. In vitro inhibition by NaCl, often used as a defining characteristic of most
oxacillinases, was also observed for PoxB. This inhibition, although readily detected in
crude extracts from PoxB-expressing cells, was only slightly noticeable by the broth
microdilution method (Chapter 2, Figures 2.9 and 2.11).
In summary, although exhibiting relatively low homology to other class D
enzymes, in most respects, PoxB is a typical class D carbapenemase. In general, CHDLs
do not significantly hydrolyze extended-spectrum cephalosporins but do exhibit some
level of hydrolysis against the penicillins, mainly benzylpenicillin, ampicillin, piperacillin
and ticarcillin (680, 693, 960). Additionally, CHDLs display low Km values for
imipenem, lower than for other β-lactams, suggesting very high affinity for this substrate
(680, 685, 960). Hydrolysis rates for both imipenem and meropenem, however, remain
very low.
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In its natural host and under the conditions tested, poxB seems to be expressed at
very low levels which do not contribute to the intrinsic resistance of PA01. This raises the
question of the natural role of this operon in P. aeruginosa. Does the poxAB operon play
a yet unidentified role besides that of resistance? Further, we know that increasing the
expression of PoxB can lead to decreased susceptibility or resistance against the
carbapenems, but the relevance of OXA-50 in the clinical setting is not yet known.
Although poxB expression appears to be constitutive and unregulated, it is
possible that mutations in the promoter region or insertion elements could lead to its
expression in a way that contributes to resistance as seen in other bacteria. For example,
A. baumannii often carries the chromosomal ampC but lacking ampR, expression is
normally non-inducible (961, 962). Ceftazidime resistance in this pathogen however, has
been linked to increased expression of ampC due to the presence of the upstream
insertion element ISAba1 with strong promoter sequences (963, 964). ISAba1 was absent
from ceftazidime-susceptible strains (724, 965). This insertion sequence seems to be
prevalent in carbapenem-resistant A. baumannii isolates where it has been reported in
association with blaOXA-51-like and blaOXA-23-like genes (700, 725, 727). Although ISAba1
has not been reported in P. aeruginosa, promoter sequences in ISPa12 have been found
to drive expression of the extended-spectrum β-lactamase-encoding gene blaPER-1 in P.
aeruginosa, Providencia stuartii, A. baumannii and Salmonella enterica serovar
Typhimurium (728). Similarly, expression of the extended-spectrum β-lactamaseencoding gene, blaVEB-1, in ceftazidime-resistant P. aeruginosa isolates was found to be
driven by promoter sequences within the upstream-located IS1999 (966). Thus,
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upregulation of gene expression by insertion sequences is a plausible mechanism of PoxB
overexpression.
As a sole mechanism of resistance, poxB expression may be easy to overlook as
the changes in MIC against carbapenems may not be substantial. Moreover, carbapenem
resistance is often linked to mutations or insertions in oprD, and screening of the poxB
ORF and its promoter are not routinely done. This work showed that, when combined,
the concerted expression of poxB and the loss of oprD can lead to resistance and/or
significant MIC changes. Thus, although constitutively expressed in PA01, the role of
PoxB in P. aeruginosa in the clinical setting may currently be overlooked.

5.3 Regulation of poxB. After establishing the role of PoxB as a carbapenemhydrolyzing class D β-lactamase, its regulation was investigated (Chapter 3). As previous
work pointed to the involvement of the transcriptional regulator AmpR (710), expression
of poxB was examined by RT-PCR in the presence and absence of ampR (Figure 3.3). A
small but significant increase in expression was observed in the absence of ampR and in
the presence of β-lactams suggesting AmpR normally acts to downregulate poxB
expression. Similarly, promoter studies using reporter strains carrying Ppox-lacZ fusions
were in agreement with the mRNA data (Figure 3.8). Specifically, induction of poxB
could be achieved only in the absence of ampR and in the presence of β-lactams (Chapter
3). Interestingly these changes could not be observed at the protein level in terms of βlactamase activity.
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AmpR is an interesting candidate for regulator of pox expression. As a LysR-type
transcriptional regulator, AmpR carries an N-terminal HTH motif to interact with DNA
and an effector binding domain in the C-terminus for ligand interaction (852, 856, 897).
As detailed in Chapter 4 of this dissertation, AmpR activates transcription of ampC in the
presence of β-lactams but maintains expression at low basal levels in the absence of such
compounds, thus acting as both a negative and positive regulator of ampC expression
(710, 711, 776). AmpR has additionally been shown to have an extensive regulon that
includes a number of characterized and putative transcriptional and sigma factors, as well
as genes involved in quorum sensing and virulence (710, 841, 843). That the regulon of
AmpR includes transcriptional regulatory proteins suggests AmpR-dependent expression
may occur by indirect regulation. Our EMSA studies in fact, failed to show binding of
AmpR to the pox promoter (Figure 3.5), suggesting regulation by AmpR is indirect.
In an effort to identify possible pox regulators, a genome-wide approach was
undertaken using the reporter strains PA0::Ppox-lacZ and PA0∆ampR::Ppox-lacZ (Chapter
3, Section 3.4.5). The strains were mutagenized with a random mariner transposon (Tn)
in order to identify clones with increased or decreased lacZ expression indicative of
altered pox promoter expression. This study generated a wealth of clones that are still
being screened and evaluated. Two noteworthy clones however, identified based on their
increased lacZ expression, had insertions in spuE (PA0301) and PA0322, genes involved
in a characterized and a putative polyamine uptake system, respectively.
Polyamines (putrescine, cadaverine, spermidine, spermine) are essential
molecules found in all domains of life (845, 847). Bacteria can synthesize, catabolize and
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uptake these molecules for a number of diverse processes as described in Chapter 3 (845,
847, 878). Interestingly, polyamines have been found to sensitize a number of bacterial
species to multiple β-lactams including penicillins, cephalosporins and monobactams
(886, 893). This sensitization did not appear to occur by an increase in outer membrane
permeability as expected of polyamines given their cationic nature. On the other hand,
polyamines provided resistance against the β-lactam imipenem in P. aeruginosa
seemingly through blockage of OprD, the major route of entry for imipenem into the cell
(893).
In order to determine if the increased lacZ expression in mutants containing Tn
insertions in spuE and PA0322, was due to an increase in pox expression, the
susceptibility of the mutants to carbapenems was investigated in the presence and
absence of polyamines (Chapter 3, Table 3.7). Our studies show that polyamines
significantly increased MICs, or decreased susceptibility, against ceftazidime, piperacillin
and the carbapenems, but not against aztreonam, in both unmutagenized and Tnmutagenized strains. This increased in MIC is likely the result of blockage of OprD as
well as other porins, as ceftazidime and piperacillin are not known to use the OprD porin
for passage into the cell. If resistance is occurring by blocking of porins, then the
polyamines do not necessarily need to come into the cell to exert their action. This would
explain why polyamines could raise MICs in what appear to be a strain-independent
manner. The resistance provided was independent of polyamine uptake pathways and as
such the spuE and PA0322 Tn insertions did not affect susceptibility. That the polyamine
spermidine (10 mM) could induce resistance against both imipenem and meropenem
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(>32 µg/ml) likely suggests that polyamines more efficiently block OprD than other
porins and that meropenem and imipenem preferentially enter the cell via this route.
Alternatively, although the function of these genes may be impaired, since there
are other polyamine transport systems, both putative and characterized, the disruptions
imposed by the Tn insertions could potentially be overcome by other such systems.
Thus, polyamines could still enter the cell to exert their action, e.g., modulation of gene
expression. For instance, SpuE is a periplasmic binding protein that specifically binds
spermidine, but the spuABCDEFGH gene cluster that encodes it also encodes SpuD,
another periplasmic binding protein that although preferentially binds to putrescine, can
also bind and transport spermidine (864, 883). Thus, this system is also likely involved in
the uptake and transport of both spermidine and putrescine. The presence of
spuABCDEFGH probably also compensates for the loss of PA0322 a putative, not yet
proven putrescine transporter. Other putative polyamine transport and utilization systems
are also encoded in the general vicinity of the spu gene cluster. The redundancy of such
system may illustrate how essential these molecules are for survival.
It is worth noting that the Tn insertion into spuE likely also led to disruption of
transcription for the rest of the operon, spuFGH, encoding the ATPase for transport and
the two permeases, respectively. Since the Tn contained an outwardly-directed promoter
and the insertion occurred with the promoter in the direction of transcription of these
genes, it is likely that transcription of these downstream ORFs did occur. As experiments
revealed in Chapter 3, the outward-facing promoter of this mariner transposon was very
strong.
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An alternative explanation for the polyamine-dependent MIC increase could be
the induction of genes that themselves confer resistance, such as those involved in efflux.
Although polyamines have not been shown to induce expression of efflux pumps,
spermidine did provide resistance against cationic peptides and quinolones by inducing
expression of oprH-phoPQ and the LPS modification operon (885). It is likely we don’t
yet know all the current targets of polyamines.
The β-lactamase profiles of spuE (PA0301) and PA0322 Tn mutants were not
altered as compared to wild-type as would be expected if such insertions affected pox
expression. Although the increased lacZ expression phenotype displayed by these
mutants appears to be unconnected to Ppox expression, that we have stumbled upon yet
another condition that contributes to carbapenem resistance is very interesting. To
conclusively prove pox involvement, the transcript levels would have to be quantified in
spuE and PA0322 mutants.

5.4 Future directions. Previous studies showed poxB is ubiquitous in P. aeruginosa
clinical and environmental isolates (741), yet its expression and contribution to β-lactam
resistance has not been analyzed in such backgrounds. Traditionally, carbapenem
resistance in P. aeruginosa has been provided by the loss of OprD and the expression of
class B β-lactamases, especially the VIM and IMP-types (549, 947, 955, 967-969). OXA50, however, is not routinely screened for and thus its true contribution in the clinical
setting is unknown.
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Future studies should elucidate on the role of PoxB in clinical isolates, especially
for those that are shown to be carbapenem non-susceptible (intermediate and resistant
phenotypes). Using PCR-based methods, the gold standard for identifying β-lactamases,
the presence of metallo-β-lactamases and OXA-type enzymes, including OXA-50, could
be detected. Since the mere presence of PoxB does not imply its expression, its mRNA
levels should be quantified. Alternatively, the actual protein could be quantified by doing
Western blot. Sequencing of the oprD ORF should also be done in carbapenem nonsusceptible isolates to determine contribution of this porin to resistance.
Another area of this research to expand could involve identification of other
potential roles for PoxB and the pox operon besides that of resistance. Phenotypic
microarrays (Biolog, Hayward, CA) could help identify other such functions. Such arrays
typically measure the rate of respiration over a period of time under a number of
environmental conditions including ranges of salinity, pH, nitrogen, carbon, phosphorus
and sulfur sources, as well as many antimicrobial drugs and chemical compounds. In this
respect two strains will be critical: poxB and poxAB deletion mutants.
A phenotypic microarray has been carried out in PA0∆poxA and pointed to a
growth defect in the presence of NaNO3, leading us to investigate morphology in anoxic
and oxic environments. While the NaNO3 phenotype could not be reproduced, we did
observed PoxA-expressing strains were able to bind the dye Congo red (CR) better
presumably because of increased production of an extracellular polymeric substance. The
CR-binding phenotype was not reproducible or readily observed in liquid media as is
often seen with strains that overproduce Pel and Psl polysaccharides. Thus, it is likely

216

that the CR-binding phenotype is due to production of a polysaccharide or a CR-binding
substance other than Pel or Psl. In order to rule out the involvement of Pel or Psl
polysaccharides, expression of some of the genes of pel an psl operons could be
quantified by RT-PCR. Additionally, the carbohydrate composition of the CR-binding
substance being produced in PoxA-expressing cells could be investigated by gas
chromatography/mass spectrometry as previously described (768, 825).
Although screening and confirmation of the Tn mutant library was well
underway, more than 50% of the library still remains to be screened and/or evaluated.
Thus, a continuing project could involve further screening with the clones that still
remain to be investigated. Although the relationship between pox expression and
polyamine transport identified by the transposon screening is not yet clear, polyamineinduced resistance and susceptibility in P. aeruginosa is by itself an interesting and
worthy area of study. A microarray could elucidate on the targets of these essential
molecules and the link to carbapenem resistance.
Carbapenem resistance has become an increasing problem in the nosocomial
pathogen A. baumannii with the predominant mechanism of resistance being the
expression of OXA enzymes (622, 692, 708, 709, 726, 820). Carbapenems are often the
drug of choice for treating organisms expressing extended-spectrum β-lactamases
(ESBLs) which can hydrolyze penicillins and cephalosporins. There is a real concern that
treatment with such compounds can lead to ESBLs that additionally can hydrolyze
carbapenems. Thus, there is a need to develop effective class D β-lactamase inhibitors.
Although not yet prevalent in P. aeruginosa, CHDLs have the potential to become

217

widespread, as they have in the closely related Pseudomonadales species A. baumannii,
given its genomic plasticity and ability to acquire resistance genes from the environment.
P. aeruginosa already carries PoxB, a chromosomal carbapenem-hydrolyzing βlactamase, ubiquitous in clinical and environmental isolates, and with the potential to
become yet another tool in the arsenal of this intractable pathogen against the β-lactam
antibiotics.
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SUPPLEMENTAL MATERIAL
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Table S1: Bacterial strains, plasmids, and primers used in this study
Strains/ Plasmids
Escherichia coli
E. coli DH5α

Relevant phenotype and genotype
-

F Φ80lacZΔM15 Δ (lacZYA-argF)U169 deoR recA1
+
endA1 hsdR17 (rk mk ) phoA supE44 λ thi-1 gyrA96
relA1

Pseudomonas aeruginosa
PA01
Wild-type
PA06358
PA0rpoN , PA01 containing in-frame deletion of a
0.9-kb fragment from the rpoN gene (PA4462)
PKM106
PA0attB::mini-CTX-lacZ; TcR
PKM107
PA0attB::PampC352-lacZ; TcR
PKM108
PA0attB::PampC193-lacZ; TcR
PKM109
PA0attB::PampC171-lacZ; TcR
PKM110
PA0attB::PampC151-lacZ; TcR
PKM111
PA0attB::PampC-130-lacZ; TcR
PKM112
PA0attB::PampC-111-lacZ; TcR
PKM113
PA0attB::PampC90-lacZ; TcR
PKM114
PA0attB::PampC70-lacZ; TcR
PKM115
PA0attB::PampC51-lacZ; TcR
PKM116
PA0attB::PampR193-lacZ; TcR
PKM201
PA0ampC , PA01 containing in-frame deletion of
ampC
PKM315
PA0ampR , PA01 containing in-frame deletion of
ampR
PKM318
PA0ampRVSV-G; VSV-G tag added in-frame to AmpR
Plasmids
pBSK(+)
pEXG2
pP30ΔFRT-MvaT-V
pSJ01
pTrcphoA
pTrclacZ

ApR; ColE1ori lacZα
GmR; pMB1ori sacB
GmR; ColE1ori RP4 (mob) aacC1, integrationproficient vector containing VSV-G epitope tag
ApR, pGEMEX-1 with a 1220-bp EcoRI-BamHIflanked fragment containing ampR
ApR, low-copy trc promoter expression vector
q
carrying lacI and phoA
ApR, low-copy trc promoter expression vector
q
carrying lacI and lacZ

Mini-CTX-lacZ

Tc ; Integration-proficient vector for single-copy
chromosomal lacZ fusion at the attB site

pMMB67EH-Gm

GmR; IncQ, RSF1010, lacI Ptac expression vector
with ampR::aacC1 insertion at DraI

R

q
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Source
New
England
Biolabs

(762)
(970)
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
(760)
(843)
This study
Stratagene
(759)
(908)
(710)
(911)
(911)
(853)
(763)

pP30FRT-AmpR-V
pOC1
pOC2
pOC3
pOC4
pOC5
pOC6
pOC7
pOC8
pOC9
pOC10
pOC11
pOC12
pOC13
pOC14
pOC15
pOC16
pOC17
pOC18
pOC19
pOC20
pOC21
pOC22
pOC23
pOC24
pOC25
pOC26
pKK862
pKK863
pKK864

pP30FRT-MvaT-V digested with HindIII and NotI
to release mvaT and carrying 540-bp 3’ fragment of
ampR fused in-frame with VSV-G tag
TcR; PampC352 fused to the lacZ of mini-CTX-lacZ
TcR; PampC193 fused to the lacZ of mini-CTX-lacZ
TcR; PampC171 fused to the lacZ of mini-CTX-lacZ
TcR; PampC151 fused to the lacZ of mini-CTX-lacZ
TcR; PampC130 fused to the lacZ of mini-CTX-lacZ
TcR; PampC111 fused to the lacZ of mini-CTX-lacZ
TcR; PampC90 fused to the lacZ of mini-CTX-lacZ
TcR; PampC70 fused to the lacZ of mini-CTX-lacZ
TcR; PampC51 fused to the lacZ of mini-CTX-lacZ
TcR; PampR193 fused to the lacZ of mini-CTX-lacZ
ApR; pBSK-AmpR-His6 (933-bp EcoRI-BamHI
fragment containing AmpR His-tagged at Cterminus)
ApR; pOC11-AmpRSer38Ala
ApR; pOC11-AmpRHis39Ala
ApR; pOC11-AmpRLys42Ala
ApR; pOC11-AmpRSer43Ala
ApR; pOC11-AmpRGlu46Ala
ApR; pOC11-AmpRGly102Glu
ApR; pOC11-AmpRAsp135Asn
GmR; pMMB67EHGM containing 933-bp EcoRIBamHI ampR-His6 fragment from pOC11
GmR; pMMB67EHGM with EcoRI-BamHI fragment
containing AmpR-His6- Ser38Ala from pOC12
GmR; pMMB67EHGM with EcoRI-BamHI fragment
containing AmpR-His6- His39Ala from pOC13
GmR; pMMB67EHGM with EcoRI-BamHI fragment
containing AmpR-His6-Lys42Ala from pOC14
GmR; pMMB67EHGM with EcoRI-BamHI fragment
containing AmpR-His6-Ser43Ala from pOC15
GmR; pMMB67EHGM with EcoRI-BamHI fragment
containing AmpR-His6-Glu46Ala from pOC16
GmR; pMMB67EHGM with EcoRI-BamHI fragment
containing AmpR-His6-Gly102Glu from pOC17
GmR; pMMB67EHGM with EcoRI-BamHI fragment
containing AmpR-His6-Asp135Asn from pOC18
ApR, pTrclacZ derivative with a 1220-bp fragment
containing ampR and the lacZ gene at HindIII site
ApR, pTrcphoA derivative with a 1220-bp fragment
containing ampR and the phoA gene at HindIII site
ApR, pTrclacZ derivative with a 1220-bp fragment
containing ampR and the lacZ gene at HincII site
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This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
pAmpRHis6, This
study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study

pKK865
pKK866
pKK867
Primers
DZampCUF1

ApR, pTrcphoA derivative with a 1220-bp fragment
containing ampR and the phoA gene at HincII site
ApR, pTrclacZ derivative with a 1220-bp fragment
containing ampR and the lacZ gene at PstI site
ApR, pTrcphoA derivative with a 1220-bp fragment
containing ampR and the phoA gene at PstI site

This study
This study
This study

OCPampC For193
OCPampC For173
OCPampC For151
OCPampC For131
OCPampC For111

5’-GGAATTCAAGACGATGCTCCGGGTCAGTG-3’
5’-GATACCAGATTCCCCTGCCTGTCTAGCTAGCTAGA
ATGCTC-3’
5’-CTAGCTAGCTAGAATGCTCAAGCGCGCTCGCGAGG
GCGA CGGA-3’
5’-CGGGATCCGACCCTGCATACCATCAAGG-3’
5’-GGAATTCAGCCTGGAACTTCCGCAATCTCGACG
AGA-3’
5’GAGCATTCTAGCTAGCTAGGTTCGCCACCGAAGT
GAGTACC-3’
5’-CTAGCTAGCTAGAATGCTCAATGGGGTCGAACCAA
TCTCT GCTCC-3’
5’ CGGGATCCGATGCTCGGGTTGGAATAGA-3’
5’-ACAGAATTCGAAGGAGATATACCTTGGTTCGACCC
CATTT GCC-3’
5’-GAGGATCCTTAGTGATGATGATGATGATGTCTCCC
CCGCGCCTCAACGGCAGCC-3’
5’-GGAATTCTGAGGCCGCGCGGCAGACGCTTGAACA3’
5’-CGGGAATTCGCGGCAAATGGGGTCGAACC-3’
5’-CGGGAATTCTCTCTGCTCCAAATTTTTCT-3’
5’-CGGGAATTCAATGGCTGCCGCGAGTATTCG-3’
5’-CGGGAATTCTCGTTTGCCGCAAATCCTGC-3’
5’-CGGGAATTCGCAAGCCTAGATTTTCCCCG-3’

OCPampC For91

5’-CGGGAATTCCCCGCCGATCAAGGAGCGCT-3’

This study

OCPampC For71
OCPampC For51
OCPampC RevBc
OCPampR Rev193
OCPampR ForEc
alg44 For
alg44 Rev
AmpRSer38AlaFor
AmpRSer38AlaRev
AmpRHis39AlaFor
AmpRHis39AlaRev
AmpRLys42AlaFor

5’-CGGGAATTCCCCGGGGCGGTTTCTCATGC-3’
5’-CGGGAATTCAGCCAACGACAAAGGACGC-3’
5’-CGGGGATCCTCAGGGGAATCTGGTATCGCG-3’C
5’-CGGGGATCCGCGGCAAATGGGGTCGAACC-3’
5’-CGGGAATTCCAGGGGAATCTGGTATCGCGC-3’
5’-CGAAGCCCAGCGCCAGTTCG-3’
5’-GGTCCACCGAGCGCACCTGG-3’
5’-ACCCAGGCGGCGGTCGCCCACCAGGTGAAGAGC-3’
5’-GCTCTTCACCTGGTGGGCGACCGCCGCCTGGGT-3’
5’-CAGGCGGCGGTCAGCGCCCAGGTGAAGAGCCTC-3’
5’-GAGGCTCTTCACCTGGGCGCTGACCGCCGCCTG-3’
5’-GTCAGCCACCAGGTGGCGAGCCTCGAGGAGCGT-3’

This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study

DZampCUR1
DZampCDF2
DZampCDR2
KMampRUF1
KMampRUR1
KMampRDF2
KMampRDR2
OCAmpR-His-For
OCAmpR-His-Rev
SBJ03ampCRFor
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(760)
(760)
(760)
(760)
(843)
(843)
(843)
(843)
This study
This study
This study
This study
This study
This study
This study
This study

AmpRLys42AlaRev
AmpRSer43AlaFor
AmpRSer43AlaRev
AmpRGlu46AlaFor
AmpRGlu46AlaRev

5’-ACGCTCCTCGAGGCTCGCCACCTGGTGGCTGAC-3’
5’-AGCCACCAGGTGAAGGCCCTCGAGGAGCGTCTC-3’
5’-GAGACGCTCCTCGAGGGCCTTCACCTGGTGGCT-3’
5’-GTGAAGAGCCTCGAGGCGCGTCTCGGCGTGGCC-3’
5’-GGCCACGCCGAGACGCGCCTCGAGGCTCTTCAC-3’
5’AmpRGly102GluFor
CACCGTCGGCGCGGTCGAAACCTTCACGGTCGGTT-3’
5’AmpRGly102GluRev
AACCGACCGTGAAGGTTTCGACCGCGCCGACGGTG-3’
AmpRAsp135Asn
5’-CCCACAACAACCGCGTCAACATCGCCGCCGAGGGFor
3’
AmpRAsp135Asn
5’-CCCTCGGCGGCGATGTTGACGCGGTTGTTGTGGGRev
3’
5RA-PampC233
5’-GGGTCTCCGGCGTCACCCGG-3’
5RA-PampC154
5’-GGCTACGGCCAGGCCCGG-3’
5RA-PampC113
5’-CCGGTTGTACGGCGGCGTCG-3’
5RA-PampR229
5’-GCAGGCCGGCGATGCGGTCG-3’
5RA-PampR169
5’-GGTCAGCATGAGGCCGCGCG-3’
5RA-PampR99
5’-CCTGGTGGCTGACCGCCGCC-3’
5’Qt
GCCAGGTGAGCAGGAGTGACGGGAATTCAGCTGGAT
CCTGCACCCTTTTTTTTTTTTTTTTTT-3’

This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
(764)

Q0

5’- GCCAGGTGAGCAGGAGTGACG-3’

(764)

Qi

5’-GGAATTCAGCTGGATCCTGCACCC-3’

(764)

DBS_ChIP_ampCF

5’-GGTCGAACCAATCTCTGCTCCAAA-3’

(841)

DBS_ChIP_ampCR

5’-TTGTCGTTGGCTGCATGAGAAACC-3’

(841)

DBS_qRT_clpXF

5'-TGCGATTACGATGTGGAGA-3'

(843)

DBS_qRT_clpXR

5'-CCCTCGATGAGCTTCAGCA-3'

(843)

DBS_QRTAmpRFwd

5’-CATTGGCCTTCATCACCGGTTGTA-3’

(760)

DBS_QRTAmpRRev

5’-GGTTTCTCATGCAGCCAACGACAA-3’

(760)

qRT_ampCF

5'-CGCCGTACAACCGGTGAT-3'

(971)

qRT_ampCR

5'-CGGCCGTCCTCTTTCGA-3'

(971)
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His-tagged AmpR is functional. PA0ΔampR was complemented with the vector,
pMMB67EH-Gm, or with the His-tagged AmpR. β-lactamase assays show that in the
absence of AmpR there is low constitutive ampC expression (Table S2). However,
overexpression of AmpR-His6 in PA0ΔampR in the presence of β-lactams restores the βlactamase activity to that of the wild-type induced strain. Additionally, the inherently
resistant PA01 strain shows a significant increase in sensitivity to both amoxicillin and
ampicillin when ampR is deleted, as determined by E-test (Table S2). The resistance is
restored upon complementation with AmpR-His6. The AmpR-His6 construct thus
complements the ampR deletion and retains its native function.

Table S2: Complementing assays showing His-tagged AmpR is functional.
Minimum Inhibitory

β-Lactamase Specific Activity

Concentration (µg ml-1) *

(nmol min-1 mg protein-1) †

Strains
AmpicillinAmoxicillin

- β-lactam

+ β-lactam

Sulbactam
PA01
PA0∆ampR (pVector)^

>256

>256

0.040 + 0.012

0.872 + 0.032

7

14

0.035 + 0.007

0.031 + 0.011

>256

>256

0.042 + 0.002

1.295 + 0.008

PA0∆ampR (pAmpRHis6)
*Etests were performed in the presence of 1 mM of IPTG.
^The vector used to construct pAmpR-His6 was pMMB67EH-Gm.
†
Cultures were induced with 1 mM of IPTG and β-lactamase activity was quantified in presence and
absence of β-lactams (penicillin G at 200 µg ml-1 for 1h). Assays were performed in triplicates using
sonicated lysate and nitrocefin as a chromogenic substrate.
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VSV-G-tagged AmpR is functional. The VSV-G-tagged AmpR was introduced into
PA0ΔampR.

The inherently resistant PA01 strain shows a significant increase in

sensitivity to both amoxicillin and ampicillin-sublactam when ampR is deleted, as
determined by E-test (Table S3). The resistance is restored upon integration of ampRVSV-G. The AmpR-VSV-G complements the ampR deletion and retains its native
function.

Table S3: Complementing assays showing VSV-G-tagged AmpR is functional.
Minimum Inhibitory Concentration (µg ml-1) *
Strains

PA01
PA0∆ampR
PAO∆ampR::ampR-VSV-G

Amoxicillin

Ampicillin-Sulbactam

>256

>256

8

48

>256

>256

*MIC was determined by Etest.
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Figure S1. Multiple alignment of the ampR-ampC intergenic region. The C. freundii, E.
cloacae and P. aeruginosa ampR-ampC intergenic regions were aligned using ClustalW2.
The ampR and ampC ORFs (arrows), TSSs (triangles), and sigma sequences (underlined)
are depicted in blue and green, respectively. A downstream shift in the P. aeruginosa
ampR TSS is likely responsible for the change in sigma factor control observed here.
Orange arrows denote palindromic sequences.

A

226

B

Figure S2. Localization studies of P. aeruginosa AmpR. (A) Restriction map and
topology of AmpR. The topology of AmpR was investigated by introducing phoA and
lacZ fusions at the restriction sites HindIII, HincII and PstI restriction sites corresponding
to amino acid positions Glu15, Val134 and Gln185, respectively. Fusions at Glu15 were
LacZ-positive but PhoA-negative, whereas fusions at Val134 and Gln185 were PhoApositive and LacZ-negative. (B) Spheroplasts of PA0ΔampR (pAmpR-His6) were
obtained and treated with 10 µg/ml of Proteinase K for varying lengths of time. AntiAmpR antibodies were used to monitor the presence of the full-length AmpR (32 kDA)
and the shaved product (10 kDa) by Western blotting. The membranes were stripped and
re-probed with anti-σ70 antibodies.
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Figure S3. Multiple alignment of the AmpR HTH motif. N-terminal sequences from P.
aeruginosa, C. freundii, E. cloacae, K. pneumonia, A. tumefaciens, O. anthropic, and L.
hongkongensis
AmpR
were
aligned
using
ClustalW2
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). Asterisks denote conserved residues that
do not deviate from those in the reference sequence of P. aeruginosa. Residues denoted
in red were replaced with alanine in P. aeruginosa AmpR-His6 by site-directed
mutagenesis.

SUPPLEMENTAL MATERIALS AND METHODS
β-lactamase assay. The β-lactamase assay was modified from a previously published
protocol (765). Briefly, stationary-phase cultures were diluted in 30 ml of LB broth to an
OD600 of 0.02 and incubated with shaking at 37°C. At an OD600 of 0.2, cells containing
the expression plasmid were induced with 1 mM IPTG for an hour. At an OD600 of 0.6,
the remaining cultures were induced with 200 µg ml-1 of penicillin G for an hour before
harvesting. Cells were harvested by centrifugation, resuspended in 1 ml of 50 mM of
sodium phosphate buffer and sonicated on ice for 1 min 20 s (20-sec pulse ON, 20-sec
pulse OFF, amplitude 30%). The sonicated cells were centrifuged at 10,000 X g at 4°C
for 30 minutes to collect the β-lactamase-containing supernatant. A 2-µl aliquot of cell
lysate is added to nitrocefin (final concentration, 100 µM) in 1 ml of assay buffer. The
reaction was incubated at 37°C for 20 minutes and the hydrolysis of nitrocefin was
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measured spectrophotometrically at 482 nm. Total protein concentration was determined
with Bradford on the same supernatant. The activity was expressed as nmol of nitrocefin
degraded per minute per milligram of total protein.

Minimum Inhibitory concentration (MIC). The MIC was determined by the E-test
system according to the manufacturer’s instructions (bioMérieux, Marcy l’Etoile).
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